Report Analysis

Generated at 2020-10-13T23:56:09+0000 for charles.hoffman@me.com. This page will remain online for about 48 hours.

Report

Submitted: http://www.sec.gov/Archives/edgar/data/1651625/000095010318003508/aciu-20171231.xml
For more information: http://logicalcontracts.com/xbrl-and-sbrm-reporting/
DISCLAIMER: this analysis is provided by software still under development, and likely incomplete or even erroneous; do NOT use it other than for experimental, inconsequential purposes

User Alterations

NONE

	TERMS
000100 - Document - Document and Entity Information	Structures	Facts
010000 - Statement - Balance Sheets	Structures	Facts
020000 - Statement - Statements of Income / (Loss)	Structures	Facts
030000 - Statement - Statements of Comprehensive Income / (Loss)	Structures	Facts
030100 - Statement - Statements of Comprehensive Income / (Loss) (Parenthetical)	Structures	Facts
040000 - Statement - Statements of Changes in Equity	Structures	Facts
050000 - Statement - Statements of Cash Flows	Structures	Facts
050100 - Statement - Statements of Cash Flows (Parenthetical)	Structures	Facts
060100 - Disclosure - General information	Structures	Facts
060200 - Disclosure - Basis of preparation	Structures	Facts
060300 - Disclosure - Summary of significant accounting policies	Structures	Facts
060400 - Disclosure - Property, plant and equipment	Structures	Facts
060500 - Disclosure - Financial Assets	Structures	Facts
060600 - Disclosure - Prepaid expenses and accrued income	Structures	Facts
060700 - Disclosure - Other current receivables	Structures	Facts
060800 - Disclosure - Cash and cash equivalents	Structures	Facts
060900 - Disclosure - Share capital	Structures	Facts
061000 - Disclosure - Trade payables and accrued liabilities	Structures	Facts
061100 - Disclosure - Deferred income	Structures	Facts
061200 - Disclosure - Long term financing obligation	Structures	Facts
061300 - Disclosure - Revenues	Structures	Facts
061400 - Disclosure - Expenses by category	Structures	Facts
061500 - Disclosure - Related-party transactions	Structures	Facts
061600 - Disclosure - Income taxes	Structures	Facts
061700 - Disclosure - Retirement benefit plan	Structures	Facts
061800 - Disclosure - Share-based compensation	Structures	Facts
061900 - Disclosure - Commitments and contingencies	Structures	Facts
062000 - Disclosure - Earnings per share	Structures	Facts
062100 - Disclosure - Financial instruments and risk management	Structures	Facts
062200 - Disclosure - Capital risk management	Structures	Facts
062300 - Disclosure - Post balance sheet events	Structures	Facts
070300 - Disclosure - Summary of significant accounting policies (Policies)	Structures	Facts
080300 - Disclosure - Summary of significant accounting policies (Tables)	Structures	Facts
080400 - Disclosure - Property, plant and equipment (Tables)	Structures	Facts
080600 - Disclosure - Prepaid expenses and accrued income (Tables)	Structures	Facts
080700 - Disclosure - Other current receivables (Tables)	Structures	Facts
080800 - Disclosure - Cash and cash equivalents (Tables)	Structures	Facts
080900 - Disclosure - Share capital (Tables)	Structures	Facts
081000 - Disclosure - Trade payables and accrued liabilities (Tables)	Structures	Facts
081300 - Disclosure - Revenues (Tables)	Structures	Facts
081400 - Disclosure - Expenses by category (Tables)	Structures	Facts
081500 - Disclosure - Related-party transactions (Tables)	Structures	Facts
081600 - Disclosure - Income taxes (Tables)	Structures	Facts
081700 - Disclosure - Retirement benefit plan (Tables)	Structures	Facts
081800 - Disclosure - Share-based compensation (Tables)	Structures	Facts
081900 - Disclosure - Commitments and contingencies (Tables)	Structures	Facts
082000 - Disclosure - Earnings per share (Tables)	Structures	Facts
082100 - Disclosure - Financial instruments and risk management (Tables)	Structures	Facts
090100 - Disclosure - General information (Details)	Structures	Facts
090200 - Disclosure - Basis of preparation (Details)	Structures	Facts
090300 - Disclosure - Summary of significant accounting policies, Property, plant and equipment (Details)	Structures	Facts
090302 - Disclosure - Summary of significant accounting policies, Share capital and Initial Public Offering, Preferred Shares (Details)	Structures	Facts
090304 - Disclosure - Summary of significant accounting policies, Share capital and Initial Public Offering (Details)	Structures	Facts
090306 - Disclosure - Summary of significant accounting policies, Income taxes and Segment reporting (Details)	Structures	Facts
090400 - Disclosure - Property, plant and equipment (Details)	Structures	Facts
090500 - Disclosure - Financial Assets (Details)	Structures	Facts
090600 - Disclosure - Prepaid expenses and accrued income (Details)	Structures	Facts
090700 - Disclosure - Other current receivables (Details)	Structures	Facts
090800 - Disclosure - Cash and cash equivalents (Details)	Structures	Facts
090900 - Disclosure - Share capital (Details)	Structures	Facts
091000 - Disclosure - Trade payables and accrued liabilities (Details)	Structures	Facts
091100 - Disclosure - Deferred income (Details)	Structures	Facts
091200 - Disclosure - Long term financing obligation (Details)	Structures	Facts
091300 - Disclosure - Revenues (Details)	Structures	Facts
091400 - Disclosure - Expenses by category (Details)	Structures	Facts
091500 - Disclosure - Related-party transactions (Details)	Structures	Facts
091600 - Disclosure - Income taxes (Details)	Structures	Facts
091602 - Disclosure - Income taxes, Unrecognized Deductible Temporary Differences, Unused Tax Losses and Unused Tax Credits (Details)	Structures	Facts
091700 - Disclosure - Retirement benefit plan (Details)	Structures	Facts
091702 - Disclosure - Retirement benefit plan, Changes in Defined Benefit Obligation (Details)	Structures	Facts
091704 - Disclosure - Retirement benefit plan, Changes in Fair Value of Plan Assets (Details)	Structures	Facts
091706 - Disclosure - Retirement benefit plan, Change in Net Definied Benefit Liability (Details)	Structures	Facts
091708 - Disclosure - Retirement benefit plan, Actuarial Assumptions and Sensitivity Analysis (Details)	Structures	Facts
091800 - Disclosure - Share-based compensation, Plans Outstanding (Details)	Structures	Facts
091802 - Disclosure - Share-based compensation, Weighted Average Exercise Prices (Details)	Structures	Facts
091804 - Disclosure - Share-based compensation, Summary Information (Details)	Structures	Facts
091806 - Disclosure - Share-based compensation, Non-vested Share Awards (Details)	Structures	Facts
091900 - Disclosure - Commitments and contingencies (Details)	Structures	Facts
092000 - Disclosure - Earnings per share (Details)	Structures	Facts
092100 - Disclosure - Financial instruments and risk management (Details)	Structures	Facts
092300 - Disclosure - Post balance sheet events (Details)	Structures	Facts
	RULES
	Errors and Warnings

Terms

Terms shown are only those effectively used by the report instance.

#	Label	Data Type	Period Type	Balance Type	Abstract	Prefix	Name, Documentation, References
1	Income / (loss) before income tax	xbrli:monetaryItemType	duration	credit		ifrs-full	AccountingProfit
2	Accruals	xbrli:monetaryItemType	instant	credit		ifrs-full	Accruals
3	Deferred income [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	AccrualsAndDeferredIncomeAbstract
4	Accumulated depreciation and amortisation [member]	nonnum:domainItemType	duration		true	ifrs-full	AccumulatedDepreciationAndAmortisationMember
5	Actuarial assumption of discount rates	num:percentItemType	instant			ifrs-full	ActuarialAssumptionOfDiscountRates
6	Actuarial assumption of discount rates [member]	nonnum:domainItemType	duration		true	ifrs-full	ActuarialAssumptionOfDiscountRatesMember
7	Actuarial assumption of expected rates of pension increases	num:percentItemType	instant			ifrs-full	ActuarialAssumptionOfExpectedRatesOfPensionIncreases
8	Actuarial assumption of expected rates of pension increases [member]	nonnum:domainItemType	duration		true	ifrs-full	ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember
9	Actuarial assumption of expected rates of salary increases	num:percentItemType	instant			ifrs-full	ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
10	Actuarial assumption of expected rates of salary increases [member]	nonnum:domainItemType	duration		true	ifrs-full	ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember
11	Actuarial assumptions [axis]	xbrli:stringItemType	duration		true	ifrs-full	ActuarialAssumptionsAxis
12	Actuarial assumptions [member]	nonnum:domainItemType	duration		true	ifrs-full	ActuarialAssumptionsMember
13	Actuarial gains (losses) arising from changes in demographic assumptions, net defined benefit liability (asset)	xbrli:monetaryItemType	duration	debit		ifrs-full	ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
14	Actuarial gains (losses) arising from changes in financial assumptions, net defined benefit liability (asset)	xbrli:monetaryItemType	duration	debit		ifrs-full	ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
15	Additions other than through business combinations, property, plant and equipment	xbrli:monetaryItemType	duration	debit		ifrs-full	AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
16	Adjusted weighted average number of ordinary shares outstanding	xbrli:sharesItemType	duration			ifrs-full	AdjustedWeightedAverageShares
17	Adjustments for decrease (increase) in other operating receivables	xbrli:monetaryItemType	duration	debit		ifrs-full	AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
18	Adjustments for depreciation expense	xbrli:monetaryItemType	duration	debit		ifrs-full	AdjustmentsForDepreciationExpense
19	Adjustments for finance income (cost)	xbrli:monetaryItemType	duration	credit		ifrs-full	AdjustmentsForFinanceIncomeCost
20	Adjustments for increase (decrease) in deferred income	xbrli:monetaryItemType	duration	debit		ifrs-full	AdjustmentsForIncreaseDecreaseInDeferredIncome
21	Adjustments for increase (decrease) in employee benefit liabilities	xbrli:monetaryItemType	duration	debit		ifrs-full	AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
22	Adjustments for increase (decrease) in trade accounts payable	xbrli:monetaryItemType	duration	debit		ifrs-full	AdjustmentsForIncreaseDecreaseInTradeAccountPayable
23	Adjustments to reconcile profit (loss) [abstract]	xbrli:stringItemType	duration		true	ifrs-full	AdjustmentsForReconcileProfitLossAbstract
24	Adjustments for share-based payments	xbrli:monetaryItemType	duration	debit		ifrs-full	AdjustmentsForSharebasedPayments
25	Aggregated time bands [member]	nonnum:domainItemType	duration		true	ifrs-full	AggregatedTimeBandsMember
26	Applicable tax rate	num:percentItemType	duration			ifrs-full	ApplicableTaxRate
27	Assets	xbrli:monetaryItemType	instant	debit		ifrs-full	Assets
28	Assets [abstract]	xbrli:stringItemType	duration		true	ifrs-full	AssetsAbstract
29	Basic earnings (loss) per share	num:perShareItemType	duration			ifrs-full	BasicEarningsLossPerShare
30	Bottom of range [member]	nonnum:domainItemType	duration		true	ifrs-full	BottomOfRangeMember
31	Carrying amount, accumulated depreciation, amortization and impairment and gross carrying amount [axis]	xbrli:stringItemType	duration		true	ifrs-full	CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis
32	Carrying amount [member]	nonnum:domainItemType	duration		true	ifrs-full	CarryingAmountMember
33	Cash [abstract]	xbrli:stringItemType	duration		true	ifrs-full	CashAbstract
34	Cash and cash equivalents	xbrli:monetaryItemType	instant	debit		ifrs-full	CashAndCashEquivalents
35	Cash and cash equivalents [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	CashAndCashEquivalentsAbstract
36	Cash flows from (used in) financing activities	xbrli:monetaryItemType	duration	debit		ifrs-full	CashFlowsFromUsedInFinancingActivities
37	Cash flows from (used in) financing activities [abstract]	xbrli:stringItemType	duration		true	ifrs-full	CashFlowsFromUsedInFinancingActivitiesAbstract
38	Cash flows from (used in) investing activities	xbrli:monetaryItemType	duration	debit		ifrs-full	CashFlowsFromUsedInInvestingActivities
39	Cash flows from (used in) investing activities [abstract]	xbrli:stringItemType	duration		true	ifrs-full	CashFlowsFromUsedInInvestingActivitiesAbstract
40	Cash flows from (used in) operating activities	xbrli:monetaryItemType	duration			ifrs-full	CashFlowsFromUsedInOperatingActivities
41	Cash flows from (used in) operating activities [abstract]	xbrli:stringItemType	duration		true	ifrs-full	CashFlowsFromUsedInOperatingActivitiesAbstract
42	Cash flows from (used in) operations	xbrli:monetaryItemType	duration			ifrs-full	CashFlowsFromUsedInOperations
43	Categories of financial assets [axis]	xbrli:stringItemType	duration		true	ifrs-full	CategoriesOfFinancialAssetsAxis
44	Categories of financial liabilities [axis]	xbrli:stringItemType	duration		true	ifrs-full	CategoriesOfFinancialLiabilitiesAxis
45	Categories of related parties [axis]	xbrli:stringItemType	duration		true	ifrs-full	CategoriesOfRelatedPartiesAxis
46	Share capital [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	ChangesInEquityAbstract
47	Changes in net defined benefit liability (asset) [abstract]	xbrli:stringItemType	duration		true	ifrs-full	ChangesInNetDefinedBenefitLiabilityAssetAbstract
48	Classes of property, plant and equipment [axis]	xbrli:stringItemType	duration		true	ifrs-full	ClassesOfPropertyPlantAndEquipmentAxis
49	Classes of share capital [axis]	xbrli:stringItemType	duration		true	ifrs-full	ClassesOfShareCapitalAxis
50	Share Capital [member]	nonnum:domainItemType	duration		true	ifrs-full	ClassesOfShareCapitalMember
51	Closing foreign exchange rate	xbrli:decimalItemType	instant			ifrs-full	ClosingForeignExchangeRate
52	Components of equity [axis]	xbrli:stringItemType	duration		true	ifrs-full	ComponentsOfEquityAxis
53	Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]	xbrli:stringItemType	duration		true	ifrs-full	ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract
54	Comprehensive income	xbrli:monetaryItemType	duration	credit		ifrs-full	ComprehensiveIncome
55	Computers / IT [Member]	nonnum:domainItemType	duration		true	ifrs-full	ComputerEquipmentMember
56	Contributions to plan by employer, net defined benefit liability (asset)	xbrli:monetaryItemType	duration	debit		ifrs-full	ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
57	Contributions to plan by plan participants, net defined benefit liability (asset)	xbrli:monetaryItemType	duration	debit		ifrs-full	ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
58	Credit risk [member]	nonnum:domainItemType	duration		true	ifrs-full	CreditRiskMember
59	Currency risk [member]	nonnum:domainItemType	duration		true	ifrs-full	CurrencyRiskMember
60	Current accrued expenses and other current liabilities	xbrli:monetaryItemType	instant	credit		ifrs-full	CurrentAccruedExpensesAndOtherCurrentLiabilities
61	Current accrued income	xbrli:monetaryItemType	instant	debit		ifrs-full	CurrentAccruedIncome
62	Current assets	xbrli:monetaryItemType	instant	debit		ifrs-full	CurrentAssets
63	Current assets [abstract]	xbrli:stringItemType	duration		true	ifrs-full	CurrentAssetsAbstract
64	Current liabilities	xbrli:monetaryItemType	instant	credit		ifrs-full	CurrentLiabilities
65	Current liabilities [abstract]	xbrli:stringItemType	duration		true	ifrs-full	CurrentLiabilitiesAbstract
66	Current prepaid expenses	xbrli:monetaryItemType	instant	debit		ifrs-full	CurrentPrepaidExpenses
67	Current prepayments	xbrli:monetaryItemType	instant	debit		ifrs-full	CurrentPrepayments
68	Current prepayments and current accrued income	xbrli:monetaryItemType	instant	debit		ifrs-full	CurrentPrepaymentsAndCurrentAccruedIncome
69	Current provisions for employee benefits	xbrli:monetaryItemType	instant	credit		ifrs-full	CurrentProvisionsForEmployeeBenefits
70	Current receivables from taxes other than income tax	xbrli:monetaryItemType	instant	debit		ifrs-full	CurrentReceivablesFromTaxesOtherThanIncomeTax
71	Current service cost, net defined benefit liability (asset)	xbrli:monetaryItemType	duration	credit		ifrs-full	CurrentServiceCostNetDefinedBenefitLiabilityAsset
72	Current value added tax receivables	xbrli:monetaryItemType	instant	debit		ifrs-full	CurrentValueAddedTaxReceivables
73	Deferred income classified as current	xbrli:monetaryItemType	instant	credit		ifrs-full	DeferredIncomeClassifiedAsCurrent
74	Deferred tax assets	xbrli:monetaryItemType	instant	debit		ifrs-full	DeferredTaxAssets
75	Deferred tax liabilities	xbrli:monetaryItemType	instant	credit		ifrs-full	DeferredTaxLiabilities
76	Deferred tax liability (asset)	xbrli:monetaryItemType	instant	credit		ifrs-full	DeferredTaxLiabilityAsset
77	Defined benefit plans [axis]	xbrli:stringItemType	duration		true	ifrs-full	DefinedBenefitPlansAxis
78	Defined benefit plans [member]	nonnum:domainItemType	duration		true	ifrs-full	DefinedBenefitPlansMember
79	Depreciation, property, plant and equipment	xbrli:monetaryItemType	duration			ifrs-full	DepreciationPropertyPlantAndEquipment
80	Description of accounting policy for earnings per share [text block]	nonnum:textBlockItemType	duration			ifrs-full	DescriptionOfAccountingPolicyForEarningsPerShareExplanatory
81	Description of accounting policy for employee benefits [text block]	nonnum:textBlockItemType	duration			ifrs-full	DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory
82	Description of accounting policy for foreign currency translation [text block]	nonnum:textBlockItemType	duration			ifrs-full	DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
83	Description of accounting policy for income tax [text block]	nonnum:textBlockItemType	duration			ifrs-full	DescriptionOfAccountingPolicyForIncomeTaxExplanatory
84	Description of accounting policy for issued capital [text block]	nonnum:textBlockItemType	duration			ifrs-full	DescriptionOfAccountingPolicyForIssuedCapitalExplanatory
85	Description of accounting policy for property, plant and equipment [text block]	nonnum:textBlockItemType	duration			ifrs-full	DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
86	Description of accounting policy for provisions [text block]	nonnum:textBlockItemType	duration			ifrs-full	DescriptionOfAccountingPolicyForProvisionsExplanatory
87	Description of accounting policy for recognition of revenue [text block]	nonnum:textBlockItemType	duration			ifrs-full	DescriptionOfAccountingPolicyForRecognitionOfRevenue
88	Description of accounting policy for research and development expense [text block]	nonnum:textBlockItemType	duration			ifrs-full	DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
89	Description of accounting policy for segment reporting [text block]	nonnum:textBlockItemType	duration			ifrs-full	DescriptionOfAccountingPolicyForSegmentReportingExplanatory
90	Expected volatility, share options granted	num:percentItemType	duration			ifrs-full	DescriptionOfExpectedVolatilityShareOptionsGranted
91	Option life, share options granted	xbrli:decimalItemType	duration			ifrs-full	DescriptionOfOptionLifeShareOptionsGranted
92	Risk free interest rate, share options granted	num:percentItemType	duration			ifrs-full	DescriptionOfRiskFreeInterestRateShareOptionsGranted
93	Diluted earnings (loss) per share	num:perShareItemType	duration			ifrs-full	DilutedEarningsLossPerShare
94	Dilutive effect of convertible instruments on number of ordinary shares	xbrli:sharesItemType	duration			ifrs-full	DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares
95	Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory
96	Disclosure of basis of preparation of financial statements [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
97	Disclosure of cash and cash equivalents [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfCashAndCashEquivalentsExplanatory
98	Disclosure of classes of share capital [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfClassesOfShareCapitalExplanatory
99	Disclosure of classes of share capital [line items]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfClassesOfShareCapitalLineItems
100	Disclosure of classes of share capital [table]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfClassesOfShareCapitalTable
101	Disclosure of commitments and contingent liabilities [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory
102	Disclosure of contingent liabilities [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfContingentLiabilitiesExplanatory
103	Deferred income	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfDeferredIncomeExplanatory
104	Retirement benefit plan [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfDefinedBenefitPlansAbstract
105	Disclosure of detailed information about property, plant and equipment [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
106	Disclosure of disaggregation of revenue from contracts with customers [abstract]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract
107	Disclosure of disaggregation of revenue from contracts with customers [line items]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
108	Disclosure of disaggregation of revenue from contracts with customers [table]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable
109	Disclosure of earnings per share [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfEarningsPerShareExplanatory
110	Disclosure of employee benefits [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfEmployeeBenefitsExplanatory
111	Disclosure of events after reporting period [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfEventsAfterReportingPeriodExplanatory
112	Disclosure of expenses [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfExpensesExplanatory
113	Disclosure of fair value of plan assets [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfFairValueOfPlanAssetsExplanatory
114	Financial Result, net	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfFinanceIncomeExpenseExplanatory
115	Financial Assets [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfFinancialAssetsAbstract
116	Disclosure of financial risk management [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfFinancialRiskManagementExplanatory
117	Disclosure of general and administrative expense [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfGeneralAndAdministrativeExpenseExplanatory
118	Income taxes	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfIncomeTaxExplanatory
119	Summary of significant accounting policies [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract
120	Financial instruments and risk management [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract
121	Disclosure of nature and extent of risks arising from financial instruments [line items]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems
122	Disclosure of nature and extent of risks arising from financial instruments [table]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable
123	Disclosure of net defined benefit liability (asset) [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory
124	Disclosure of net defined benefit liability (asset) [line items]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfNetDefinedBenefitLiabilityAssetLineItems
125	Disclosure of net defined benefit liability (asset) [table]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfNetDefinedBenefitLiabilityAssetTable
126	Disclosure of non-adjusting events after reporting period [abstract]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract
127	Disclosure of non-adjusting events after reporting period [line items]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems
128	Disclosure of non-adjusting events after reporting period [table]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfNonadjustingEventsAfterReportingPeriodTable
129	Disclosure of number and weighted average exercise prices of other equity instruments [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
130	Disclosure of number and weighted average exercise prices of share options [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
131	Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract
132	Capital risk management [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract
133	Disclosure of objectives, policies and processes for managing capital [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory
134	Disclosure of operating segments [abstract]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfOperatingSegmentsAbstract
135	Property, plant and equipment [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfPropertyPlantAndEquipmentAbstract
136	Disclosure of property, plant and equipment [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfPropertyPlantAndEquipmentExplanatory
137	Disclosure of detailed information about property, plant and equipment [line items]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfPropertyPlantAndEquipmentLineItems
138	Disclosure of detailed information about property, plant and equipment [table]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfPropertyPlantAndEquipmentTable
139	Disclosure of related party [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfRelatedPartyExplanatory
140	Disclosure of research and development expense [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfResearchAndDevelopmentExpenseExplanatory
141	Disclosure of restricted cash and cash equivalents [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfRestrictedCashAndCashEquivalentsExplanatory
142	Disclosure of revenue [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfRevenueExplanatory
143	Disclosure of sensitivity analysis for actuarial assumptions [abstract]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract
144	Disclosure of sensitivity analysis for actuarial assumptions [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory
145	Disclosure of sensitivity analysis for actuarial assumptions [line items]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems
146	Disclosure of sensitivity analysis for actuarial assumptions [table]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable
147	Disclosure of share capital, reserves and other equity interest [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
148	Disclosure of share-based payment arrangements [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfSharebasedPaymentArrangementsExplanatory
149	Disclosure of significant accounting policies [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory
150	Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract
151	Disclosure of temporary difference, unused tax losses and unused tax credits [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory
152	Disclosure of temporary difference, unused tax losses and unused tax credits [line items]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems
153	Disclosure of temporary difference, unused tax losses and unused tax credits [table]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable
154	Share-based compensation [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract
155	Disclosure of terms and conditions of share-based payment arrangement [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory
156	Disclosure of terms and conditions of share-based payment arrangement [line items]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
157	Disclosure of terms and conditions of share-based payment arrangement [table]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
158	Disclosure of trade and other payables [text block]	nonnum:textBlockItemType	duration			ifrs-full	DisclosureOfTradeAndOtherPayablesExplanatory
159	Related-party transactions [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfTransactionsBetweenRelatedPartiesAbstract
160	Disclosure of transactions between related parties [line items]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfTransactionsBetweenRelatedPartiesLineItems
161	Disclosure of transactions between related parties [table]	xbrli:stringItemType	duration		true	ifrs-full	DisclosureOfTransactionsBetweenRelatedPartiesTable
162	Dividends recognised as distributions to owners	xbrli:monetaryItemType	duration	debit		ifrs-full	DividendsPaid
163	Domestic defined benefit plans [member]	nonnum:domainItemType	duration		true	ifrs-full	DomesticDefinedBenefitPlansMember
164	Earnings per share [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	EarningsPerShareAbstract
165	Earnings per share [text block]	nonnum:textBlockItemType	duration			ifrs-full	EarningsPerShareExplanatory
166	Effect of exchange rate changes on cash and cash equivalents	xbrli:monetaryItemType	duration	debit		ifrs-full	EffectOfExchangeRateChangesOnCashAndCashEquivalents
167	Entity's total for related parties [member]	nonnum:domainItemType	duration		true	ifrs-full	EntitysTotalForRelatedPartiesMember
168	Equity	xbrli:monetaryItemType	instant	credit		ifrs-full	Equity
169	Shareholders' equity	xbrli:stringItemType	duration		true	ifrs-full	EquityAbstract
170	Equity and liabilities	xbrli:monetaryItemType	instant	credit		ifrs-full	EquityAndLiabilities
171	SHAREHOLDERS' EQUITY AND LIABILITIES	xbrli:stringItemType	duration		true	ifrs-full	EquityAndLiabilitiesAbstract
172	Equity [Member]	nonnum:domainItemType	duration		true	ifrs-full	EquityMember
173	Exercise price, share options granted	xbrli:monetaryItemType	duration			ifrs-full	ExercisePriceShareOptionsGranted
174	Expense from share-based payment transactions with employees	xbrli:monetaryItemType	duration	debit		ifrs-full	ExpenseFromSharebasedPaymentTransactionsWithEmployees
175	Finance costs paid, classified as operating activities	xbrli:monetaryItemType	duration	credit		ifrs-full	FinanceCostsPaidClassifiedAsOperatingActivities
176	Finance income / (expense), net	xbrli:monetaryItemType	duration	credit		ifrs-full	FinanceIncome
177	Finance income (cost)	xbrli:monetaryItemType	duration	credit		ifrs-full	FinanceIncomeCost
178	Finance income received, classified as operating activities	xbrli:monetaryItemType	duration	debit		ifrs-full	FinanceIncomeReceivedClassifiedAsOperatingActivities
179	Financial assets	xbrli:monetaryItemType	instant	debit		ifrs-full	FinancialAssets
180	Financial assets, category [member]	nonnum:domainItemType	duration		true	ifrs-full	FinancialAssetsCategoryMember
181	Financial liabilities	xbrli:monetaryItemType	instant	credit		ifrs-full	FinancialLiabilities
182	Financial liabilities, category [member]	nonnum:domainItemType	duration		true	ifrs-full	FinancialLiabilitiesCategoryMember
183	Furniture [Member]	nonnum:domainItemType	duration		true	ifrs-full	FixturesAndFittingsMember
184	Foreign exchange gain (loss)	xbrli:monetaryItemType	duration	credit		ifrs-full	GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
185	Acquisition Cost [Member]	nonnum:domainItemType	duration		true	ifrs-full	GrossCarryingAmountMember
186	Statements of Income / (Loss) [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	IncomeStatementAbstract
187	Tax expense (income), continuing operations	xbrli:monetaryItemType	duration	debit		ifrs-full	IncomeTaxExpenseContinuingOperations
188	Income tax relating to remeasurements of defined benefit plans of other comprehensive income	xbrli:monetaryItemType	duration	debit		ifrs-full	IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
189	Increase (decrease) in cash and cash equivalents	xbrli:monetaryItemType	duration	debit		ifrs-full	IncreaseDecreaseInCashAndCashEquivalents
190	Increase in tax losses available as an offset	xbrli:monetaryItemType	duration	credit		ifrs-full	IncreaseDecreaseInDeferredTaxLiabilityAsset
191	Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption	xbrli:monetaryItemType	instant	credit		ifrs-full	IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption
192	Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption	xbrli:monetaryItemType	instant	credit		ifrs-full	IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
193	Increase (decrease) in net defined benefit liability (asset)	xbrli:monetaryItemType	duration	credit		ifrs-full	IncreaseDecreaseInNetDefinedBenefitLiabilityAsset
194	Increase (decrease) in number of ordinary shares issued	xbrli:sharesItemType	duration			ifrs-full	IncreaseDecreaseInNumberOfOrdinarySharesIssued
195	Increase (decrease) through exercise of options, equity	xbrli:monetaryItemType	duration	credit		ifrs-full	IncreaseDecreaseThroughExerciseOfOptions
196	Increase (decrease) through share-based payment transactions, equity	xbrli:monetaryItemType	duration	credit		ifrs-full	IncreaseDecreaseThroughSharebasedPaymentTransactions
197	Incremental fair value granted, modified share-based payment arrangements	xbrli:monetaryItemType	duration			ifrs-full	IncrementalFairValueGrantedModifiedSharebasedPaymentArrangements
198	Interest expense	xbrli:monetaryItemType	duration	debit		ifrs-full	InterestExpense
199	Interest income/ (expense)	xbrli:monetaryItemType	duration	credit		ifrs-full	InterestRevenueExpense
200	Issued capital	xbrli:monetaryItemType	instant	credit		ifrs-full	IssuedCapital
201	Issued capital [member]	nonnum:domainItemType	duration		true	ifrs-full	IssuedCapitalMember
202	Key management personnel compensation	xbrli:monetaryItemType	duration	debit		ifrs-full	KeyManagementPersonnelCompensation
203	Post-employment benefits	xbrli:monetaryItemType	duration	debit		ifrs-full	KeyManagementPersonnelCompensationPostemploymentBenefits
204	Share-based compensation	xbrli:monetaryItemType	duration	debit		ifrs-full	KeyManagementPersonnelCompensationSharebasedPayment
205	Short-term employee benefits	xbrli:monetaryItemType	duration	debit		ifrs-full	KeyManagementPersonnelCompensationShorttermEmployeeBenefits
206	Executives and Directors [Member]	nonnum:domainItemType	duration		true	ifrs-full	KeyManagementPersonnelOfEntityOrParentMember
207	More Than Five Years [Member]	nonnum:domainItemType	duration		true	ifrs-full	LaterThanFiveYearsMember
208	Later than four years and not later than five years [member]	nonnum:domainItemType	duration		true	ifrs-full	LaterThanFourYearsAndNotLaterThanFiveYearsMember
209	Between One and Three Years [Member]	nonnum:domainItemType	duration		true	ifrs-full	LaterThanOneYearAndNotLaterThanThreeYearsMember
210	Later than one year and not later than two years [member]	nonnum:domainItemType	duration		true	ifrs-full	LaterThanOneYearAndNotLaterThanTwoYearsMember
211	Between Three and Five Years [Member]	nonnum:domainItemType	duration		true	ifrs-full	LaterThanThreeYearsAndNotLaterThanFiveYearsMember
212	Later than three years and not later than four years [member]	nonnum:domainItemType	duration		true	ifrs-full	LaterThanThreeYearsAndNotLaterThanFourYearsMember
213	Later than two years and not later than three years [member]	nonnum:domainItemType	duration		true	ifrs-full	LaterThanTwoYearsAndNotLaterThanThreeYearsMember
214	Lease liabilities	xbrli:monetaryItemType	instant	credit		ifrs-full	LeaseLiabilities
215	Leasehold Improvements [Member]	nonnum:domainItemType	duration		true	ifrs-full	LeaseholdImprovementsMember
216	Liabilities	xbrli:monetaryItemType	instant	credit		ifrs-full	Liabilities
217	Net defined benefit liability (asset)	xbrli:monetaryItemType	instant	credit		ifrs-full	LiabilityAssetOfDefinedBenefitPlans
218	Liquidity risk [member]	nonnum:domainItemType	duration		true	ifrs-full	LiquidityRiskMember
219	Income taxes [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	MajorComponentsOfTaxExpenseIncomeAbstract
220	Major purchases of assets [member]	nonnum:domainItemType	duration		true	ifrs-full	MajorPurchasesOfAssetsMember
221	Maturity [axis]	xbrli:stringItemType	duration		true	ifrs-full	MaturityAxis
222	Net defined benefit liability (asset) [axis]	xbrli:stringItemType	duration		true	ifrs-full	NetDefinedBenefitLiabilityAssetAxis
223	Net defined benefit liability (asset) [member]	nonnum:domainItemType	duration		true	ifrs-full	NetDefinedBenefitLiabilityAssetMember
224	Non-adjusting events after reporting period [axis]	xbrli:stringItemType	duration		true	ifrs-full	NonadjustingEventsAfterReportingPeriodAxis
225	Non-adjusting events after reporting period [member]	nonnum:domainItemType	duration		true	ifrs-full	NonadjustingEventsMember
226	Non-current assets	xbrli:monetaryItemType	instant	debit		ifrs-full	NoncurrentAssets
227	Non-current assets [abstract]	xbrli:stringItemType	duration		true	ifrs-full	NoncurrentAssetsAbstract
228	Non-current financial liabilities	xbrli:monetaryItemType	instant	credit		ifrs-full	NoncurrentFinancialLiabilities
229	Non-current interest payable	xbrli:monetaryItemType	instant	credit		ifrs-full	NoncurrentInterestPayable
230	Non-current liabilities	xbrli:monetaryItemType	instant	credit		ifrs-full	NoncurrentLiabilities
231	Non-current liabilities [abstract]	xbrli:stringItemType	duration		true	ifrs-full	NoncurrentLiabilitiesAbstract
232	Non-current provisions for employee benefits	xbrli:monetaryItemType	instant	credit		ifrs-full	NoncurrentProvisionsForEmployeeBenefits
233	Deposits in escrow accounts	xbrli:monetaryItemType	instant	debit		ifrs-full	NoncurrentRestrictedCashAndCashEquivalents
234	Loss Expiry, December 31, 2017 [Member]	nonnum:domainItemType	duration		true	ifrs-full	NotLaterThanOneYearMember
235	Number of restricted shares granted (in shares)	xbrli:decimalItemType	duration			ifrs-full	NumberOfInstrumentsOtherEquityInstrumentsGranted
236	Shares vested (in shares)	xbrli:decimalItemType	duration			ifrs-full	NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
237	Cancelled during the year (in shares)	xbrli:decimalItemType	duration			ifrs-full	NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement
238	Number of other equity instruments forfeited in share-based payment arrangement	xbrli:decimalItemType	duration			ifrs-full	NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
239	Number of other equity instruments outstanding in share-based payment arrangement	xbrli:decimalItemType	instant			ifrs-full	NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
240	Number of share options outstanding in share-based payment arrangement	xbrli:decimalItemType	instant			ifrs-full	NumberOfOutstandingShareOptions
241	Number of share options exercisable in share-based payment arrangement	xbrli:decimalItemType	instant			ifrs-full	NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
242	Number of share options exercised in share-based payment arrangement	xbrli:decimalItemType	duration			ifrs-full	NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
243	Number of share options expired in share-based payment arrangement	xbrli:decimalItemType	duration			ifrs-full	NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
244	Number of share options forfeited in share-based payment arrangement	xbrli:decimalItemType	duration			ifrs-full	NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
245	Granted during the year (in shares)	xbrli:decimalItemType	duration			ifrs-full	NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
246	Issuance of shares:	xbrli:stringItemType	duration		true	ifrs-full	NumberOfSharesIssuedAbstract
247	Number of shares outstanding	xbrli:sharesItemType	instant			ifrs-full	NumberOfSharesOutstanding
248	Operating expense	xbrli:monetaryItemType	duration	debit		ifrs-full	OperatingExpense
249	Ordinary shares [member]	nonnum:domainItemType	duration		true	ifrs-full	OrdinarySharesMember
250	Other comprehensive income	xbrli:monetaryItemType	duration	credit		ifrs-full	OtherComprehensiveIncome
251	Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	xbrli:monetaryItemType	duration	credit		ifrs-full	OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
252	Other current liabilities	xbrli:monetaryItemType	instant	credit		ifrs-full	OtherCurrentLiabilities
253	Other current receivables	xbrli:monetaryItemType	instant	debit		ifrs-full	OtherCurrentReceivables
254	Other finance income/(expense)	xbrli:monetaryItemType	duration	credit		ifrs-full	OtherFinanceIncomeCost
255	Par value per share	num:perShareItemType	instant			ifrs-full	ParValuePerShare
256	Payments for share issue costs	xbrli:monetaryItemType	duration	credit		ifrs-full	PaymentsForShareIssueCosts
257	Payments from plan, net defined benefit liability (asset)	xbrli:monetaryItemType	duration	debit		ifrs-full	PaymentsFromPlanNetDefinedBenefitLiabilityAsset
258	Percentage of reasonably possible decrease in actuarial assumption	num:percentItemType	instant			ifrs-full	PercentageOfReasonablyPossibleDecreaseInActuarialAssumption
259	Percentage of reasonably possible increase in actuarial assumption	num:percentItemType	instant			ifrs-full	PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
260	Plan assets, at fair value	xbrli:monetaryItemType	instant	debit		ifrs-full	PlanAssetsAtFairValue
261	Plan assets [member]	nonnum:domainItemType	duration		true	ifrs-full	PlanAssetsMember
262	Post-employment benefit expense, defined benefit plans	xbrli:monetaryItemType	duration	debit		ifrs-full	PostemploymentBenefitExpenseDefinedBenefitPlans
263	Preference shares [member]	nonnum:domainItemType	duration		true	ifrs-full	PreferenceSharesMember
264	Prepaid expenses and accrued income [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	PrepaymentsAndAccruedIncomeAbstract
265	Present value of defined benefit obligation [member]	nonnum:domainItemType	duration		true	ifrs-full	PresentValueOfDefinedBenefitObligationMember
266	Proceeds from long-term debt	xbrli:monetaryItemType	duration	debit		ifrs-full	ProceedsFromBorrowingsClassifiedAsFinancingActivities
267	Proceeds from exercise of options	xbrli:monetaryItemType	duration	debit		ifrs-full	ProceedsFromExerciseOfOptions
268	Proceeds from issue of ordinary shares	xbrli:monetaryItemType	duration	debit		ifrs-full	ProceedsFromIssueOfOrdinaryShares
269	Private placement extension financing	xbrli:monetaryItemType	duration	debit		ifrs-full	ProceedsFromIssueOfPreferenceShares
270	Products and services [axis]	xbrli:stringItemType	duration		true	ifrs-full	ProductsAndServicesAxis
271	Products and services [member]	nonnum:domainItemType	duration		true	ifrs-full	ProductsAndServicesMember
272	Net income / (loss) for the period	xbrli:monetaryItemType	duration	credit		ifrs-full	ProfitLoss
273	Profit (loss), attributable to ordinary equity holders of parent entity [abstract]	xbrli:stringItemType	duration		true	ifrs-full	ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract
274	Profit (loss) before tax	xbrli:monetaryItemType	duration	credit		ifrs-full	ProfitLossBeforeTax
275	Profit (loss) from operating activities	xbrli:monetaryItemType	duration	credit		ifrs-full	ProfitLossFromOperatingActivities
276	Property, plant and equipment	xbrli:monetaryItemType	instant	debit		ifrs-full	PropertyPlantAndEquipment
277	Property, plant and equipment [member]	nonnum:domainItemType	duration		true	ifrs-full	PropertyPlantAndEquipmentMember
278	Provisions	xbrli:monetaryItemType	instant	credit		ifrs-full	Provisions
279	Purchase of property, plant and equipment, classified as investing activities	xbrli:monetaryItemType	duration	credit		ifrs-full	PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
280	Range [axis]	xbrli:stringItemType	duration		true	ifrs-full	RangeAxis
281	Ranges [member]	nonnum:domainItemType	duration		true	ifrs-full	RangesMember
282	Reconciliation of accounting profit multiplied by applicable tax rates [abstract]	xbrli:stringItemType	duration		true	ifrs-full	ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract
283	Reconciliation of changes in property, plant and equipment [abstract]	xbrli:stringItemType	duration		true	ifrs-full	ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract
284	Rental expense	xbrli:monetaryItemType	duration	debit		ifrs-full	RentalExpense
285	Research and development expense	xbrli:monetaryItemType	duration	debit		ifrs-full	ResearchAndDevelopmentExpense
286	Retained earnings	xbrli:monetaryItemType	instant	credit		ifrs-full	RetainedEarnings
287	Retained earnings [member]	nonnum:domainItemType	duration		true	ifrs-full	RetainedEarningsMember
288	Return on plan assets, net defined benefit liability (asset)	xbrli:monetaryItemType	duration	debit		ifrs-full	ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
289	Revenue	xbrli:monetaryItemType	duration	credit		ifrs-full	Revenue
290	Revenues [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	RevenueAbstract
291	Revenue from contracts with customers	xbrli:monetaryItemType	duration	credit		ifrs-full	RevenueFromContractsWithCustomers
292	Interest income	xbrli:monetaryItemType	duration	credit		ifrs-full	RevenueFromInterest
293	Selling, general and administrative expense	xbrli:monetaryItemType	duration	debit		ifrs-full	SellingGeneralAndAdministrativeExpense
294	Share issue related cost	xbrli:monetaryItemType	duration	debit		ifrs-full	ShareIssueRelatedCost
295	Share premium	xbrli:monetaryItemType	instant	credit		ifrs-full	SharePremium
296	Share Premium [Member]	nonnum:domainItemType	duration		true	ifrs-full	SharePremiumMember
297	Share-based payment arrangements [member]	nonnum:domainItemType	duration		true	ifrs-full	SharebasedPaymentArrangementsMember
298	Statements of Cash Flows [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	StatementOfCashFlowsAbstract
299	Statements of Changes in Equity [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	StatementOfChangesInEquityAbstract
300	Statement of changes in equity [line items]	xbrli:stringItemType	duration		true	ifrs-full	StatementOfChangesInEquityLineItems
301	Statement of changes in equity [table]	xbrli:stringItemType	duration		true	ifrs-full	StatementOfChangesInEquityTable
302	Statements of Comprehensive Income / (Loss) [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	StatementOfComprehensiveIncomeAbstract
303	Balance Sheets [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	StatementOfFinancialPositionAbstract
304	Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense	xbrli:monetaryItemType	duration	credit		ifrs-full	TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense
305	Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce deferred tax expense	xbrli:monetaryItemType	duration	credit		ifrs-full	TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense
306	Tax effect of revenues exempt from taxation	xbrli:monetaryItemType	duration	credit		ifrs-full	TaxEffectOfRevenuesExemptFromTaxation2011
307	Tax expense / (benefit) calculated at the statutory rate of 20.5% (21% for 2016 and 22% for 2015)	xbrli:monetaryItemType	duration	debit		ifrs-full	TaxExpenseIncomeAtApplicableTaxRate
308	Temporary difference, unused tax losses and unused tax credits [axis]	xbrli:stringItemType	duration		true	ifrs-full	TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis
309	Temporary difference, unused tax losses and unused tax credits [member]	nonnum:domainItemType	duration		true	ifrs-full	TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember
310	Top of range [member]	nonnum:domainItemType	duration		true	ifrs-full	TopOfRangeMember
311	Trade and other current payables	xbrli:monetaryItemType	instant	credit		ifrs-full	TradeAndOtherCurrentPayables
312	Trade payables and accrued liabilities [Abstract]	xbrli:stringItemType	duration		true	ifrs-full	TradeAndOtherCurrentPayablesAbstract
313	Trade and other receivables [abstract]	xbrli:stringItemType	duration		true	ifrs-full	TradeAndOtherReceivablesAbstract
314	Types of contracts [axis]	xbrli:stringItemType	duration		true	ifrs-full	TypesOfContractsAxis
315	Types of contracts [member]	nonnum:domainItemType	duration		true	ifrs-full	TypesOfContractsMember
316	Types of risks [axis]	xbrli:stringItemType	duration		true	ifrs-full	TypesOfRisksAxis
317	Risks [member]	nonnum:domainItemType	duration		true	ifrs-full	TypesOfRisksMember
318	Types of share-based payment arrangements [axis]	xbrli:stringItemType	duration		true	ifrs-full	TypesOfSharebasedPaymentArrangementsAxis
319	Unused tax credits [member]	nonnum:domainItemType	duration		true	ifrs-full	UnusedTaxCreditsMember
320	Unused tax losses for which no deferred tax asset recognised	xbrli:monetaryItemType	instant			ifrs-full	UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
321	Unused tax losses [member]	nonnum:domainItemType	duration		true	ifrs-full	UnusedTaxLossesMember
322	Useful lives or depreciation rates, property, plant and equipment	xbrli:stringItemType	duration			ifrs-full	UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment
323	Weighted average duration of defined benefit obligation	xbrli:decimalItemType	duration			ifrs-full	WeightedAverageDurationOfDefinedBenefitObligation
324	Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement	xbrli:monetaryItemType	duration			ifrs-full	WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
325	Weighted average exercise price of other equity instruments expired in share-based payment arrangement	xbrli:monetaryItemType	duration			ifrs-full	WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement
326	Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement	xbrli:monetaryItemType	duration			ifrs-full	WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
327	Weighted average exercise price of other equity instruments granted in share-based payment arrangement	xbrli:monetaryItemType	duration			ifrs-full	WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement
328	Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement	xbrli:monetaryItemType	instant			ifrs-full	WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
329	Weighted average exercise price of share options exercisable in share-based payment arrangement	xbrli:monetaryItemType	instant			ifrs-full	WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement
330	Exercised during the year (in CHF per share)	xbrli:monetaryItemType	duration			ifrs-full	WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement
331	Cancelled during the year (in CHF per share)	xbrli:monetaryItemType	duration			ifrs-full	WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement
332	Forfeited during the year (in CHF per share)	xbrli:monetaryItemType	duration			ifrs-full	WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement
333	Granted during the year (in CHF per share)	xbrli:monetaryItemType	duration			ifrs-full	WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement
334	Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise	xbrli:monetaryItemType	duration			ifrs-full	WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise
335	Weighted average exercise price of share options outstanding in share-based payment arrangement	xbrli:monetaryItemType	instant			ifrs-full	WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement
336	Weighted average fair value at measurement date, share options granted	xbrli:monetaryItemType	instant	credit		ifrs-full	WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
337	Weighted average remaining contractual life of outstanding share options	xbrli:decimalItemType	instant			ifrs-full	WeightedAverageRemainingContractualLifeOfOutstandingShareOptions
338	Weighted average share price	xbrli:monetaryItemType	duration			ifrs-full	WeightedAverageSharePrice
339	Weighted average share price, share options granted	xbrli:monetaryItemType	duration			ifrs-full	WeightedAverageSharePriceShareOptionsGranted
340	Weighted average number of ordinary shares outstanding	xbrli:sharesItemType	duration			ifrs-full	WeightedAverageShares
341	Amendment Flag	xbrli:booleanItemType	duration			dei	AmendmentFlag
342	Current Fiscal Year End Date	xbrli:gMonthDayItemType	duration			dei	CurrentFiscalYearEndDate
343	Document Period End Date	xbrli:dateItemType	duration			dei	DocumentPeriodEndDate
344	Entity [Domain]	nonnum:domainItemType	duration		true	dei	EntityDomain
345	Entity Well-known Seasoned Issuer	dei:yesNoItemType	duration			dei	EntityWellKnownSeasonedIssuer
346	Entity Voluntary Filers	dei:yesNoItemType	duration			dei	EntityVoluntaryFilers
347	Entity Current Reporting Status	dei:yesNoItemType	duration			dei	EntityCurrentReportingStatus
348	Entity Filer Category	dei:filerCategoryItemType	duration			dei	EntityFilerCategory
349	Entity Public Float	xbrli:monetaryItemType	instant	credit		dei	EntityPublicFloat
350	Entity Registrant Name	xbrli:normalizedStringItemType	duration			dei	EntityRegistrantName
351	Entity Central Index Key	dei:centralIndexKeyItemType	duration			dei	EntityCentralIndexKey
352	Entity Common Stock, Shares Outstanding	xbrli:sharesItemType	instant			dei	EntityCommonStockSharesOutstanding
353	Document Fiscal Year Focus	xbrli:gYearItemType	duration			dei	DocumentFiscalYearFocus
354	Document Fiscal Period Focus	dei:fiscalPeriodItemType	duration			dei	DocumentFiscalPeriodFocus
355	Legal Entity [Axis]	xbrli:stringItemType	duration		true	dei	LegalEntityAxis
356	Document Type	dei:submissionTypeItemType	duration			dei	DocumentType
357	Switzerland, Francs	nonnum:domainItemType	duration		true	currency	CHF
358	Euro Member Countries, Euro	nonnum:domainItemType	duration		true	currency	EUR
359	United States of America, Dollars	nonnum:domainItemType	duration		true	currency	USD
360	All Currencies [Domain]	nonnum:domainItemType	duration		true	currency	AllCurrenciesDomain
361	Document and Entity Information [Abstract]	xbrli:stringItemType	duration		true	aciu	DocumentAndEntityInformationAbstract
362	Current accrued income and grant receivables	xbrli:monetaryItemType	instant	debit	false	aciu	CurrentAccruedIncomeAndGrantReceivables The amount of current accrued income and grant receivables.
363	Current receivables classified as other and value added and withholding taxes	xbrli:monetaryItemType	instant	debit	false	aciu	CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes The amount of current other receivables and receivables from value added taxes and withholding taxes.
364	Expenses, Operating [Abstract]	xbrli:stringItemType	duration		true	aciu	ExpensesOperatingAbstract
365	Proceeds from issuing shares, net of underwriting fees	xbrli:monetaryItemType	duration	debit	false	aciu	ProceedsFromIssuingSharesNetOfUnderwritingFees The cash inflow from issuing ordinary shares net of underwriting fees.
366	Issue of Equity, Restricted Share Awards	xbrli:monetaryItemType	duration	credit	false	aciu	IssueOfEquityRestrictedShareAwards The increase in equity through the issue of restricted share awards.
367	Issue of equity, preference shares, series E	xbrli:monetaryItemType	duration	credit	false	aciu	IssueOfEquityPreferenceSharesSeriesE The increase in equity through the issue of series E preference equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim.
368	Issue of equity, extension preference shares, series E	xbrli:monetaryItemType	duration	credit	false	aciu	IssueOfEquityExtensionPreferenceSharesSeriesE The increase in equity through the issue of series E extension preference equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim.
369	Changes in working capital [Abstract]	xbrli:stringItemType	duration		true	aciu	ChangesInWorkingCapitalAbstract
370	Adjustments for decrease (increase) in prepaid expense	xbrli:monetaryItemType	duration	credit	false	aciu	AdjustmentsForDecreaseIncreaseInPrepaidExpense Adjustments for decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.
371	Adjustments for decrease (increase) in accrued income	xbrli:monetaryItemType	duration	debit	false	aciu	AdjustmentsForDecreaseIncreaseInAccruedIncome Adjustments for decrease (increase) in accrued income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]
372	Adjustments for increase (decrease) in accrued expenses	xbrli:monetaryItemType	duration	credit	false	aciu	AdjustmentsForIncreaseDecreaseInAccruedExpenses Adjustments for increase (decrease) in accrued expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.
373	Proceeds from loan repayments	xbrli:monetaryItemType	duration	debit	false	aciu	ProceedsFromLoanRepayments The cash inflow from repayments to settle amounts loaned, classified as financing activities.
374	Adjustments for Accrued Interest Payable	xbrli:monetaryItemType	duration	debit	false	aciu	AdjustmentsForAccruedInterestPayable Adjustments for increase (decrease) in interest payable, to reconcile profit (loss) to net cash flow from (used in) operating activities.
375	Adjustments for Increase (Decrease) Long-term Financial Liabilities	xbrli:monetaryItemType	duration	credit	false	aciu	AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities Adjustments for increase (decrease) in long-term financial liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.
376	Cash Advances for Rent Deposit	xbrli:monetaryItemType	duration	credit	false	aciu	CashAdvancesForRentDeposit The cash outflow for deposit of rent.
377	Post balance sheet events [Abstract]	xbrli:stringItemType	duration		true	aciu	PostBalanceSheetEventsAbstract
378	Long term financing obligation [Abstract]	xbrli:stringItemType	duration		true	aciu	LongTermFinancingObligationAbstract
379	Disclosure of Long term financing obligation [Text Block]	nonnum:textBlockItemType	duration		false	aciu	DisclosureOfLongTermFinancingObligationTextBlock The disclosure of long term financing obligations.
380	Long term financing obligation [Table]	xbrli:stringItemType	duration		true	aciu	LongTermFinancingObligationTable Schedule disclosing information related to details of long term financing obligations.
381	Grants, LuMind Research Down Syndrome Foundation [Member]	nonnum:domainItemType	duration		true	aciu	GrantsLuMindResearchDownSyndromeFoundationMember Funding provided for certain types of expenditures in connection with research and development activities over a contractually-defined period from the LuMind Research Down Syndrome Foundation.
382	Long term financing obligation [Line Items]	xbrli:stringItemType	duration		true	aciu	LongTermFinancingObligationLineItems Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.
383	Reimbursement percentage of funding commitment.	num:percentItemType	duration		false	aciu	ReimbursementPercentageOfFundingCommitment The percentage of funding commitment amount required to be reimbursed as per a research grant agreement of which the amount includes the entire funding commitment plus an additional upcharge.
384	Funding commitment	xbrli:monetaryItemType	instant	credit	false	aciu	FundingCommitment The amount of contractual commitments for funding research grants.
385	Actuarial losses (gains) arising from changes in benefit plan, net defined benefit liability (asset)	xbrli:monetaryItemType	duration	debit	false	aciu	ActuarialLossesGainsArisingFromChangesInBenefitPlanNetDefinedBenefitLiabilityAsset The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in the substantive terms of an existing defined benefit plan or the initiation of a new plan.
386	Actuarial gains (losses) arising from changes in other assumptions, net defined benefit liability (asset)	xbrli:monetaryItemType	duration	debit	false	aciu	ActuarialGainsLossesArisingFromChangesInOtherAssumptionsNetDefinedBenefitLiabilityAsset The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in other assumptions that result in remeasurements of the net defined benefit liability (asset).
387	Interest cost, net defined benefit liability (asset)	xbrli:monetaryItemType	duration	credit	false	aciu	InterestCostNetDefinedBenefitLiabilityAsset The decrease in the net defined benefit liability (asset) resulting from interest costs resulting from the passage of time.
388	Defined benefits plan, Employee [Member]	nonnum:domainItemType	duration		true	aciu	DefinedBenefitsPlanEmployeeMember This member stands for the employee portion of a domestic defined benefit plan.
389	Defined benefits plan, Employer [Member]	nonnum:domainItemType	duration		true	aciu	DefinedBenefitsPlanEmployerMember This member stands for the employee portion of a domestic defined benefit plan.
390	Defined benefit pension plan amount recognized in balance sheet [Abstract]	xbrli:stringItemType	duration		true	aciu	DefinedBenefitPensionPlanAmountRecognizedInBalanceSheetAbstract
391	Net pension cost in statement of income [Abstract]	xbrli:stringItemType	duration		true	aciu	NetPensionCostInStatementOfIncomeAbstract
392	Defined benefit plan, percentage of contribution	num:percentItemType	duration		false	aciu	DefinedBenefitPlanPercentageOfContribution The contributions paid to the plan are computed as a percentage of salary, adjusted for the age of the employee.
393	Interest income, net defined benefit liability (asset)	xbrli:monetaryItemType	duration	debit	false	aciu	InterestIncomeNetDefinedBenefitLiabilityAsset The increase in the net defined benefit liability (asset) resulting from the passage of time.
394	Issued Actuarial Tables, Switzerland	xbrli:stringItemType	duration		false	aciu	IssuedActuarialTablesSwitzerland Published actuarial tables that detail assumptions about mortality and disability rates which are used to determine benefit obligations for defined benefit plans.
395	Sensitivity analysis, actuarial assumptions [Abstract]	xbrli:stringItemType	duration		true	aciu	SensitivityAnalysisActuarialAssumptionsAbstract
396	Percentage of reasonably possible increase in actuarial assumption [Member]	nonnum:domainItemType	duration		true	aciu	PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation.
397	Percentage of reasonably possible decrease in actuarial assumption [Member]	nonnum:domainItemType	duration		true	aciu	PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation.
398	Change in net defined benefit liability [Abstract]	xbrli:stringItemType	duration		true	aciu	ChangeInNetDefinedBenefitLiabilityAbstract
399	Number of escrow deposit accounts	xbrli:integerItemType	duration		false	aciu	NumberOfEscrowDepositAccounts The number of escrow accounts with cash deposits of the entity.
400	Laboratory equipment [Member]	nonnum:domainItemType	duration		true	aciu	LaboratoryEquipmentMember This member stands for a class of property, plant and equipment representing laboratory equipment.
401	Disclosure of prepaid expenses and accrued income [Text Block]	nonnum:textBlockItemType	duration		false	aciu	DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock The disclosure of prepayments and accrued income.
402	Disclosure of detailed information about prepaid expenses and accrued income [Table Text Block]	nonnum:textBlockItemType	duration		false	aciu	DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock The disclosure of detailed information about prepaid expenses and accrued income.
403	Prepaid Expenses and Accrued Income [Table]	xbrli:stringItemType	duration		true	aciu	PrepaidExpensesAndAccruedIncomeTable Schedule disclosing information related to details of Prepaid expenses and accrued income.
404	Prepaid Expenses and Accrued Income [Line Items]	xbrli:stringItemType	duration		true	aciu	PrepaidExpensesAndAccruedIncomeLineItems Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.
405	Collaboration agreement of 2016, Biogen [Member]	nonnum:domainItemType	duration		true	aciu	CollaborationAgreementOf2016BiogenMember The 2016 contractual research agreement associated with collaboration with Biogen.
406	Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]	nonnum:domainItemType	duration		true	aciu	CollaborationAgreementOf2014JanssenPharmaceuticalsMember The 2014 contractual research agreement associated with collaboration with Janssen Pharmaceuticals.
407	Changes in fair value of plan assets [Abstract]	xbrli:stringItemType	duration		true	aciu	ChangesInFairValueOfPlanAssetsAbstract
408	Additional lease space	num:areaItemType	duration		false	aciu	AdditionalLeaseSpace The additional lease area to expand premises under lease contract.
409	Purchase of lab equipment	xbrli:monetaryItemType	duration	debit	false	aciu	PurchaseOfLabEquipment The amount agreed to purchase previous tenant's lab equipment under lease contract.
410	Reportable segments, number	xbrli:integerItemType	duration		false	aciu	ReportableSegmentsNumber Number of reportable segments reported by the entity.
411	Operating segments, number	xbrli:integerItemType	duration		false	aciu	OperatingSegmentsNumber Number of operating segments reported by the entity.
412	Income tax loss, Carryforward period	xbrli:durationItemType	duration		false	aciu	IncomeTaxLossCarryforwardPeriod The period or time limit over which financial losses of the entity for preceding years can be deducted from the taxable revenue for a period.
413	Description of accounting policy for accounting judgments and estimates [Policy Text Block]	nonnum:textBlockItemType	duration		false	aciu	DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock The description of the entity's accounting policy for judgments that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognized in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year.
414	Disclosure of accounting policy for changes in accounting policies not yet adopted [Policy Text Block]	nonnum:textBlockItemType	duration		false	aciu	DisclosureOfAccountingPolicyForChangesInAccountingPoliciesNotYetAdoptedPolicyTextBlock The description of the entity's accounting policy for changes to accounting policies not yet adopted by the entity.
415	Description of accounting policy for classification of assets and liabilities [Policy Text Block]	nonnum:textBlockItemType	duration		false	aciu	DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock The description of the entity's accounting policy for the basis for how the entity classifies assets and liabilities as current and non-current.
416	Financial assets and liabilities [Policy Text Block]	nonnum:textBlockItemType	duration		false	aciu	FinancialAssetsAndLiabilitiesPolicyTextBlock The description of the entity's accounting policy for financial assets and liabilities.
417	Commitments and contingencies [Abstract]	xbrli:stringItemType	duration		true	aciu	CommitmentsAndContingenciesAbstract
418	Weighted average number of equity awards outstanding,	xbrli:sharesItemType	duration		false	aciu	WeightedAverageNumberOfEquityAwardsOutstanding The number of equity awards outstanding during the period multiplied by a time-weighting factor.
419	Disclosure of information about commitments and contingencies [Table]	xbrli:stringItemType	duration		true	aciu	DisclosureOfInformationAboutCommitmentsAndContingenciesTable Schedule of disclosing information related to commitments and contingencies.
420	Disclosure of information about commitments and contingencies [Line Items]	xbrli:stringItemType	duration		true	aciu	DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.
421	Commitments [Abstract]	xbrli:stringItemType	duration		true	aciu	CommitmentsAbstract
422	Rental contract, period for notice of cancellation	xbrli:durationItemType	duration		false	aciu	RentalContractPeriodForNoticeOfCancellation The period of time required by the lessee in a lease agreement to provide notice of cancellation of a lease to the lessor.
423	Provisions, research contracts	xbrli:monetaryItemType	instant	credit	false	aciu	ProvisionsResearchContracts The amount of provisions for research contracts with external providers.
424	Provision, royalty obligation	xbrli:monetaryItemType	instant	credit	false	aciu	ProvisionRoyaltyObligation The amount of provision for contractual obligations requiring payment of royalties to a third party.
425	Schedule of information about property, plant and equipment useful life [Table Text Block]	nonnum:textBlockItemType	duration		false	aciu	ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock The disclosure of detailed information about the useful life of property, plant and equipment.
426	Residual value over its estimated useful life [Abstract]	xbrli:stringItemType	duration		true	aciu	ResidualValueOverItsEstimatedUsefulLifeAbstract
427	Leasehold improvements and fixtures and fittings [Member]	nonnum:domainItemType	duration		true	aciu	LeaseholdImprovementsAndFixturesAndFittingsMember This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement and fixtures and fittings that are not permanently attached to real property.
428	Disclosure of detailed information about carrying amounts of financial assets and financial liabilities [Table Text Block]	nonnum:textBlockItemType	duration		false	aciu	DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock The disclosure of detailed information about carrying amounts of financial assets and financial liabilities.
429	Basis of preparation [Abstract]	xbrli:stringItemType	duration		true	aciu	BasisOfPreparationAbstract
430	Preference shares, Series E [Member]	nonnum:domainItemType	duration		true	aciu	PreferenceSharesSeriesEMember This member stands for series E equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]
431	Initial Public Offering [Member]	nonnum:domainItemType	duration		true	aciu	InitialPublicOfferingMember This member represents the equity instruments that are the first or initial sale of equity shares by a private company to the public.
432	Disclosure of going concern [Table]	xbrli:stringItemType	duration		true	aciu	DisclosureOfGoingConcernTable Schedule disclosing information related to the entity's ability to continue as a going concern.
433	Disclosure of classes of going concern [Line Items]	xbrli:stringItemType	duration		true	aciu	DisclosureOfClassesOfGoingConcernLineItems Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.
434	Genentech [Member]	nonnum:domainItemType	duration		true	aciu	GenentechMember A biotechnology company that develops medicines.
435	Janssen Pharmaceuticals [Member]	nonnum:domainItemType	duration		true	aciu	JanssenPharmaceuticalsMember A pharmaceutical company.
436	Going Concern [Abstract]	xbrli:stringItemType	duration		true	aciu	GoingConcernAbstract
437	Collaborative arrangements, milestone payment received	xbrli:monetaryItemType	duration	debit	false	aciu	CollaborativeArrangementsMilestonePaymentReceived The cash inflow from milestone payments from collaborative arrangements with third parities.
438	Preferred Shares [Abstract]	xbrli:stringItemType	duration		true	aciu	PreferredSharesAbstract
439	Voting rights, number of votes per share held	xbrli:integerItemType	duration		false	aciu	VotingRightsNumberOfVotesPerShareHeld The number of voting rights entitled to a share holder for each share owned. For example, one vote for one share owned, or two votes for one share owned.
440	Convertible shares, conversion ratio	xbrli:pureItemType	duration		false	aciu	ConvertibleSharesConversionRatio The ratio applied to the conversion of one class of stock convertible to another class of stock. For example one preferred share can be converted to one common share or one preferred share can be converted to two common shares.
441	Stock split conversion ratio	xbrli:pureItemType	duration		false	aciu	StockSplitConversionRatio The ratio applied to the conversion of a stock split. For example, one share converted to two shares or one share converted to four shares.
442	Share Price, Private Placement, Sale of Stock	num:perShareItemType	instant		false	aciu	SharePricePrivatePlacementSaleOfStock Price per share received for common stock issued or sold in a private placement transaction.
443	Number of capital increases	xbrli:integerItemType	duration		false	aciu	NumberOfCapitalIncreases The number of equity transactions with owners of the entity to increase the capital of the entity.
444	Increase (decrease) in number of preferred shares issued	xbrli:sharesItemType	duration		false	aciu	IncreaseDecreaseInNumberOfPreferredSharesIssued The increase (decrease) in the number of preferred shares issued.
445	Term of equity financing, preferred stock	xbrli:durationItemType	duration		false	aciu	TermOfEquityFinancingPreferredStock The term over which preferred shares have been the primary source of equity financing.
446	Share subscription amount	xbrli:monetaryItemType	instant	credit	false	aciu	ShareSubscriptionAmount The nominal value of subscription shares.
447	Number of classes of preferred stock outstanding	xbrli:integerItemType	duration		false	aciu	NumberOfClassesOfPreferredStock The number of classes of the entity's preferred stock outstanding.
448	Percentage of shares outstanding held by preference stock owners	num:percentItemType	duration		false	aciu	PercentageOfSharesOutstandingHeldByPreferenceStockOwners The percentage of outstanding common shares of the entity held by preferred stock owners.
449	Financial assets and liabilities [Abstract]	xbrli:stringItemType	duration		true	aciu	FinancialAssetsAndLiabilitiesAbstract
450	Financial risks [Abstract]	xbrli:stringItemType	duration		true	aciu	FinancialRisksAbstract
451	Closing foreign exchange rate, increase	num:percentItemType	instant		false	aciu	ClosingForeignExchangeRateIncrease The percentage increase to spot exchange rate at the end of the reporting period.
452	Closing foreign exchange rate, decrease	num:percentItemType	instant		false	aciu	ClosingForeignExchangeRateDecrease The percentage decrease to spot exchange rate at the end of the reporting period.
453	Number of banks holding deposits, cash and cash equivalents	xbrli:integerItemType	duration		false	aciu	NumberOfBanksHoldingDepositsCashAndCashEquivalents The number of banks holding the entity's deposits of cash and cash equivalents.
454	Decrease in net loss, foreign exchange rate increase	xbrli:monetaryItemType	duration	credit	false	aciu	DecreaseInNetLossForeignExchangeRateIncrease The decrease in net loss arising from a increase in the foreign exchange rate.
455	Liquidity management, rolling forecast period	xbrli:durationItemType	duration		false	aciu	LiquidityManagementRollingForecastPeriod The periodic interval in which the entity performs a rolling forecast of the entity's cash position.
456	Increase in net loss, foreign exchange rate decrease	xbrli:monetaryItemType	duration	debit	false	aciu	IncreaseInNetLossForeignExchangeRateDecrease The increase in net loss arising from a decrease in the foreign exchange rate.
457	Accrued Expenses [Member]	nonnum:domainItemType	duration		true	aciu	AccruedExpensesMember This member stands for accrued expenses.
458	Long-term Financial Liabilities [Member]	nonnum:domainItemType	duration		true	aciu	LongTermFinancialLiabilitiesMember This member stands for long-term financial liabilities.
459	Trade and Other Payables [Member]	nonnum:domainItemType	duration		true	aciu	TradeAndOtherPayablesMember This member stands for trade and other payables.
460	Cash on hand and cash equivalents [Member]	nonnum:domainItemType	duration		true	aciu	CashOnHandAndCashEquivalentsMember This member represents cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.
461	Other receivables [Member]	nonnum:domainItemType	duration		true	aciu	OtherReceivablesMember This member represents receivables classified as other.
462	Initial Public Offering [Abstract]	xbrli:stringItemType	duration		true	aciu	InitialPublicOfferingAbstract
463	Increase (decrease) to share premium through issuance of equity	xbrli:monetaryItemType	duration	credit	false	aciu	IncreaseDecreaseToSharePremiumThroughIssuanceOfEquity The increase (decrease) to the balance of share premium which is the amount received or receivable from the issuance of the entity's shares in excess of nominal value.
464	Share Price, initial public offering,	num:perShareItemType	instant		false	aciu	SharePriceInitialPublicOffering Price per share received for common stock issued or sold an initial public offering.
465	Option for Over-Allotment [Member]	nonnum:domainItemType	duration		true	aciu	OptionForOverAllotmentMember This member represents the equity instruments from the right of the underwriter to sell additional equity shares over the initial allotment.
466	General information [Abstract]	xbrli:stringItemType	duration		true	aciu	GeneralInformationAbstract
467	Disclosure of general information about the entity explanatory [Text Block]	nonnum:textBlockItemType	duration		false	aciu	DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock The entire disclosure for general information about the entity.
468	Number of technology platforms	xbrli:integerItemType	instant		false	aciu	NumberOfTechnologyPlatforms The number of unique proprietary platform technologies to discover, design and develop medicines and diagnostics to target misfolded proteins.
469	Underwriting fees, in noncash financing activities	xbrli:monetaryItemType	duration	credit	false	aciu	UnderwritingFeesInNoncashFinancingActivities The value of underwriting fees in a noncash transaction related to share issue costs.
470	Effective tax rate	num:percentItemType	duration		false	aciu	EffectiveTaxRate The effective income tax rate.
471	Tax benefit, income tax holiday	xbrli:monetaryItemType	duration	credit	false	aciu	TaxBenefitIncomeTaxHoliday The tax benefit recognized from a reduction in income taxes granted by the taxing jurisdiction.
472	Number of persons, key management, Executive Management	xbrli:integerItemType	duration		false	aciu	NumberOfPersonsKeyManagementExecutiveManagement The number of persons that comprise key management of the entity that are Executive Management.
473	Number of persons, key management, Board of Directors	xbrli:integerItemType	duration		false	aciu	NumberOfPersonsKeyManagementBoardOfDirectors The number of persons that comprise key management of the entity that are the included in Board of Directors excluding the Chief Executive Officer.
474	Former Chief Financial Officer [Member]	nonnum:domainItemType	duration		true	aciu	FormerChiefFinancialOfficerMember An former executive officer responsible for overseeing the financial activities of the entity.
475	Executive Management [Member]	nonnum:domainItemType	duration		true	aciu	ExecutiveManagementMember Key managers, or ranking officers of an entity, appointed to their position by the board of directors.
476	Board of Directors and Executive Management [Member]	nonnum:domainItemType	duration		true	aciu	BoardOfDirectorsAndExecutiveManagementMember Key managers of an entity who collectively have responsibility of governing the entity and Key managers, or ranking officers of an entity, appointed to their position by the board of directors.
477	Board of Directors [Member]	nonnum:domainItemType	duration		true	aciu	BoardOfDirectorsMember Key managers of an entity who collectively have responsibility of governing the entity.
478	Restricted Stock Units [Member]	nonnum:domainItemType	duration		true	aciu	RestrictedStockUnitsMember This member stands for equity instruments that are convertible to stock after a specified period of time.
479	Disclosure of detailed information about income tax losses expiry [Table Text Block]	nonnum:textBlockItemType	duration		false	aciu	DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock The disclosure of detailed information about the expiration of income tax losses.
480	Disclosure of detailed information about income tax reconciliation [Table Text Block]	nonnum:textBlockItemType	duration		false	aciu	DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock The disclosure of detailed information about income tax reconciliation.
481	Later than six years and not later than seven years [Member]	nonnum:domainItemType	duration		true	aciu	LaterThanSixYearsAndNotLaterThanSevenYearsMember This member stands for a time band of later than six years and not later than seven years.
482	Later than five years and not later than six years [Member]	nonnum:domainItemType	duration		true	aciu	LaterThanFiveYearsAndNotLaterThanSixYearsMember This member stands for a time band of later than five years and not later than six years.
483	Later Than Six Years And Not Later Than Eight Years [Member]	nonnum:domainItemType	duration		true	aciu	LaterThanSixYearsAndNotLaterThanEightYearsMember This member stands for a time band of later than seven years and not later than eight years.
484	Tax losses split by expiry date [Abstract]	xbrli:stringItemType	duration		true	aciu	TaxLossesSplitByExpiryDateAbstract
485	Share-based payment arrangement [Abstract]	xbrli:stringItemType	duration		true	aciu	ShareBasedPaymentArrangementAbstract
486	Maximum term of options granted for share-based payment arrangement	xbrli:durationItemType	duration		false	aciu	MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement The maximum term of options granted for a type of share-based payment arrangement that existed at any time during the period.
487	Former Chief Executive Financial Officer [Member]	nonnum:domainItemType	duration		true	aciu	FormerChiefExecutiveFinancialOfficerMember An former executive officer responsible for overseeing the financial activities of the entity.
488	Disclosure of detailed information about cash and cash equivalents [Table Text Block]	nonnum:textBlockItemType	duration		false	aciu	DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTableTextBlock The disclosure of detailed information about cash and cash equivalents.
489	Number of Options [Abstract]	xbrli:stringItemType	duration		true	aciu	NumberOfOptionsAbstract
490	Weighted Average Remaining [Abstract]	xbrli:stringItemType	duration		true	aciu	WeightedAverageRemainingAbstract
491	Weighted average remaining contractual life of exercisable share options	xbrli:decimalItemType	instant		false	aciu	WeightedAverageRemainingContractualLifeOfExercisableShareOptions The weighted average remaining contractual life of exercisable share options.
492	Weighted Average Exercise Price [Abstract]	xbrli:stringItemType	duration		true	aciu	WeightedAverageExercisePriceAbstract
493	Cash and cash equivalents [Table]	xbrli:stringItemType	duration		true	aciu	CashAndCashEquivalentsTable Schedule of cash and cash equivalent balances, including foreign currencies in which the balances are denominated.
494	Cash and cash equivalent [Line Items]	xbrli:stringItemType	duration		true	aciu	CashAndCashEquivalentLineItems Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.
495	Current accrued research and development costs	xbrli:monetaryItemType	instant	credit	false	aciu	CurrentAccruedResearchAndDevelopmentCosts The amount of current accrued research and development costs.
496	Deferred income [Table]	xbrli:stringItemType	duration		true	aciu	DeferredIncomeTable Schedule disclosing information related to details of deferred income.
497	Deferred income [Line Items]	xbrli:stringItemType	duration		true	aciu	DeferredIncomeLineItems Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.
498	Revenue, upfront fees received	xbrli:monetaryItemType	duration	credit	false	aciu	RevenueUpfrontFeesReceived The cash inflow from payments from collaboration agreements where entity recognizes revenue from upfront fees under the collaboration agreements pro-rata over the term of the estimated period of performance under each agreement.
499	Restricted Shares and Restricted Share Units [Member]	nonnum:domainItemType	duration		true	aciu	RestrictedSharesAndRestrictedShareUnitsMember This member stands for share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.
500	Restricted shares [Member]	nonnum:domainItemType	duration		true	aciu	RestrictedSharesMember This member stands for equity instruments that are prohibited for sale for a specified period of time.
501	Weighted average exercise price of other equity instruments vested in share-based payment arrangement	xbrli:monetaryItemType	duration		false	aciu	WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement The weighted average exercise price of other equity instruments (ie other than share options) vested in a share-based payment arrangement. [Refer: Weighted average [member]]
502	Number Of Non-vested Shares [Abstract]	xbrli:stringItemType	duration		true	aciu	NumberOfNonVestedSharesAbstract
503	Number of other equity instruments vested in share-based payment arrangement	xbrli:decimalItemType	duration		false	aciu	NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement The number of other equity instruments (ie other than share options) vested in a share-based payment arrangement.
504	Maximum Term Of Other Equity Instruments Granted For Share Based Payment Arrangement	xbrli:durationItemType	duration		false	aciu	MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement The maximum term of other equity instruments (ie other than share options) granted for a type of share-based payment arrangement that existed at any time during the period.
505	Vesting requirements for share-based payment arrangement, award vesting period	xbrli:durationItemType	duration		false	aciu	VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod For vesting requirements for a type of share-based payment arrangement that existed at any time during the period, this element represents the period which an employees right to exercise and award in no longer contingent on satisfaction of a service condition.
506	Ordinary and Preference Shares [Member]	nonnum:domainItemType	duration		true	aciu	OrdinaryAndPreferenceSharesMember This member stands for equity instruments that are subordinate to all other classes of equity instruments and that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim.
507	Shares issued, conversion of stock	xbrli:sharesItemType	duration		false	aciu	SharesIssuedConversionOfStock The number of new shares issued upon the conversion of stock.
508	Share-based plans outstanding [Abstract]	xbrli:stringItemType	duration		true	aciu	ShareBasedPlansOutstandingAbstract
509	Employees [Member]	nonnum:domainItemType	duration		true	aciu	EmployeesMember Refers to personnel employed by the entity.
510	Stock option plan A [Member]	nonnum:domainItemType	duration		true	aciu	StockOptionPlanAMember A share-based payment arrangement that existed at any time during the reporting period.
511	2016 Share Option and Incentive Plan [Member]	nonnum:domainItemType	duration		true	aciu	Two016ShareOptionAndIncentivePlanMember The 2016 Plan authorizes the grant of incentive and non-qualified share options, share appreciation rights, restricted share awards, restricted share units, unrestricted share awards, performance share awards, performance-based awards to covered employees and dividend equivalent rights.
512	Stock option plan B [Member]	nonnum:domainItemType	duration		true	aciu	StockOptionPlanBMember A share-based payment arrangement that existed at any time during the reporting period.
513	Stock option plan C1 [Member]	nonnum:domainItemType	duration		true	aciu	StockOptionPlanC1Member A share-based payment arrangement that existed at any time during the reporting period.
514	Number of Equity-based Instrument Plans	xbrli:integerItemType	duration		false	aciu	NumberOfEquityBasedInstrumentPlans Number of equity-based instrument plans approved by the entity.
515	Disclosure of detailed information about trade payables and accrued liabilities [Table Text Block]	nonnum:textBlockItemType	duration		false	aciu	DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock The disclosure of detailed information about trade payables and accrued liabilities.
516	Other current receivables [Abstract]	xbrli:stringItemType	duration		true	aciu	OtherCurrentReceivablesAbstract
517	Disclosure of other current receivables [Text Block]	nonnum:textBlockItemType	duration		false	aciu	DisclosureOfOtherCurrentReceivablesTextBlock The disclosure of other current receivables.
518	Disclosure of other current receivables [Table]	xbrli:stringItemType	duration		true	aciu	DisclosureOfOtherCurrentReceivablesTable Schedule disclosing information related to other current receivables.
519	Disclosure of other current receivables [Line Items]	xbrli:stringItemType	duration		true	aciu	DisclosureOfOtherCurrentReceivablesLineItems Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.
520	Period of maturity, receivables fair value carrying amount	xbrli:durationItemType	duration		false	aciu	PeriodOfMaturityReceivablesFairValueCarryingAmount Refers to the maturity period over which the entity considers carrying value of current receivables to correspond to their fair value.
521	Disclosure of detailed information about other current receivables [Table Text Block]	nonnum:textBlockItemType	duration		false	aciu	DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock The disclosure of detailed information about other current receivables.
522	Grant revenue	xbrli:monetaryItemType	duration	credit	false	aciu	GrantRevenue Revenue from public institutions and foundations for a contractually-defined purpose and period.
523	Alpha-synuclein and TDP-43 PET tracer in AD [Member]	nonnum:domainItemType	duration		true	aciu	AlphaSynucleinAndTDP43PETTracerInADMember The research and development of medicines for the treatment of Alzheimer's disease.
524	Tau-PET imaging agent in AD [Member]	nonnum:domainItemType	duration		true	aciu	TauPETImagingAgentInADMember The research and development of medicines for the treatment of Alzheimer's disease through molecular imaging.
525	Tau Vaccine in AD [Member]	nonnum:domainItemType	duration		true	aciu	TauVaccineInADMember The research and development of a vaccine for the treatment of Alzheimer's disease.
526	Recombinant Protein Therapeutic Candidate [Member]	nonnum:domainItemType	duration		true	aciu	RecombinantProteinTherapeuticCandidateMember The research and development of medicines for the treatment of recombinant protein therapeutic candidate.
527	Anti-tau antibody in AD [Member]	nonnum:domainItemType	duration		true	aciu	AntiTauAntibodyInADMember The research and development of medicines for the treatment of Alzheimer's disease.
528	Revenue Recognition Amortization Period	xbrli:durationItemType	duration		false	aciu	RevenueRecognitionAmortizationPeriod Amortized period over which revenue is recognized in income, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
529	Collaborative agreement, Cumulative payments received	xbrli:monetaryItemType	instant	credit	false	aciu	CollaborativeAgreementCumulativePaymentsReceived The cumulative payments received related to revenue from upfront license fees, milestone payments and revenue from research agreements associated with a collaborative agreement.
530	Collaborative agreement, Receivable expected	xbrli:monetaryItemType	instant	debit	false	aciu	CollaborativeAgreementReceivableExpected The amount that the entity is eligible to receive from a collaborative agreement.
531	Collaborative agreement, Number of indications	xbrli:integerItemType	duration		false	aciu	CollaborativeAgreementNumberOfIndications The number of indications built on the same research program associated with a collaborative agreement.
532	Collaborative Agreement, Joint Research Collaboration, Subsequently Amended Period	xbrli:durationItemType	duration		false	aciu	CollaborativeAgreementJointResearchCollaborationSubsequentlyAmendedPeriod The subsequently amended period over which collaborating entities are contracted to perform research, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
533	Collaborative agreement, Milestone payment received	xbrli:monetaryItemType	duration	credit	false	aciu	CollaborativeAgreementMilestonePaymentReceived Payment(s) received for milestone payments associated with a collaborative agreement.
534	Collaborative agreement, Number of companies entered into joint research collaboration	xbrli:integerItemType	duration		false	aciu	CollaborativeAgreementNumberOfCompaniesEnteredIntoJointResearchCollaboration The number of companies involved in joint research collaboration.
535	Period for Initial Research Plan	xbrli:durationItemType	duration		false	aciu	PeriodForInitialResearchPlan Period for initial research plan under a collaborative agreement.
536	Collaborative agreement, Collaboration contract receivable for regulatory, commercialization and sales milestones	xbrli:monetaryItemType	instant	debit	false	aciu	CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones The amount that the entity is eligible to receive for regulatory, commercialization and sales milestones from a collaborative agreement.
537	Term of grant	xbrli:durationItemType	duration		false	aciu	TermOfGrant The term of a grant agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
538	Revenue recognition deferral period	xbrli:durationItemType	duration		false	aciu	RevenueRecognitionDeferralPeriod The period over which deferred revenue is recognized in income, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
539	Anti-Abeta antibody in AD [Member]	nonnum:domainItemType	duration		true	aciu	AntiAbetaAntibodyInADMember The research and development of medicines for the treatment of Alzheimer's disease.
540	Collaborative agreement, Notice of contract termination period	xbrli:durationItemType	duration		false	aciu	CollaborativeAgreementNoticeOfContractTerminationPeriod Period of time that notice is required to be given for cancellation of the collaborative agreement contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
541	Collaborative agreement, Collaboration contract receivable for clinical milestones	xbrli:monetaryItemType	instant	debit	false	aciu	CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones The amount that the entity is eligible to receive for clinical milestones from a collaborative agreement..
542	Collaborative Agreement, Cumulative Payments Recognized	xbrli:monetaryItemType	duration	credit	false	aciu	CollaborativeAgreementCumulativePaymentsRecognized The cumulative payments recognized related to revenue from upfront license fees, technology fees, milestone payments and revenue from research agreements and associated with a collaborative agreement.
543	Collaborative agreement, Joint research collaboration period	xbrli:durationItemType	duration		false	aciu	CollaborativeAgreementJointResearchCollaborationPeriod The period over which collaborating entities are contracted to perform research, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
544	Grant revenue [Member]	nonnum:domainItemType	duration		true	aciu	GrantRevenueMember Revenue earned from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.
545	Grants, Michael J. Fox Foundation [Member]	nonnum:domainItemType	duration		true	aciu	GrantsMichaelJFoxFoundationMember Funding provided for certain types of expenditures in connection with research and development activities over a contractually-defined period from the Michael J. Fox Foundation.
546	Collaboration and License Revenue Agreements [Member]	nonnum:domainItemType	duration		true	aciu	CollaborationAndLicenseRevenueAgreementsMember Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.
547	Collaboration With Essex Bio-Technology Limited [Member]	nonnum:domainItemType	duration		true	aciu	CollaborationWithEssexBioTechnologyLimitedMember The contractual research agreement associated with collaboration with Essex Bio-Technology Limited.
548	Collaboration agreement of 2012, Genentech [Member]	nonnum:domainItemType	duration		true	aciu	CollaborationAgreementOf2012GenentechMember The 2012 contractual research agreement associated with collaboration with Genentech.
549	Collaboration agreement of 2006, Genentech [Member]	nonnum:domainItemType	duration		true	aciu	CollaborationAgreementOf2006GenentechMember The 2006 contractual research agreement associated with collaboration with Genentech.
550	License and collaboration agreement of 2014, Piramal Imaging [Member]	nonnum:domainItemType	duration		true	aciu	LicenseAndCollaborationAgreementOf2014PiramalImagingMember The 2014 contractual research agreement associated with collaboration with Piramal Imaging.
551	Collaborative Agreement, Milestone Payment Recognized	xbrli:monetaryItemType	duration	credit	false	aciu	CollaborativeAgreementMilestonePaymentRecognized The amount of consideration recognized for the milestone payment(s) associated with a collaborative agreement during the period.
552	Disclosure of detailed information about revenue [Table Text Block]	nonnum:textBlockItemType	duration		false	aciu	DisclosureOfDetailedInformationAboutRevenueTableTextBlock The disclosure of detailed information about revenue.
553	Expenses by category [Abstract]	xbrli:stringItemType	duration		true	aciu	ExpensesByCategoryAbstract
554	Research and Development Expenses [Abstract]	xbrli:stringItemType	duration		true	aciu	ResearchAndDevelopmentExpensesAbstract
555	Research and development expense allocation, wages and salaries	xbrli:monetaryItemType	duration	debit	false	aciu	ResearchAndDevelopmentExpenseAllocationWagesAndSalaries A class of employee benefits expense that represents wages and salaries that are allocated to research and development expenses. [Refer: Employee benefits expense]
556	Research and development expense allocation, operating expense	xbrli:monetaryItemType	duration	debit	false	aciu	ResearchAndDevelopmentExpenseAllocationOperatingExpense The amount of all operating expenses allocated to research and development expenses.
557	General and Administration [Abstract]	xbrli:stringItemType	duration		true	aciu	GeneralAndAdministrationAbstract
558	General and administrative expense allocation, operating expense	xbrli:monetaryItemType	duration	debit	false	aciu	GeneralAndAdministrativeExpenseAllocationOperatingExpense The amount of all operating expenses allocated to general and administrative expenses.
559	Research and development expense allocation, expense from share-based payment transactions with employees	xbrli:monetaryItemType	duration	debit	false	aciu	ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees The amount of expense from share-based payment transactions with employees that are allocated to research and development expenses.
560	General and administrative expense allocation, expense from share-based payment transactions with employees	xbrli:monetaryItemType	duration	debit	false	aciu	GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees The amount of expense from share-based payment transactions with employees allocated to general and administrative expense.
561	General and administrative expense allocation, wages and salaries	xbrli:monetaryItemType	duration	debit	false	aciu	GeneralAndAdministrativeExpenseAllocationWagesAndSalaries A class of employee benefits expense that represents wages and salaries that are allocated to general and administrative expense. [Refer: Employee benefits expense]
562	Financial Result, net [Abstract]	xbrli:stringItemType	duration		true	aciu	FinancialResultNetAbstract
563	Currency [Axis]	xbrli:stringItemType	duration		true	us-gaap	CurrencyAxis

Model Structures

Model Structure
Network	000100 - Document - Document and Entity Information (http://acimume.com/role/DocumentAndEntityInformation)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Document and Entity Information [Abstract]	Abstract	duration		aciu:DocumentAndEntityInformationAbstract
2	Entity Registrant Name	Concept (String-Normalized)	duration		dei:EntityRegistrantName
3	Entity Central Index Key	Concept (xbrli:tokenItemType)	duration		dei:EntityCentralIndexKey
4	Current Fiscal Year End Date	Concept (gMonthDay)	duration		dei:CurrentFiscalYearEndDate
5	Entity Well-known Seasoned Issuer	Concept (xbrli:tokenItemType)	duration		dei:EntityWellKnownSeasonedIssuer
6	Entity Voluntary Filers	Concept (xbrli:tokenItemType)	duration		dei:EntityVoluntaryFilers
7	Entity Current Reporting Status	Concept (xbrli:tokenItemType)	duration		dei:EntityCurrentReportingStatus
8	Entity Filer Category	Concept (xbrli:stringItemType)	duration		dei:EntityFilerCategory
9	Entity Public Float	Concept (Monetary)	instant	credit	dei:EntityPublicFloat
10	Entity Common Stock, Shares Outstanding	Concept (Shares)	instant		dei:EntityCommonStockSharesOutstanding
11	Document Fiscal Year Focus	Concept (gYear)	duration		dei:DocumentFiscalYearFocus
12	Document Fiscal Period Focus	Concept (xbrli:tokenItemType)	duration		dei:DocumentFiscalPeriodFocus
13	Document Type	Concept (xbrli:stringItemType)	duration		dei:DocumentType
14	Amendment Flag	Concept (Boolean)	duration		dei:AmendmentFlag
15	Document Period End Date	Concept (Date)	duration		dei:DocumentPeriodEndDate

Model Structure
Network	010000 - Statement - Balance Sheets (http://acimume.com/role/BalanceSheets)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Balance Sheets [Abstract]	Abstract	duration		ifrs-full:StatementOfFinancialPositionAbstract
2	Assets	Abstract	duration		ifrs-full:AssetsAbstract
3	Non-current assets	Abstract	duration		ifrs-full:NoncurrentAssetsAbstract
4	Property, plant and equipment	Concept (Monetary)	instant	debit	ifrs-full:PropertyPlantAndEquipment
5	Financial assets	Concept (Monetary)	instant	debit	ifrs-full:NoncurrentRestrictedCashAndCashEquivalents
6	Total non-current assets	Concept (Monetary)	instant	debit	ifrs-full:NoncurrentAssets
7	Current assets	Abstract	duration		ifrs-full:CurrentAssetsAbstract
8	Prepaid expenses	Concept (Monetary)	instant	debit	ifrs-full:CurrentPrepaidExpenses
9	Accrued income	Concept (Monetary)	instant	debit	aciu:CurrentAccruedIncomeAndGrantReceivables
10	Other current receivables	Concept (Monetary)	instant	debit	aciu:CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes
11	Cash and cash equivalents	Concept (Monetary)	instant	debit	ifrs-full:CashAndCashEquivalents
12	Total current assets	Concept (Monetary)	instant	debit	ifrs-full:CurrentAssets
13	Total assets	Concept (Monetary)	instant	debit	ifrs-full:Assets
14	SHAREHOLDERS' EQUITY AND LIABILITIES	Abstract	duration		ifrs-full:EquityAndLiabilitiesAbstract
15	Shareholders' equity	Abstract	duration		ifrs-full:EquityAbstract
16	Share capital	Concept (Monetary)	instant	credit	ifrs-full:IssuedCapital
17	Share premium	Concept (Monetary)	instant	credit	ifrs-full:SharePremium
18	Accumulated losses	Concept (Monetary)	instant	credit	ifrs-full:RetainedEarnings
19	Total shareholders' equity	Concept (Monetary)	instant	credit	ifrs-full:Equity
20	Non-current liabilities	Abstract	duration		ifrs-full:NoncurrentLiabilitiesAbstract
21	Accrued interest - long-term	Concept (Monetary)	instant	credit	ifrs-full:NoncurrentInterestPayable
22	Long-term financing obligation	Concept (Monetary)	instant	credit	ifrs-full:NoncurrentFinancialLiabilities
23	Net employee defined benefit liabilities	Concept (Monetary)	instant	credit	ifrs-full:NoncurrentProvisionsForEmployeeBenefits
24	Total non-current liabilities	Concept (Monetary)	instant	credit	ifrs-full:NoncurrentLiabilities
25	Current liabilities	Abstract	duration		ifrs-full:CurrentLiabilitiesAbstract
26	Trade payables and other payables	Concept (Monetary)	instant	credit	ifrs-full:TradeAndOtherCurrentPayables
27	Accrued expenses	Concept (Monetary)	instant	credit	ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
28	Deferred income	Concept (Monetary)	instant	credit	ifrs-full:DeferredIncomeClassifiedAsCurrent
29	Total current liabilities	Concept (Monetary)	instant	credit	ifrs-full:CurrentLiabilities
30	Total liabilities	Concept (Monetary)	instant	credit	ifrs-full:Liabilities
31	Total shareholders' equity and liabilities	Concept (Monetary)	instant	credit	ifrs-full:EquityAndLiabilities

Model Structure
Network	020000 - Statement - Statements of Income / (Loss) (http://acimume.com/role/StatementsOfIncomeLoss)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Statements of Income / (Loss) [Abstract]	Abstract	duration		ifrs-full:IncomeStatementAbstract
2	Revenue	Abstract	duration		ifrs-full:RevenueAbstract
3	Contract revenue	Concept (Monetary)	duration	credit	ifrs-full:RevenueFromContractsWithCustomers
4	Total revenue	Concept (Monetary)	duration	credit	ifrs-full:Revenue
5	Operating expenses	Abstract	duration		aciu:ExpensesOperatingAbstract
6	Research and development expenses	Concept (Monetary)	duration	debit	ifrs-full:ResearchAndDevelopmentExpense
7	General and administrative expenses	Concept (Monetary)	duration	debit	ifrs-full:SellingGeneralAndAdministrativeExpense
8	Total operating expenses	Concept (Monetary)	duration	debit	ifrs-full:OperatingExpense
9	Operating income / (loss)	Concept (Monetary)	duration	credit	ifrs-full:ProfitLossFromOperatingActivities
10	Finance income / (expense), net	Concept (Monetary)	duration	credit	ifrs-full:FinanceIncome
11	Interest income	Concept (Monetary)	duration	credit	ifrs-full:RevenueFromInterest
12	Interest expense	Concept (Monetary)	duration	debit	ifrs-full:InterestExpense
13	Finance result, net	Concept (Monetary)	duration	credit	ifrs-full:FinanceIncomeCost
14	Income / (loss) before tax	Concept (Monetary)	duration	credit	ifrs-full:ProfitLossBeforeTax
15	Income tax expense	Concept (Monetary)	duration	debit	ifrs-full:IncomeTaxExpenseContinuingOperations
16	Income / (loss) for the period	Concept (Monetary)	duration	credit	ifrs-full:ProfitLoss
17	Earnings / (loss) per share (EPS):	Abstract	duration		ifrs-full:EarningsPerShareAbstract
18	Basic, income / (loss) for the period attributable to equity holders (in CHF per share)	Concept (Per-Share)	duration		ifrs-full:BasicEarningsLossPerShare
19	Diluted, income / (loss) for the period attributable to equity holders (in CHF per share)	Concept (Per-Share)	duration		ifrs-full:DilutedEarningsLossPerShare
20	Weighted-average number of shares used to compute EPS basic (in shares)	Concept (Shares)	duration		ifrs-full:WeightedAverageShares
21	Weighted-average number of shares used to compute EPS fully diluted (in shares)	Concept (Shares)	duration		ifrs-full:AdjustedWeightedAverageShares

Model Structure
Network	030000 - Statement - Statements of Comprehensive Income / (Loss) (http://acimume.com/role/StatementsOfComprehensiveIncomeLoss)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Statements of Comprehensive Income / (Loss) [Abstract]	Abstract	duration		ifrs-full:StatementOfComprehensiveIncomeAbstract
2	Income / (loss) for the period	Concept (Monetary)	duration	credit	ifrs-full:ProfitLoss
3	Other comprehensive income / (loss) not to be reclassified to income or loss in subsequent periods (net of tax)	Abstract	duration		ifrs-full:ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract
4	- Re-measurement losses on defined benefit plans (net of tax of CHF 0 for all periods)	Concept (Monetary)	duration	credit	ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
5	Total comprehensive income / (loss), net of tax	Concept (Monetary)	duration	credit	ifrs-full:ComprehensiveIncome

Model Structure
Network	030100 - Statement - Statements of Comprehensive Income / (Loss) (Parenthetical) (http://acimume.com/role/StatementsOfComprehensiveIncomeLossParenthetical)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Statements of Comprehensive Income / (Loss) [Abstract]	Abstract	duration		ifrs-full:StatementOfComprehensiveIncomeAbstract
2	Other comprehensive income / (loss) not to be reclassified to income or loss in subsequent periods (net of tax)	Abstract	duration		ifrs-full:ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract
3	Income tax expense	Concept (Monetary)	duration	debit	ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome

Model Structure
Network	040000 - Statement - Statements of Changes in Equity (http://acimume.com/role/StatementsOfChangesInEquity)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Statements of Changes in Equity [Abstract]	Abstract	duration		ifrs-full:StatementOfChangesInEquityAbstract
2	Statement of changes in equity [table]	Table	duration		ifrs-full:StatementOfChangesInEquityTable
3	Components of equity [axis]	Axis	duration		ifrs-full:ComponentsOfEquityAxis
4	Equity [Member]	Member	duration		ifrs-full:EquityMember
5	Share Capital [Member]	Member	duration		ifrs-full:IssuedCapitalMember
6	Share Premium [Member]	Member	duration		ifrs-full:SharePremiumMember
7	Accumulated Losses [Member]	Member	duration		ifrs-full:RetainedEarningsMember
8	Statement of changes in equity [line items]	LineItems	duration		ifrs-full:StatementOfChangesInEquityLineItems
9	Balance, beginning of period	Concept (Monetary)	instant	credit	ifrs-full:Equity
10	Net income / (loss) for the period	Concept (Monetary)	duration	credit	ifrs-full:ProfitLoss
11	Other comprehensive loss	Concept (Monetary)	duration	credit	ifrs-full:OtherComprehensiveIncome
12	Total comprehensive income / (loss), net of tax	Concept (Monetary)	duration	credit	ifrs-full:ComprehensiveIncome
13	Share-based payments	Concept (Monetary)	duration	credit	ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
14	Issuance of preferred Series E shares	Concept (Monetary)	duration	credit	aciu:IssueOfEquityPreferenceSharesSeriesE
15	Preferred Series E extension shares	Concept (Monetary)	duration	credit	aciu:IssueOfEquityExtensionPreferenceSharesSeriesE
16	Proceeds from IPO net of underwriting fees	Concept (Monetary)	duration	debit	aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees
17	Issuance of shares:	Abstract	duration		ifrs-full:NumberOfSharesIssuedAbstract
18	Restricted Share Awards	Concept (Monetary)	duration	credit	aciu:IssueOfEquityRestrictedShareAwards
19	Exercise of options	Concept (Monetary)	duration	credit	ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
20	Transaction costs	Concept (Monetary)	duration	debit	ifrs-full:ShareIssueRelatedCost
21	Balance, end of period	Concept (Monetary)	instant	credit	ifrs-full:Equity

Model Structure
Network	050000 - Statement - Statements of Cash Flows (http://acimume.com/role/StatementsOfCashFlows)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Statements of Cash Flows [Abstract]	Abstract	duration		ifrs-full:StatementOfCashFlowsAbstract
2	Operating activities	Abstract	duration		ifrs-full:CashFlowsFromUsedInOperatingActivitiesAbstract
3	Income / (loss) for the period	Concept (Monetary)	duration	credit	ifrs-full:ProfitLoss
4	Adjustments to reconcile net income for the period to net cash flows:	Abstract	duration		ifrs-full:AdjustmentsForReconcileProfitLossAbstract
5	Depreciation of property, plant and equipment	Concept (Monetary)	duration	debit	ifrs-full:AdjustmentsForDepreciationExpense
6	Finance result, net	Concept (Monetary)	duration	credit	ifrs-full:AdjustmentsForFinanceIncomeCost
7	Share-based compensation expense	Concept (Monetary)	duration	debit	ifrs-full:AdjustmentsForSharebasedPayments
8	Changes in pensions	Concept (Monetary)	duration	debit	ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities
9	Accrued interest on long-term debt	Concept (Monetary)	duration	debit	aciu:AdjustmentsForAccruedInterestPayable
10	Changes in working capital:	Abstract	duration		aciu:ChangesInWorkingCapitalAbstract
11	Prepaid expenses	Concept (Monetary)	duration	credit	aciu:AdjustmentsForDecreaseIncreaseInPrepaidExpense
12	Accrued income	Concept (Monetary)	duration	debit	aciu:AdjustmentsForDecreaseIncreaseInAccruedIncome
13	Other current receivables	Concept (Monetary)	duration	debit	ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
14	Accrued expenses	Concept (Monetary)	duration	credit	aciu:AdjustmentsForIncreaseDecreaseInAccruedExpenses
15	Deferral of unearned revenue	Concept (Monetary)	duration	debit	ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome
16	Long-term financing obligation	Concept (Monetary)	duration	credit	aciu:AdjustmentsForIncreaseDecreaseLongTermFinancialLiabilities
17	Accounts payable	Concept (Monetary)	duration	debit	ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
18	Cash provided by/(used in) operating activities	Concept (Monetary)	duration		ifrs-full:CashFlowsFromUsedInOperations
19	Interest income	Concept (Monetary)	duration	debit	ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities
20	Finance costs	Concept (Monetary)	duration	credit	ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities
21	Net cash flows provided by/(used in) operating activities	Concept (Monetary)	duration		ifrs-full:CashFlowsFromUsedInOperatingActivities
22	Investing activities	Abstract	duration		ifrs-full:CashFlowsFromUsedInInvestingActivitiesAbstract
23	Purchases of property, plant and equipment	Concept (Monetary)	duration	credit	ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
24	Rent deposit	Concept (Monetary)	duration	credit	aciu:CashAdvancesForRentDeposit
25	Net cash flows used in investing activities	Concept (Monetary)	duration	debit	ifrs-full:CashFlowsFromUsedInInvestingActivities
26	Financing activities	Abstract	duration		ifrs-full:CashFlowsFromUsedInFinancingActivitiesAbstract
27	Proceeds from issuance of preferred Series E	Concept (Monetary)	duration	debit	ifrs-full:ProceedsFromIssueOfPreferenceShares
28	Proceeds from issuance of common shares	Concept (Monetary)	duration	debit	aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees
29	Transaction costs of issue of shares	Concept (Monetary)	duration	credit	ifrs-full:PaymentsForShareIssueCosts
30	Proceeds from issuance of shares-option plans	Concept (Monetary)	duration	debit	ifrs-full:ProceedsFromExerciseOfOptions
31	Proceeds from long-term debt	Concept (Monetary)	duration	debit	ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
32	Proceeds from employee loan repayments	Concept (Monetary)	duration	debit	aciu:ProceedsFromLoanRepayments
33	Net cash flows provided by financing activities	Concept (Monetary)	duration	debit	ifrs-full:CashFlowsFromUsedInFinancingActivities
34	Net increase / (decrease) in cash and cash equivalents	Concept (Monetary)	duration	debit	ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
35	Cash and cash equivalents, beginning of period	Concept (Monetary)	instant	debit	ifrs-full:CashAndCashEquivalents
36	Exchange gains on cash and cash equivalents	Concept (Monetary)	duration	debit	ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
37	Cash and cash equivalents, end of period	Concept (Monetary)	instant	debit	ifrs-full:CashAndCashEquivalents
38	Net increase / (decrease) in cash and cash equivalents	Concept (Monetary)	duration	debit	ifrs-full:IncreaseDecreaseInCashAndCashEquivalents

Model Structure
Network	050100 - Statement - Statements of Cash Flows (Parenthetical) (http://acimume.com/role/StatementsOfCashFlowsParenthetical)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Statements of Cash Flows [Abstract]	Abstract	duration		ifrs-full:StatementOfCashFlowsAbstract
2	Financing activities	Abstract	duration		ifrs-full:CashFlowsFromUsedInFinancingActivitiesAbstract
3	Underwriting fees	Concept (Monetary)	duration	credit	aciu:UnderwritingFeesInNoncashFinancingActivities

Model Structure
Network	060100 - Disclosure - General information (http://acimume.com/role/GeneralInformation)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	General information [Abstract]	Abstract	duration		aciu:GeneralInformationAbstract
2	General information	Concept (TextBlock)	duration		aciu:DisclosureOfGeneralInformationAboutTheEntityExplanatoryTextBlock

Model Structure
Network	060200 - Disclosure - Basis of preparation (http://acimume.com/role/BasisOfPreparation)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Basis of preparation [Abstract]	Abstract	duration		aciu:BasisOfPreparationAbstract
2	Basis of preparation	Concept (TextBlock)	duration		ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory

Model Structure
Network	060300 - Disclosure - Summary of significant accounting policies (http://acimume.com/role/SummaryOfSignificantAccountingPolicies)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Summary of significant accounting policies [Abstract]	Abstract	duration		ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract
2	Summary of significant accounting policies	Concept (TextBlock)	duration		ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory

Model Structure
Network	060400 - Disclosure - Property, plant and equipment (http://acimume.com/role/PropertyPlantAndEquipment)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Property, plant and equipment [Abstract]	Abstract	duration		ifrs-full:DisclosureOfPropertyPlantAndEquipmentAbstract
2	Property, plant and equipment	Concept (TextBlock)	duration		ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory

Model Structure
Network	060500 - Disclosure - Financial Assets (http://acimume.com/role/FinancialAssets)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Financial Assets [Abstract]	Abstract	duration		ifrs-full:DisclosureOfFinancialAssetsAbstract
2	Financial Assets	Concept (TextBlock)	duration		ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory

Model Structure
Network	060600 - Disclosure - Prepaid expenses and accrued income (http://acimume.com/role/PrepaidExpensesAndAccruedIncome)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Prepaid expenses and accrued income [Abstract]	Abstract	duration		ifrs-full:PrepaymentsAndAccruedIncomeAbstract
2	Prepaid expenses and accrued income	Concept (TextBlock)	duration		aciu:DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock

Model Structure
Network	060700 - Disclosure - Other current receivables (http://acimume.com/role/OtherCurrentReceivables)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Other current receivables [Abstract]	Abstract	duration		aciu:OtherCurrentReceivablesAbstract
2	Other current receivables	Concept (TextBlock)	duration		aciu:DisclosureOfOtherCurrentReceivablesTextBlock

Model Structure
Network	060800 - Disclosure - Cash and cash equivalents (http://acimume.com/role/CashAndCashEquivalents)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Cash and cash equivalents [Abstract]	Abstract	duration		ifrs-full:CashAndCashEquivalentsAbstract
2	Cash and cash equivalents	Concept (TextBlock)	duration		ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory

Model Structure
Network	060900 - Disclosure - Share capital (http://acimume.com/role/ShareCapital)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Share capital [Abstract]	Abstract	duration		ifrs-full:ChangesInEquityAbstract
2	Share capital	Concept (TextBlock)	duration		ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory

Model Structure
Network	061000 - Disclosure - Trade payables and accrued liabilities (http://acimume.com/role/TradePayablesAndAccruedLiabilities)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Trade payables and accrued liabilities [Abstract]	Abstract	duration		ifrs-full:TradeAndOtherCurrentPayablesAbstract
2	Trade payables and accrued liabilities	Concept (TextBlock)	duration		ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory

Model Structure
Network	061100 - Disclosure - Deferred income (http://acimume.com/role/DeferredIncome)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Deferred income [Abstract]	Abstract	duration		ifrs-full:AccrualsAndDeferredIncomeAbstract
2	Deferred income	Concept (TextBlock)	duration		ifrs-full:DisclosureOfDeferredIncomeExplanatory

Model Structure
Network	061200 - Disclosure - Long term financing obligation (http://acimume.com/role/LongTermFinancingObligation)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Long term financing obligation [Abstract]	Abstract	duration		aciu:LongTermFinancingObligationAbstract
2	Disclosure of Long term financing obligation	Concept (TextBlock)	duration		aciu:DisclosureOfLongTermFinancingObligationTextBlock

Model Structure
Network	061300 - Disclosure - Revenues (http://acimume.com/role/Revenues)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Revenues [Abstract]	Abstract	duration		ifrs-full:RevenueAbstract
2	Revenues	Concept (TextBlock)	duration		ifrs-full:DisclosureOfRevenueExplanatory

Model Structure
Network	061400 - Disclosure - Expenses by category (http://acimume.com/role/ExpensesByCategory)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Expenses by category [Abstract]	Abstract	duration		aciu:ExpensesByCategoryAbstract
2	Expenses by category	Concept (TextBlock)	duration		ifrs-full:DisclosureOfExpensesExplanatory

Model Structure
Network	061500 - Disclosure - Related-party transactions (http://acimume.com/role/RelatedpartyTransactions)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Related-party transactions [Abstract]	Abstract	duration		ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesAbstract
2	Related-party transactions	Concept (TextBlock)	duration		ifrs-full:DisclosureOfRelatedPartyExplanatory

Model Structure
Network	061600 - Disclosure - Income taxes (http://acimume.com/role/IncomeTaxes)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Income taxes [Abstract]	Abstract	duration		ifrs-full:MajorComponentsOfTaxExpenseIncomeAbstract
2	Income taxes	Concept (TextBlock)	duration		ifrs-full:DisclosureOfIncomeTaxExplanatory

Model Structure
Network	061700 - Disclosure - Retirement benefit plan (http://acimume.com/role/RetirementBenefitPlan)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Retirement benefit plan [Abstract]	Abstract	duration		ifrs-full:DisclosureOfDefinedBenefitPlansAbstract
2	Retirement benefit plan	Concept (TextBlock)	duration		ifrs-full:DisclosureOfEmployeeBenefitsExplanatory

Model Structure
Network	061800 - Disclosure - Share-based compensation (http://acimume.com/role/SharebasedCompensation)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Share-based compensation [Abstract]	Abstract	duration		ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract
2	Share-based compensation	Concept (TextBlock)	duration		ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory

Model Structure
Network	061900 - Disclosure - Commitments and contingencies (http://acimume.com/role/CommitmentsAndContingencies)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Commitments and contingencies [Abstract]	Abstract	duration		aciu:CommitmentsAndContingenciesAbstract
2	Commitments and contingencies	Concept (TextBlock)	duration		ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory

Model Structure
Network	062000 - Disclosure - Earnings per share (http://acimume.com/role/EarningsPerShare)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Earnings per share [Abstract]	Abstract	duration		ifrs-full:EarningsPerShareAbstract
2	Earnings per share	Concept (TextBlock)	duration		ifrs-full:DisclosureOfEarningsPerShareExplanatory

Model Structure
Network	062100 - Disclosure - Financial instruments and risk management (http://acimume.com/role/FinancialInstrumentsAndRiskManagement)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Financial instruments and risk management [Abstract]	Abstract	duration		ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract
2	Financial instruments and risk management	Concept (TextBlock)	duration		ifrs-full:DisclosureOfFinancialRiskManagementExplanatory

Model Structure
Network	062200 - Disclosure - Capital risk management (http://acimume.com/role/CapitalRiskManagement)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Capital risk management [Abstract]	Abstract	duration		ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract
2	Capital risk management	Concept (TextBlock)	duration		ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory

Model Structure
Network	062300 - Disclosure - Post balance sheet events (http://acimume.com/role/PostBalanceSheetEvents)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Post balance sheet events [Abstract]	Abstract	duration		aciu:PostBalanceSheetEventsAbstract
2	Post balance sheet events	Concept (TextBlock)	duration		ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory

Model Structure
Network	070300 - Disclosure - Summary of significant accounting policies (Policies) (http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPolicies)
Table	(implied)

#	Label	Report Element Class	Period Type	Name
1	Summary of significant accounting policies [Abstract]	Abstract	duration	ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract
2	Current vs. non-current classification	Concept (TextBlock)	duration	aciu:DescriptionOfAccountingPolicyForClassificationOfAssetsAndLiabilitiesPolicyTextBlock
3	Foreign currency transactions	Concept (TextBlock)	duration	ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
4	Revenue recognition	Concept (TextBlock)	duration	ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue
5	Research and development services	Concept (TextBlock)	duration	ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
6	Property, plant and equipment	Concept (TextBlock)	duration	ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
7	Financial assets and liabilities	Concept (TextBlock)	duration	aciu:FinancialAssetsAndLiabilitiesPolicyTextBlock
8	Share capital and Initial Public Offering	Concept (TextBlock)	duration	ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory
9	Employee benefits	Concept (TextBlock)	duration	ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory
10	Provisions	Concept (TextBlock)	duration	ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory
11	Taxation	Concept (TextBlock)	duration	ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory
12	Earnings per share	Concept (TextBlock)	duration	ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory
13	Critical judgments and accounting estimates	Concept (TextBlock)	duration	aciu:DescriptionOfAccountingPolicyForAccountingJudgmentsAndEstimatesPolicyTextBlock
14	Segment reporting	Concept (TextBlock)	duration	ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory
15	Accounting pronouncements - not yet adopted	Concept (TextBlock)	duration	aciu:DisclosureOfAccountingPolicyForChangesInAccountingPoliciesNotYetAdoptedPolicyTextBlock

Model Structure
Network	080300 - Disclosure - Summary of significant accounting policies (Tables) (http://acimume.com/role/SummaryOfSignificantAccountingPoliciesTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Summary of significant accounting policies [Abstract]	Abstract	duration		ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract
2	Estimated useful life	Concept (TextBlock)	duration		aciu:ScheduleOfInformationAboutPropertyPlantAndEquipmentUsefulLifeTableTextBlock

Model Structure
Network	080400 - Disclosure - Property, plant and equipment (Tables) (http://acimume.com/role/PropertyPlantAndEquipmentTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Property, plant and equipment [Abstract]	Abstract	duration		ifrs-full:DisclosureOfPropertyPlantAndEquipmentAbstract
2	Property, plant and equipment	Concept (TextBlock)	duration		ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory

Model Structure
Network	080600 - Disclosure - Prepaid expenses and accrued income (Tables) (http://acimume.com/role/PrepaidExpensesAndAccruedIncomeTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Prepaid expenses and accrued income [Abstract]	Abstract	duration		ifrs-full:PrepaymentsAndAccruedIncomeAbstract
2	Prepaid expenses and accrued income	Concept (TextBlock)	duration		aciu:DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock

Model Structure
Network	080700 - Disclosure - Other current receivables (Tables) (http://acimume.com/role/OtherCurrentReceivablesTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Other current receivables [Abstract]	Abstract	duration		aciu:OtherCurrentReceivablesAbstract
2	Other current receivables	Concept (TextBlock)	duration		aciu:DisclosureOfDetailedInformationAboutOtherCurrentReceivablesTableTextBlock

Model Structure
Network	080800 - Disclosure - Cash and cash equivalents (Tables) (http://acimume.com/role/CashAndCashEquivalentsTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Cash and cash equivalents [Abstract]	Abstract	duration		ifrs-full:CashAndCashEquivalentsAbstract
2	Cash and cash equivalents	Concept (TextBlock)	duration		aciu:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsTableTextBlock

Model Structure
Network	080900 - Disclosure - Share capital (Tables) (http://acimume.com/role/ShareCapitalTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Share capital [Abstract]	Abstract	duration		ifrs-full:ChangesInEquityAbstract
2	Summary of capital structure	Concept (TextBlock)	duration		ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory

Model Structure
Network	081000 - Disclosure - Trade payables and accrued liabilities (Tables) (http://acimume.com/role/TradePayablesAndAccruedLiabilitiesTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Trade payables and accrued liabilities [Abstract]	Abstract	duration		ifrs-full:TradeAndOtherCurrentPayablesAbstract
2	Trade payables and accrued liabilities	Concept (TextBlock)	duration		aciu:DisclosureOfDetailedInformationAboutTradePayablesAndAccruedLiabilitiesTableTextBlock

Model Structure
Network	081300 - Disclosure - Revenues (Tables) (http://acimume.com/role/RevenuesTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Revenues [Abstract]	Abstract	duration		ifrs-full:RevenueAbstract
2	Revenues	Concept (TextBlock)	duration		aciu:DisclosureOfDetailedInformationAboutRevenueTableTextBlock

Model Structure
Network	081400 - Disclosure - Expenses by category (Tables) (http://acimume.com/role/ExpensesByCategoryTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Name
1	Expenses by category [Abstract]	Abstract	duration	aciu:ExpensesByCategoryAbstract
2	Research and Development	Concept (TextBlock)	duration	ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory
3	General and Administrative	Concept (TextBlock)	duration	ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory
4	Financial Result, net	Concept (TextBlock)	duration	ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory

Model Structure
Network	081500 - Disclosure - Related-party transactions (Tables) (http://acimume.com/role/RelatedpartyTransactionsTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Related-party transactions [Abstract]	Abstract	duration		ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesAbstract
2	Key management compensation	Concept (TextBlock)	duration		ifrs-full:DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesExplanatory

Model Structure
Network	081600 - Disclosure - Income taxes (Tables) (http://acimume.com/role/IncomeTaxesTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Name
1	Income taxes [Abstract]	Abstract	duration	ifrs-full:MajorComponentsOfTaxExpenseIncomeAbstract
2	Income tax expense reconciled to Income / (loss)	Concept (TextBlock)	duration	aciu:DisclosureOfDetailedInformationAboutIncomeTaxReconciliationTableTextBlock
3	Unrecognized deductible temporary differences, unused tax losses and unused tax credits	Concept (TextBlock)	duration	ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory
4	Tax losses expiry dates	Concept (TextBlock)	duration	aciu:DisclosureOfDetailedInformationAboutIncomeTaxLossesExpiryTableTextBlock

Model Structure
Network	081700 - Disclosure - Retirement benefit plan (Tables) (http://acimume.com/role/RetirementBenefitPlanTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Name
1	Retirement benefit plan [Abstract]	Abstract	duration	ifrs-full:DisclosureOfDefinedBenefitPlansAbstract
2	Defined benefit pension plan amounts recognized in the balance sheet and statement of income	Concept (TextBlock)	duration	ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory
3	Changes in defined benefit obligation, fair value of plan assets and unrecognized (gains) / losses	Concept (TextBlock)	duration	ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory
4	Actuarial assumptions and sensitivity analysis	Concept (TextBlock)	duration	ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory

Model Structure
Network	081800 - Disclosure - Share-based compensation (Tables) (http://acimume.com/role/SharebasedCompensationTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Name
1	Share-based compensation [Abstract]	Abstract	duration	ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract
2	Share-based compensation plans outstanding	Concept (TextBlock)	duration	ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory
3	Number and weighted average exercise prices of options for Plans A, B, and C1	Concept (TextBlock)	duration	ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
4	Summary of non-vested share awards (restricted share and restricted share units)	Concept (TextBlock)	duration	ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory

Model Structure
Network	081900 - Disclosure - Commitments and contingencies (Tables) (http://acimume.com/role/CommitmentsAndContingenciesTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Commitments and contingencies [Abstract]	Abstract	duration		aciu:CommitmentsAndContingenciesAbstract
2	Maturity of commitments and contingencies	Concept (TextBlock)	duration		ifrs-full:DisclosureOfContingentLiabilitiesExplanatory

Model Structure
Network	082000 - Disclosure - Earnings per share (Tables) (http://acimume.com/role/EarningsPerShareTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Earnings per share [Abstract]	Abstract	duration		ifrs-full:EarningsPerShareAbstract
2	Earnings per share	Concept (TextBlock)	duration		ifrs-full:EarningsPerShareExplanatory

Model Structure
Network	082100 - Disclosure - Financial instruments and risk management (Tables) (http://acimume.com/role/FinancialInstrumentsAndRiskManagementTables)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Financial instruments and risk management [Abstract]	Abstract	duration		ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract
2	Carrying amounts of financial assets and financial liabilities	Concept (TextBlock)	duration		aciu:DisclosureOfDetailedInformationAboutCarryingAmountsOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock

Model Structure
Network	090100 - Disclosure - General information (Details) (http://acimume.com/role/GeneralInformationDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	General information [Abstract]	Abstract	duration		aciu:GeneralInformationAbstract
2	Number of proprietary technology platforms	Concept (Integer)	instant		aciu:NumberOfTechnologyPlatforms

Model Structure
Network	090200 - Disclosure - Basis of preparation (Details) (http://acimume.com/role/BasisOfPreparationDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Basis of preparation [Abstract]	Abstract	duration		aciu:BasisOfPreparationAbstract
2	Disclosure of going concern [Table]	Table	duration		aciu:DisclosureOfGoingConcernTable
3	Classes of share capital [axis]	Axis	duration		ifrs-full:ClassesOfShareCapitalAxis
4	Share Capital [member]	Member	duration		ifrs-full:ClassesOfShareCapitalMember
5	Initial Public Offering [Member]	Member	duration		aciu:InitialPublicOfferingMember
6	Series E [Member]	Member	duration		aciu:PreferenceSharesSeriesEMember
7	Legal Entity [Axis]	Axis	duration		dei:LegalEntityAxis
8	Entity [Domain]	Member	duration		dei:EntityDomain
9	Genentech [Member]	Member	duration		aciu:GenentechMember
10	Janssen [Member]	Member	duration		aciu:JanssenPharmaceuticalsMember
11	Disclosure of classes of going concern [Line Items]	LineItems	duration		aciu:DisclosureOfClassesOfGoingConcernLineItems
12	Going concern [Abstract]	Abstract	duration		aciu:GoingConcernAbstract
13	Company's cash position	Concept (Monetary)	instant	debit	ifrs-full:CashAndCashEquivalents
14	Gross proceeds received	Concept (Monetary)	duration	debit	ifrs-full:ProceedsFromIssueOfOrdinaryShares
15	Private placement extension financing	Concept (Monetary)	duration	debit	ifrs-full:ProceedsFromIssueOfPreferenceShares
16	Receipt of clinical milestone payment	Concept (Monetary)	duration	debit	aciu:CollaborativeArrangementsMilestonePaymentReceived

Model Structure
Network	090300 - Disclosure - Summary of significant accounting policies, Property, plant and equipment (Details) (http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Name
1	Summary of significant accounting policies [Abstract]	Abstract	duration	ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract
2	Disclosure of detailed information about property, plant and equipment [table]	Table	duration	ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable
3	Classes of property, plant and equipment [axis]	Axis	duration	ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis
4	Property, plant and equipment [member]	Member	duration	ifrs-full:PropertyPlantAndEquipmentMember
5	IT Equipment [Member]	Member	duration	ifrs-full:ComputerEquipmentMember
6	Laboratory Equipment [Member]	Member	duration	aciu:LaboratoryEquipmentMember
7	Leasehold Improvements / Furniture [Member]	Member	duration	aciu:LeaseholdImprovementsAndFixturesAndFittingsMember
8	Disclosure of detailed information about property, plant and equipment [line items]	LineItems	duration	ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems
9	Residual value over its estimated useful life [Abstract]	Abstract	duration	aciu:ResidualValueOverItsEstimatedUsefulLifeAbstract
10	Useful lives or depreciation rates, property, plant and equipment	Concept (String)	duration	ifrs-full:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipment

Model Structure
Network	090302 - Disclosure - Summary of significant accounting policies, Share capital and Initial Public Offering, Preferred Shares (Details) (http://acimume.com/role/SummaryOfSignificantAccountingPoliciesShareCapitalAndInitialPublicOfferingPreferredSharesDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Summary of significant accounting policies [Abstract]	Abstract	duration		ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract
2	Disclosure of classes of share capital [table]	Table	duration		ifrs-full:DisclosureOfClassesOfShareCapitalTable
3	Classes of share capital [axis]	Axis	duration		ifrs-full:ClassesOfShareCapitalAxis
4	Share Capital [member]	Member	duration		ifrs-full:ClassesOfShareCapitalMember
5	Preferred Shares [Member]	Member	duration		ifrs-full:PreferenceSharesMember
6	Common Shares [Member]	Member	duration		ifrs-full:OrdinarySharesMember
7	Preferred Shares Series E [Member]	Member	duration		aciu:PreferenceSharesSeriesEMember
8	Disclosure of classes of share capital [line items]	LineItems	duration		ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
9	Preferred Shares [Abstract]	Abstract	duration		aciu:PreferredSharesAbstract
10	Number of preferred shares classes outstanding	Concept (Integer)	duration		aciu:NumberOfClassesOfPreferredStock
11	Conversion ratio of preferred shares to common shares	Concept (Pure)	duration		aciu:ConvertibleSharesConversionRatio
12	Number of separate capital increases	Concept (Integer)	duration		aciu:NumberOfCapitalIncreases
13	Percentage of shares outstanding owned by Preferred shareholders	Concept (Percent)	duration		aciu:PercentageOfSharesOutstandingHeldByPreferenceStockOwners
14	Term of equity financing	Concept (Duration)	duration		aciu:TermOfEquityFinancingPreferredStock
15	Number of votes entitled for each preferred share	Concept (Integer)	duration		aciu:VotingRightsNumberOfVotesPerShareHeld
16	Dividends paid to preferred shareholders	Concept (Monetary)	duration	debit	ifrs-full:DividendsPaid
17	Stock split ratio	Concept (Pure)	duration		aciu:StockSplitConversionRatio
18	Nominal value per share (in CHF per share)	Concept (Per-Share)	instant		ifrs-full:ParValuePerShare
19	Private placement shares issued (in shares)	Concept (Shares)	duration		aciu:IncreaseDecreaseInNumberOfPreferredSharesIssued
20	Private placement share price (in dollars per share)	Concept (Per-Share)	instant		aciu:SharePricePrivatePlacementSaleOfStock
21	Aggregate subscription amount	Concept (Monetary)	instant	credit	aciu:ShareSubscriptionAmount

Model Structure
Network	090304 - Disclosure - Summary of significant accounting policies, Share capital and Initial Public Offering (Details) (http://acimume.com/role/SummaryOfSignificantAccountingPoliciesShareCapitalAndInitialPublicOfferingDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Summary of significant accounting policies [Abstract]	Abstract	duration		ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract
2	Disclosure of classes of share capital [table]	Table	duration		ifrs-full:DisclosureOfClassesOfShareCapitalTable
3	Classes of share capital [axis]	Axis	duration		ifrs-full:ClassesOfShareCapitalAxis
4	Share Capital [member]	Member	duration		ifrs-full:ClassesOfShareCapitalMember
5	Initial Public Offering [Member]	Member	duration		aciu:InitialPublicOfferingMember
6	Over-Allotment Option [Member]	Member	duration		aciu:OptionForOverAllotmentMember
7	Common Shares [Member]	Member	duration		ifrs-full:OrdinarySharesMember
8	Disclosure of classes of share capital [line items]	LineItems	duration		ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
9	Initial Public Offering (IPO) [Abstract]	Abstract	duration		aciu:InitialPublicOfferingAbstract
10	Shares issued (in shares)	Concept (Shares)	duration		ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
11	IPO share price (in dollars per share)	Concept (Per-Share)	instant		aciu:SharePriceInitialPublicOffering
12	Gross proceeds received	Concept (Monetary)	duration	debit	ifrs-full:ProceedsFromIssueOfOrdinaryShares
13	Proceeds from IPO net of underwriting fees	Concept (Monetary)	duration	debit	aciu:ProceedsFromIssuingSharesNetOfUnderwritingFees
14	Increase in share premium	Concept (Monetary)	duration	credit	aciu:IncreaseDecreaseToSharePremiumThroughIssuanceOfEquity

Model Structure
Network	090306 - Disclosure - Summary of significant accounting policies, Income taxes and Segment reporting (Details) (http://acimume.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesAndSegmentReportingDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Name
1	Summary of significant accounting policies [Abstract]	Abstract	duration	ifrs-full:DisclosureOfInitialApplicationOfStandardsOrInterpretationsAbstract
2	Income taxes [Abstract]	Abstract	duration	ifrs-full:MajorComponentsOfTaxExpenseIncomeAbstract
3	Tax loss carryforward period	Concept (Duration)	duration	aciu:IncomeTaxLossCarryforwardPeriod
4	Segment reporting [Abstract]	Abstract	duration	ifrs-full:DisclosureOfOperatingSegmentsAbstract
5	Number of operating segments	Concept (Integer)	duration	aciu:OperatingSegmentsNumber
6	Number of reportable segments	Concept (Integer)	duration	aciu:ReportableSegmentsNumber

Model Structure
Network	090400 - Disclosure - Property, plant and equipment (Details) (http://acimume.com/role/PropertyPlantAndEquipmentDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Property, plant and equipment [Abstract]	Abstract	duration		ifrs-full:DisclosureOfPropertyPlantAndEquipmentAbstract
2	Disclosure of detailed information about property, plant and equipment [table]	Table	duration		ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable
3	Classes of property, plant and equipment [axis]	Axis	duration		ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis
4	Property, plant and equipment [member]	Member	duration		ifrs-full:PropertyPlantAndEquipmentMember
5	Furniture [Member]	Member	duration		ifrs-full:FixturesAndFittingsMember
6	Computers / IT [Member]	Member	duration		ifrs-full:ComputerEquipmentMember
7	Lab Equipment [Member]	Member	duration		aciu:LaboratoryEquipmentMember
8	Leasehold Improvements [Member]	Member	duration		ifrs-full:LeaseholdImprovementsMember
9	Carrying amount, accumulated depreciation, amortization and impairment and gross carrying amount [axis]	Axis	duration		ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis
10	Carrying amount [member]	Member	duration		ifrs-full:CarryingAmountMember
11	Acquisition Cost [Member]	Member	duration		ifrs-full:GrossCarryingAmountMember
12	Accumulated Depreciation [Member]	Member	duration		ifrs-full:AccumulatedDepreciationAndAmortisationMember
13	Disclosure of detailed information about property, plant and equipment [line items]	LineItems	duration		ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems
14	Property, plant and equipment [Abstract]	Abstract	duration		ifrs-full:ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract
15	Property, plant and equipment, beginning of period	Concept (Monetary)	instant	debit	ifrs-full:PropertyPlantAndEquipment
16	Acquisitions	Concept (Monetary)	duration	debit	ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
17	Depreciation expense	Concept (Monetary)	duration		ifrs-full:DepreciationPropertyPlantAndEquipment
18	Property, plant and equipment, end of period	Concept (Monetary)	instant	debit	ifrs-full:PropertyPlantAndEquipment

Model Structure
Network	090500 - Disclosure - Financial Assets (Details) (http://acimume.com/role/FinancialAssetsDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Financial Assets [Abstract]	Abstract	duration		ifrs-full:DisclosureOfFinancialAssetsAbstract
2	Number of deposits in escrow accounts	Concept (Integer)	duration		aciu:NumberOfEscrowDepositAccounts
3	Deposits in escrow accounts	Concept (Monetary)	instant	debit	ifrs-full:NoncurrentRestrictedCashAndCashEquivalents

Model Structure
Network	090600 - Disclosure - Prepaid expenses and accrued income (Details) (http://acimume.com/role/PrepaidExpensesAndAccruedIncomeDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Prepaid expenses and accrued income [Abstract]	Abstract	duration		ifrs-full:PrepaymentsAndAccruedIncomeAbstract
2	Prepaid Expenses and Accrued Income [Table]	Table	duration		aciu:PrepaidExpensesAndAccruedIncomeTable
3	Types of contracts [axis]	Axis	duration		ifrs-full:TypesOfContractsAxis
4	Types of contracts [member]	Member	duration		ifrs-full:TypesOfContractsMember
5	Biogen [Member]	Member	duration		aciu:CollaborationAgreementOf2016BiogenMember
6	Janssen [Member]	Member	duration		aciu:CollaborationAgreementOf2014JanssenPharmaceuticalsMember
7	Prepaid Expenses and Accrued Income [Line Items]	LineItems	duration		aciu:PrepaidExpensesAndAccruedIncomeLineItems
8	Prepaid expenses	Concept (Monetary)	instant	debit	ifrs-full:CurrentPrepayments
9	Accrued income	Concept (Monetary)	instant	debit	ifrs-full:CurrentAccruedIncome
10	Total	Concept (Monetary)	instant	debit	ifrs-full:CurrentPrepaymentsAndCurrentAccruedIncome

Model Structure
Network	090700 - Disclosure - Other current receivables (Details) (http://acimume.com/role/OtherCurrentReceivablesDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Other current receivables [Abstract]	Abstract	duration		aciu:OtherCurrentReceivablesAbstract
2	Disclosure of other current receivables [Table]	Table	duration		aciu:DisclosureOfOtherCurrentReceivablesTable
3	Range [axis]	Axis	duration		ifrs-full:RangeAxis
4	Ranges [member]	Member	duration		ifrs-full:RangesMember
5	Top of Range [Member]	Member	duration		ifrs-full:TopOfRangeMember
6	Disclosure of other current receivables [Line Items]	LineItems	duration		aciu:DisclosureOfOtherCurrentReceivablesLineItems
7	Other current receivables [abstract]	Abstract	duration		ifrs-full:TradeAndOtherReceivablesAbstract
8	Other receivables	Concept (Monetary)	instant	debit	ifrs-full:OtherCurrentReceivables
9	Swiss VAT	Concept (Monetary)	instant	debit	ifrs-full:CurrentValueAddedTaxReceivables
10	Withholding tax	Concept (Monetary)	instant	debit	ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax
11	Total	Concept (Monetary)	instant	debit	aciu:CurrentReceivablesClassifiedAsOtherAndValueAddedAndWithholdingTaxes
12	Maturity period of assets	Concept (Duration)	duration		aciu:PeriodOfMaturityReceivablesFairValueCarryingAmount

Model Structure
Network	090800 - Disclosure - Cash and cash equivalents (Details) (http://acimume.com/role/CashAndCashEquivalentsDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Cash and cash equivalents [Abstract]	Abstract	duration		ifrs-full:CashAndCashEquivalentsAbstract
2	Cash and cash equivalents [Table]	Table	duration		aciu:CashAndCashEquivalentsTable
3	Currency [Axis]	Axis	duration		us-gaap:CurrencyAxis
4	All Currencies [Domain]	Member	duration		currency:AllCurrenciesDomain
5	CHF [Member]	Member	duration		currency:CHF
6	EUR [Member]	Member	duration		currency:EUR
7	USD [Member]	Member	duration		currency:USD
8	Cash and cash equivalent [Line Items]	LineItems	duration		aciu:CashAndCashEquivalentLineItems
9	Cash and cash equivalents [Abstract]	Abstract	duration		ifrs-full:CashAbstract
10	Cash	Concept (Monetary)	instant	debit	ifrs-full:CashAndCashEquivalents
11	Translation rate into CHF	Concept (Decimal)	instant		ifrs-full:ClosingForeignExchangeRate

Model Structure
Network	090900 - Disclosure - Share capital (Details) (http://acimume.com/role/ShareCapitalDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Share capital [Abstract]	Abstract	duration		ifrs-full:ChangesInEquityAbstract
2	Disclosure of classes of share capital [table]	Table	duration		ifrs-full:DisclosureOfClassesOfShareCapitalTable
3	Classes of share capital [axis]	Axis	duration		ifrs-full:ClassesOfShareCapitalAxis
4	Share Capital [member]	Member	duration		ifrs-full:ClassesOfShareCapitalMember
5	Common Shares [Member]	Member	duration		ifrs-full:OrdinarySharesMember
6	Preferred Shares Series E [Member]	Member	duration		aciu:PreferenceSharesSeriesEMember
7	Common and Preferred Shares [Member]	Member	duration		aciu:OrdinaryAndPreferenceSharesMember
8	Preferred Shares [Member]	Member	duration		ifrs-full:PreferenceSharesMember
9	Types of share-based payment arrangements [axis]	Axis	duration		ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
10	Share-based payment arrangements [member]	Member	duration		ifrs-full:SharebasedPaymentArrangementsMember
11	Restricted shares [Member]	Member	duration		aciu:RestrictedSharesMember
12	Restricted Stock Units [Member]	Member	duration		aciu:RestrictedStockUnitsMember
13	Disclosure of classes of share capital [line items]	LineItems	duration		ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
14	Shares outstanding (in shares)	Concept (Shares)	instant		ifrs-full:NumberOfSharesOutstanding
15	Share capital	Concept (Monetary)	instant	credit	ifrs-full:IssuedCapital
16	Nominal value per share (in CHF per share)	Concept (Per-Share)	instant		ifrs-full:ParValuePerShare
17	Shares issued (in shares)	Concept (Shares)	duration		ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
18	Shares vested (in shares)	Concept (Decimal)	duration		ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
19	Options exercised	Concept (Decimal)	duration		ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
20	Private placement shares issued (in shares)	Concept (Shares)	duration		aciu:IncreaseDecreaseInNumberOfPreferredSharesIssued
21	Private placement share price (in dollars/CHF per share)	Concept (Per-Share)	instant		aciu:SharePricePrivatePlacementSaleOfStock
22	Subscription amount	Concept (Monetary)	instant	credit	aciu:ShareSubscriptionAmount
23	Additional shares issued upon conversion (in shares)	Concept (Shares)	duration		aciu:SharesIssuedConversionOfStock
24	Conversion ratio of preferred shares to common shares	Concept (Pure)	duration		aciu:ConvertibleSharesConversionRatio

Model Structure
Network	091000 - Disclosure - Trade payables and accrued liabilities (Details) (http://acimume.com/role/TradePayablesAndAccruedLiabilitiesDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Trade payables and accrued liabilities [Abstract]	Abstract	duration		ifrs-full:TradeAndOtherCurrentPayablesAbstract
2	Trade payables and other payables	Concept (Monetary)	instant	credit	ifrs-full:TradeAndOtherCurrentPayables
3	Accrued research and development costs	Concept (Monetary)	instant	credit	aciu:CurrentAccruedResearchAndDevelopmentCosts
4	Accrued payroll expenses	Concept (Monetary)	instant	credit	ifrs-full:CurrentProvisionsForEmployeeBenefits
5	Other accrued expenses	Concept (Monetary)	instant	credit	ifrs-full:OtherCurrentLiabilities
6	Deferred income	Concept (Monetary)	instant	credit	ifrs-full:DeferredIncomeClassifiedAsCurrent
7	Total current liabilities	Concept (Monetary)	instant	credit	ifrs-full:CurrentLiabilities
8	Accrual of performance-related remuneration	Concept (Monetary)	instant	credit	ifrs-full:Accruals

Model Structure
Network	091100 - Disclosure - Deferred income (Details) (http://acimume.com/role/DeferredIncomeDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Deferred income [Abstract]	Abstract	duration		ifrs-full:AccrualsAndDeferredIncomeAbstract
2	Deferred income [Table]	Table	duration		aciu:DeferredIncomeTable
3	Types of contracts [axis]	Axis	duration		ifrs-full:TypesOfContractsAxis
4	Types of contracts [member]	Member	duration		ifrs-full:TypesOfContractsMember
5	Biogen [Member]	Member	duration		aciu:CollaborationAgreementOf2016BiogenMember
6	Deferred income [Line Items]	LineItems	duration		aciu:DeferredIncomeLineItems
7	Deferred income	Concept (Monetary)	instant	credit	ifrs-full:DeferredIncomeClassifiedAsCurrent
8	Upfront fees	Concept (Monetary)	duration	credit	aciu:RevenueUpfrontFeesReceived

Model Structure
Network	091200 - Disclosure - Long term financing obligation (Details) (http://acimume.com/role/LongTermFinancingObligationDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Long term financing obligation [Abstract]	Abstract	duration		aciu:LongTermFinancingObligationAbstract
2	Long term financing obligation [Table]	Table	duration		aciu:LongTermFinancingObligationTable
3	Types of contracts [axis]	Axis	duration		ifrs-full:TypesOfContractsAxis
4	Types of contracts [member]	Member	duration		ifrs-full:TypesOfContractsMember
5	Grants, LuMind Research Down Syndrome Foundation [Member]	Member	duration		aciu:GrantsLuMindResearchDownSyndromeFoundationMember
6	Long term financing obligation [Line Items]	LineItems	duration		aciu:LongTermFinancingObligationLineItems
7	Funding commitment	Concept (Monetary)	instant	credit	aciu:FundingCommitment
8	Reimbursement percentage of funding commitment.	Concept (Percent)	duration		aciu:ReimbursementPercentageOfFundingCommitment
9	Accrued interest - long-term	Concept (Monetary)	instant	credit	ifrs-full:NoncurrentInterestPayable
10	Long-term financing obligation	Concept (Monetary)	instant	credit	ifrs-full:NoncurrentFinancialLiabilities

Model Structure
Network	091300 - Disclosure - Revenues (Details) (http://acimume.com/role/RevenuesDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Revenues [Abstract]	Abstract	duration		ifrs-full:RevenueAbstract
2	Contract revenue	Concept (Monetary)	duration	credit	ifrs-full:RevenueFromContractsWithCustomers
3	Total revenue	Concept (Monetary)	duration	credit	ifrs-full:Revenue
4	Disclosure of disaggregation of revenue from contracts with customers [table]	Table	duration		ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable
5	Products and services [axis]	Axis	duration		ifrs-full:ProductsAndServicesAxis
6	Products and services [member]	Member	duration		ifrs-full:ProductsAndServicesMember
7	Anti-Abeta Antibody in AD [Member]	Member	duration		aciu:AntiAbetaAntibodyInADMember
8	Anti-tau Antibody in AD [Member]	Member	duration		aciu:AntiTauAntibodyInADMember
9	Tau Vaccine in AD [Member]	Member	duration		aciu:TauVaccineInADMember
10	Tau-PET Imaging Agent in AD [Member]	Member	duration		aciu:TauPETImagingAgentInADMember
11	Alpha-synuclein and TDP-43 PET Tracer in AD [Member]	Member	duration		aciu:AlphaSynucleinAndTDP43PETTracerInADMember
12	Recombinant Protein Therapeutic Candidate [Member]	Member	duration		aciu:RecombinantProteinTherapeuticCandidateMember
13	Types of contracts [axis]	Axis	duration		ifrs-full:TypesOfContractsAxis
14	Types of contracts [member]	Member	duration		ifrs-full:TypesOfContractsMember
15	Collaboration and License Revenue [Member]	Member	duration		aciu:CollaborationAndLicenseRevenueAgreementsMember
16	Collaboration Agreement of 2006, Genentech [Member]	Member	duration		aciu:CollaborationAgreementOf2006GenentechMember
17	Collaboration Agreement of 2012, Genentech [Member]	Member	duration		aciu:CollaborationAgreementOf2012GenentechMember
18	Collaboration Agreement of 2014, Janssen Pharmaceuticals [Member]	Member	duration		aciu:CollaborationAgreementOf2014JanssenPharmaceuticalsMember
19	License and Collaboration Agreement of 2014, Piramal Imaging [Member]	Member	duration		aciu:LicenseAndCollaborationAgreementOf2014PiramalImagingMember
20	Collaboration Agreement of 2016, Biogen [Member]	Member	duration		aciu:CollaborationAgreementOf2016BiogenMember
21	Collaboration With Essex Bio-Technology Limited [Member]	Member	duration		aciu:CollaborationWithEssexBioTechnologyLimitedMember
22	Grant revenue [Member]	Member	duration		aciu:GrantRevenueMember
23	Grant from Michael J. Fox Foundation [Member]	Member	duration		aciu:GrantsMichaelJFoxFoundationMember
24	Range [axis]	Axis	duration		ifrs-full:RangeAxis
25	Ranges [member]	Member	duration		ifrs-full:RangesMember
26	Bottom of Range [Member]	Member	duration		ifrs-full:BottomOfRangeMember
27	Top of Range [Member]	Member	duration		ifrs-full:TopOfRangeMember
28	Disclosure of disaggregation of revenue from contracts with customers [line items]	LineItems	duration		ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
29	Revenues [Abstract]	Abstract	duration		ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract
30	Collaboration contract receivable	Concept (Monetary)	instant	debit	aciu:CollaborativeAgreementReceivableExpected
31	Cumulative payments received	Concept (Monetary)	instant	credit	aciu:CollaborativeAgreementCumulativePaymentsReceived
32	Milestone payment recognized	Concept (Monetary)	duration	credit	aciu:CollaborativeAgreementMilestonePaymentRecognized
33	Milestone payment received	Concept (Monetary)	duration	credit	aciu:CollaborativeAgreementMilestonePaymentReceived
34	Number of additional indications	Concept (Integer)	duration		aciu:CollaborativeAgreementNumberOfIndications
35	Number of companies entered into joint research collaboration	Concept (Integer)	duration		aciu:CollaborativeAgreementNumberOfCompaniesEnteredIntoJointResearchCollaboration
36	Period of joint research collaboration	Concept (Duration)	duration		aciu:CollaborativeAgreementJointResearchCollaborationPeriod
37	Joint research collaboration, subsequently amended period	Concept (Duration)	duration		aciu:CollaborativeAgreementJointResearchCollaborationSubsequentlyAmendedPeriod
38	Revenue recognition deferral period	Concept (Duration)	duration		aciu:RevenueRecognitionDeferralPeriod
39	Revenue recognition amortization period	Concept (Duration)	duration		aciu:RevenueRecognitionAmortizationPeriod
40	Collaboration contract receivable for clinical milestones	Concept (Monetary)	instant	debit	aciu:CollaborativeAgreementCollaborationContractReceivableForClinicalMilestones
41	Collaboration contract receivable for regulatory, commercialization and sales milestones	Concept (Monetary)	instant	debit	aciu:CollaborativeAgreementCollaborationContractReceivableForRegulatoryCommercializationAndSalesMilestones
42	Period to provide notice of termination of agreement	Concept (Duration)	duration		aciu:CollaborativeAgreementNoticeOfContractTerminationPeriod
43	Cumulative payments recognized	Concept (Monetary)	duration	credit	aciu:CollaborativeAgreementCumulativePaymentsRecognized
44	Current deferred income	Concept (Monetary)	instant	credit	ifrs-full:DeferredIncomeClassifiedAsCurrent
45	Period for initial research plan	Concept (Duration)	duration		aciu:PeriodForInitialResearchPlan
46	Term of grant	Concept (Duration)	duration		aciu:TermOfGrant
47	Grant revenue recognized	Concept (Monetary)	duration	credit	aciu:GrantRevenue

Model Structure
Network	091400 - Disclosure - Expenses by category (Details) (http://acimume.com/role/ExpensesByCategoryDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Expenses by category [Abstract]	Abstract	duration		aciu:ExpensesByCategoryAbstract
2	Research and Development [Abstract]	Abstract	duration		aciu:ResearchAndDevelopmentExpensesAbstract
3	Operating expenses	Concept (Monetary)	duration	debit	aciu:ResearchAndDevelopmentExpenseAllocationOperatingExpense
4	Payroll expenses	Concept (Monetary)	duration	debit	aciu:ResearchAndDevelopmentExpenseAllocationWagesAndSalaries
5	Share-based compensation	Concept (Monetary)	duration	debit	aciu:ResearchAndDevelopmentExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees
6	Total research and development expenses	Concept (Monetary)	duration	debit	ifrs-full:ResearchAndDevelopmentExpense
7	General and Administration [Abstract]	Abstract	duration		aciu:GeneralAndAdministrationAbstract
8	Operating expenses	Concept (Monetary)	duration	debit	aciu:GeneralAndAdministrativeExpenseAllocationOperatingExpense
9	Payroll expenses	Concept (Monetary)	duration	debit	aciu:GeneralAndAdministrativeExpenseAllocationWagesAndSalaries
10	Share-based compensation	Concept (Monetary)	duration	debit	aciu:GeneralAndAdministrativeExpenseAllocationExpenseFromShareBasedPaymentTransactionsWithEmployees
11	Total general and administrative expenses	Concept (Monetary)	duration	debit	ifrs-full:SellingGeneralAndAdministrativeExpense
12	Financial Result, net [Abstract]	Abstract	duration		aciu:FinancialResultNetAbstract
13	Interest income/ (expense)	Concept (Monetary)	duration	credit	ifrs-full:InterestRevenueExpense
14	Foreign currency remeasurement gain/(loss), net	Concept (Monetary)	duration	credit	ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
15	Other finance income/(expense)	Concept (Monetary)	duration	credit	ifrs-full:OtherFinanceIncomeCost
16	Finance result, net	Concept (Monetary)	duration	credit	ifrs-full:FinanceIncomeCost

Model Structure
Network	091500 - Disclosure - Related-party transactions (Details) (http://acimume.com/role/RelatedpartyTransactionsDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Related-party transactions [Abstract]	Abstract	duration		ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesAbstract
2	Disclosure of transactions between related parties [table]	Table	duration		ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesTable
3	Categories of related parties [axis]	Axis	duration		ifrs-full:CategoriesOfRelatedPartiesAxis
4	Entity's total for related parties [member]	Member	duration		ifrs-full:EntitysTotalForRelatedPartiesMember
5	Executive Management [Member]	Member	duration		aciu:ExecutiveManagementMember
6	Board of Directors [Member]	Member	duration		aciu:BoardOfDirectorsMember
7	Former Chief Financial Officer [Member]	Member	duration		aciu:FormerChiefFinancialOfficerMember
8	Board of Directors and Executive Management [Member]	Member	duration		aciu:BoardOfDirectorsAndExecutiveManagementMember
9	Types of share-based payment arrangements [axis]	Axis	duration		ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
10	Share-based payment arrangements [member]	Member	duration		ifrs-full:SharebasedPaymentArrangementsMember
11	Restricted Stock Units [Member]	Member	duration		aciu:RestrictedStockUnitsMember
12	Disclosure of transactions between related parties [line items]	LineItems	duration		ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesLineItems
13	Number of individuals, Board of Directors	Concept (Integer)	duration		aciu:NumberOfPersonsKeyManagementBoardOfDirectors
14	Number of individuals, Executive Management	Concept (Integer)	duration		aciu:NumberOfPersonsKeyManagementExecutiveManagement
15	Short-term employee benefits	Concept (Monetary)	duration	debit	ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
16	Post-employment benefits	Concept (Monetary)	duration	debit	ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
17	Share-based compensation	Concept (Monetary)	duration	debit	ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
18	Total	Concept (Monetary)	duration	debit	ifrs-full:KeyManagementPersonnelCompensation
19	Number of options granted (in shares)	Concept (Decimal)	duration		ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
20	Fair value of options granted	Concept (Monetary)	instant	credit	ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
21	Number of restricted shares granted (in shares)	Concept (Decimal)	duration		ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted

Model Structure
Network	091600 - Disclosure - Income taxes (Details) (http://acimume.com/role/IncomeTaxesDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Income taxes [Abstract]	Abstract	duration		ifrs-full:MajorComponentsOfTaxExpenseIncomeAbstract
2	Deferred tax assets	Concept (Monetary)	instant	debit	ifrs-full:DeferredTaxAssets
3	Deferred tax liabilities	Concept (Monetary)	instant	credit	ifrs-full:DeferredTaxLiabilities
4	Income tax expense reconciled to Income / (loss) [Abstract]	Abstract	duration		ifrs-full:ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract
5	Income / (loss) before income tax	Concept (Monetary)	duration	credit	ifrs-full:AccountingProfit
6	Tax expense / (benefit) calculated at the statutory rate of 20.5% (21% for 2016 and 22% for 2015)	Concept (Monetary)	duration	debit	ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
7	Effect of Swiss Tax Holidays	Concept (Monetary)	duration	credit	aciu:TaxBenefitIncomeTaxHoliday
8	Permanent differences	Concept (Monetary)	duration	credit	ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011
9	Effect of unrecognized carry forward tax loss	Concept (Monetary)	duration	credit	ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense
10	Effect of unused tax losses and tax offsets not recognized as deferred tax assets	Concept (Monetary)	duration	credit	ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense
11	Effective income tax rate benefit / (expense)	Concept (Monetary)	duration	debit	ifrs-full:IncomeTaxExpenseContinuingOperations
12	Corporate tax rate	Concept (Percent)	duration		ifrs-full:ApplicableTaxRate
13	Effective tax rate	Concept (Percent)	duration		aciu:EffectiveTaxRate

Model Structure
Network	091602 - Disclosure - Income taxes, Unrecognized Deductible Temporary Differences, Unused Tax Losses and Unused Tax Credits (Details) (http://acimume.com/role/IncomeTaxesUnrecognizedDeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Income taxes [Abstract]	Abstract	duration		ifrs-full:MajorComponentsOfTaxExpenseIncomeAbstract
2	Disclosure of temporary difference, unused tax losses and unused tax credits [table]	Table	duration		ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable
3	Temporary difference, unused tax losses and unused tax credits [axis]	Axis	duration		ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis
4	Temporary difference, unused tax losses and unused tax credits [member]	Member	duration		ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember
5	Tax Losses [Member]	Member	duration		ifrs-full:UnusedTaxLossesMember
6	Deductible Temporary Differences Related to the Retirement Benefit Plan [Member]	Member	duration		ifrs-full:UnusedTaxCreditsMember
7	Maturity [axis]	Axis	duration		ifrs-full:MaturityAxis
8	Aggregated time bands [member]	Member	duration		ifrs-full:AggregatedTimeBandsMember
9	Loss Expiry, December 31, 2017 [Member]	Member	duration		ifrs-full:NotLaterThanOneYearMember
10	Loss Expiry, December 31, 2018 [Member]	Member	duration		ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember
11	Loss Expiry, December 31, 2019 [Member]	Member	duration		ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember
12	Loss Expiry, December 31, 2020 [Member]	Member	duration		ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember
13	Loss Expiry, December 31, 2021 [Member]	Member	duration		ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember
14	Loss Expiry, December 31, 2022 [Member]	Member	duration		aciu:LaterThanFiveYearsAndNotLaterThanSixYearsMember
15	Loss Expiry, December 31, 2023 [Member]	Member	duration		aciu:LaterThanSixYearsAndNotLaterThanSevenYearsMember
16	Loss Expiry, December 31, 2024 [Member]	Member	duration		aciu:LaterThanSixYearsAndNotLaterThanEightYearsMember
17	Disclosure of temporary difference, unused tax losses and unused tax credits [line items]	LineItems	duration		ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems
18	Unrecognized deductible temporary differences, unused tax losses and unused tax credits [Abstract]	Abstract	duration		ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract
19	Unrecognized deductible temporary differences, unused tax losses and unused tax credits	Concept (Monetary)	instant	debit	ifrs-full:DeferredTaxAssets
20	Unused tax losses and tax credits	Concept (Monetary)	instant	credit	ifrs-full:DeferredTaxLiabilityAsset
21	Tax losses split by expiry date [Abstract]	Abstract	duration		aciu:TaxLossesSplitByExpiryDateAbstract
22	Unused tax losses	Concept (Monetary)	instant		ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
23	Increase in tax losses available as an offset	Concept (Monetary)	duration	credit	ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset

Model Structure
Network	091700 - Disclosure - Retirement benefit plan (Details) (http://acimume.com/role/RetirementBenefitPlanDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Retirement benefit plan [Abstract]	Abstract	duration		ifrs-full:DisclosureOfDefinedBenefitPlansAbstract
2	Disclosure of net defined benefit liability (asset) [table]	Table	duration		ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetTable
3	Defined benefit plans [axis]	Axis	duration		ifrs-full:DefinedBenefitPlansAxis
4	Defined benefit plans [member]	Member	duration		ifrs-full:DefinedBenefitPlansMember
5	Domestic Defined Benefit Plans [Member]	Member	duration		ifrs-full:DomesticDefinedBenefitPlansMember
6	Employee [Member]	Member	duration		aciu:DefinedBenefitsPlanEmployeeMember
7	Employer [Member]	Member	duration		aciu:DefinedBenefitsPlanEmployerMember
8	Net defined benefit liability (asset) [axis]	Axis	duration		ifrs-full:NetDefinedBenefitLiabilityAssetAxis
9	Net defined benefit liability (asset) [member]	Member	duration		ifrs-full:NetDefinedBenefitLiabilityAssetMember
10	Defined Benefit Obligation [Member]	Member	duration		ifrs-full:PresentValueOfDefinedBenefitObligationMember
11	Fair Value of Plan Assets [Member]	Member	duration		ifrs-full:PlanAssetsMember
12	Disclosure of net defined benefit liability (asset) [line items]	LineItems	duration		ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetLineItems
13	Contributions paid to the plan by computing percentage in salary	Concept (Percent)	duration		aciu:DefinedBenefitPlanPercentageOfContribution
14	Defined benefit pension plan amount recognized in balance sheet [Abstract]	Abstract	duration		aciu:DefinedBenefitPensionPlanAmountRecognizedInBalanceSheetAbstract
15	Total liability	Concept (Monetary)	instant	credit	ifrs-full:NoncurrentProvisionsForEmployeeBenefits
16	Net pension cost in statement of income [Abstract]	Abstract	duration		aciu:NetPensionCostInStatementOfIncomeAbstract
17	Service cost	Concept (Monetary)	duration	credit	ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
18	Interest cost	Concept (Monetary)	duration	credit	aciu:InterestCostNetDefinedBenefitLiabilityAsset
19	Interest income	Concept (Monetary)	duration	debit	aciu:InterestIncomeNetDefinedBenefitLiabilityAsset
20	Impact of plan amendment	Concept (Monetary)	duration	debit	aciu:ActuarialLossesGainsArisingFromChangesInBenefitPlanNetDefinedBenefitLiabilityAsset
21	Net pension cost	Concept (Monetary)	duration	credit	ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAsset

Model Structure
Network	091702 - Disclosure - Retirement benefit plan, Changes in Defined Benefit Obligation (Details) (http://acimume.com/role/RetirementBenefitPlanChangesInDefinedBenefitObligationDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Retirement benefit plan [Abstract]	Abstract	duration		ifrs-full:DisclosureOfDefinedBenefitPlansAbstract
2	Disclosure of net defined benefit liability (asset) [table]	Table	duration		ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetTable
3	Defined benefit plans [axis]	Axis	duration		ifrs-full:DefinedBenefitPlansAxis
4	Defined benefit plans [member]	Member	duration		ifrs-full:DefinedBenefitPlansMember
5	Domestic Defined Benefit Plans [Member]	Member	duration		ifrs-full:DomesticDefinedBenefitPlansMember
6	Net defined benefit liability (asset) [axis]	Axis	duration		ifrs-full:NetDefinedBenefitLiabilityAssetAxis
7	Net defined benefit liability (asset) [member]	Member	duration		ifrs-full:NetDefinedBenefitLiabilityAssetMember
8	Defined Benefit Obligation [Member]	Member	duration		ifrs-full:PresentValueOfDefinedBenefitObligationMember
9	Disclosure of net defined benefit liability (asset) [line items]	LineItems	duration		ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetLineItems
10	Changes in defined benefit obligation [Abstract]	Abstract	duration		ifrs-full:ChangesInNetDefinedBenefitLiabilityAssetAbstract
11	Defined benefit obligation, beginning of period	Concept (Monetary)	instant	credit	ifrs-full:LiabilityAssetOfDefinedBenefitPlans
12	Service cost	Concept (Monetary)	duration	credit	ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
13	Interest cost	Concept (Monetary)	duration	credit	aciu:InterestCostNetDefinedBenefitLiabilityAsset
14	Change in demographic assumptions	Concept (Monetary)	duration	debit	ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
15	Change in financial assumptions	Concept (Monetary)	duration	debit	ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
16	Other actuarial gains / (losses)	Concept (Monetary)	duration	debit	aciu:ActuarialGainsLossesArisingFromChangesInOtherAssumptionsNetDefinedBenefitLiabilityAsset
17	Plan amendment	Concept (Monetary)	duration	debit	aciu:ActuarialLossesGainsArisingFromChangesInBenefitPlanNetDefinedBenefitLiabilityAsset
18	Benefit payments	Concept (Monetary)	duration	debit	ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
19	Employees' contributions	Concept (Monetary)	duration	debit	ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
20	Defined benefit obligation, end of period	Concept (Monetary)	instant	credit	ifrs-full:LiabilityAssetOfDefinedBenefitPlans

Model Structure
Network	091704 - Disclosure - Retirement benefit plan, Changes in Fair Value of Plan Assets (Details) (http://acimume.com/role/RetirementBenefitPlanChangesInFairValueOfPlanAssetsDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Retirement benefit plan [Abstract]	Abstract	duration		ifrs-full:DisclosureOfDefinedBenefitPlansAbstract
2	Disclosure of net defined benefit liability (asset) [table]	Table	duration		ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetTable
3	Defined benefit plans [axis]	Axis	duration		ifrs-full:DefinedBenefitPlansAxis
4	Defined benefit plans [member]	Member	duration		ifrs-full:DefinedBenefitPlansMember
5	Domestic Defined Benefit Plans [Member]	Member	duration		ifrs-full:DomesticDefinedBenefitPlansMember
6	Net defined benefit liability (asset) [axis]	Axis	duration		ifrs-full:NetDefinedBenefitLiabilityAssetAxis
7	Net defined benefit liability (asset) [member]	Member	duration		ifrs-full:NetDefinedBenefitLiabilityAssetMember
8	Fair Value of Plan Assets [Member]	Member	duration		ifrs-full:PlanAssetsMember
9	Maturity [axis]	Axis	duration		ifrs-full:MaturityAxis
10	Aggregated time bands [member]	Member	duration		ifrs-full:AggregatedTimeBandsMember
11	2018 [Member]	Member	duration		ifrs-full:NotLaterThanOneYearMember
12	Disclosure of net defined benefit liability (asset) [line items]	LineItems	duration		ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetLineItems
13	Changes in fair value of plan assets [Abstract]	Abstract	duration		aciu:ChangesInFairValueOfPlanAssetsAbstract
14	Fair value of plan assets, beginning of period	Concept (Monetary)	instant	debit	ifrs-full:PlanAssetsAtFairValue
15	Interest income	Concept (Monetary)	duration	debit	aciu:InterestIncomeNetDefinedBenefitLiabilityAsset
16	Employees' contributions	Concept (Monetary)	duration	debit	ifrs-full:ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset
17	Employer's contributions	Concept (Monetary)	duration	debit	ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
18	Benefits payments	Concept (Monetary)	duration	debit	ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
19	Plan assets gains/(losses)	Concept (Monetary)	duration	debit	ifrs-full:ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset
20	Fair value of plan assets, end of period	Concept (Monetary)	instant	debit	ifrs-full:PlanAssetsAtFairValue

Model Structure
Network	091706 - Disclosure - Retirement benefit plan, Change in Net Definied Benefit Liability (Details) (http://acimume.com/role/RetirementBenefitPlanChangeInNetDefiniedBenefitLiabilityDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Retirement benefit plan [Abstract]	Abstract	duration		ifrs-full:DisclosureOfDefinedBenefitPlansAbstract
2	Disclosure of net defined benefit liability (asset) [table]	Table	duration		ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetTable
3	Defined benefit plans [axis]	Axis	duration		ifrs-full:DefinedBenefitPlansAxis
4	Defined benefit plans [member]	Member	duration		ifrs-full:DefinedBenefitPlansMember
5	Domestic Defined Benefit Plans [Member]	Member	duration		ifrs-full:DomesticDefinedBenefitPlansMember
6	Disclosure of net defined benefit liability (asset) [line items]	LineItems	duration		ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetLineItems
7	Change in net defined benefit liability [Abstract]	Abstract	duration		aciu:ChangeInNetDefinedBenefitLiabilityAbstract
8	Net defined benefit liabilities, beginning of period	Concept (Monetary)	instant	credit	ifrs-full:NoncurrentProvisionsForEmployeeBenefits
9	Net pension cost through statement of income	Concept (Monetary)	duration	debit	ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
10	Re-measurement through other comprehensive income	Concept (Monetary)	duration	credit	ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
11	Employer's contribution	Concept (Monetary)	duration	debit	ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
12	Net defined benefit liabilities, end of period	Concept (Monetary)	instant	credit	ifrs-full:NoncurrentProvisionsForEmployeeBenefits
13	Weighted average duration period for defined benefit obligation	Concept (Decimal)	duration		ifrs-full:WeightedAverageDurationOfDefinedBenefitObligation

Model Structure
Network	091708 - Disclosure - Retirement benefit plan, Actuarial Assumptions and Sensitivity Analysis (Details) (http://acimume.com/role/RetirementBenefitPlanActuarialAssumptionsAndSensitivityAnalysisDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Retirement benefit plan [Abstract]	Abstract	duration		ifrs-full:DisclosureOfDefinedBenefitPlansAbstract
2	Disclosure of sensitivity analysis for actuarial assumptions [table]	Table	duration		ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable
3	Defined benefit plans [axis]	Axis	duration		ifrs-full:DefinedBenefitPlansAxis
4	Defined benefit plans [member]	Member	duration		ifrs-full:DefinedBenefitPlansMember
5	Domestic Defined Benefit Plans [Member]	Member	duration		ifrs-full:DomesticDefinedBenefitPlansMember
6	Actuarial assumptions [axis]	Axis	duration		ifrs-full:ActuarialAssumptionsAxis
7	Actuarial assumptions [member]	Member	duration		ifrs-full:ActuarialAssumptionsMember
8	Discount Rate [Member]	Member	duration		ifrs-full:ActuarialAssumptionOfDiscountRatesMember
9	Future Salary Increase [Member]	Member	duration		ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember
10	Future Pension Cost [Member]	Member	duration		ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember
11	Types of risks [axis]	Axis	duration		ifrs-full:TypesOfRisksAxis
12	Risks [member]	Member	duration		ifrs-full:TypesOfRisksMember
13	+0.5% Increase [Member]	Member	duration		aciu:PercentageOfReasonablyPossibleIncreaseInActuarialAssumptionMember
14	-0.5% Decrease [Member]	Member	duration		aciu:PercentageOfReasonablyPossibleDecreaseInActuarialAssumptionMember
15	Disclosure of sensitivity analysis for actuarial assumptions [line items]	LineItems	duration		ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems
16	Actuarial assumptions [Abstract]	Abstract	duration		ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsAbstract
17	Discount rate	Concept (Percent)	instant		ifrs-full:ActuarialAssumptionOfDiscountRates
18	Rate of future increase in compensations	Concept (Percent)	instant		ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
19	Rate of future increase in current pensions	Concept (Percent)	instant		ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreases
20	Mortality and disability rates	Concept (String)	duration		aciu:IssuedActuarialTablesSwitzerland
21	Sensitivity analysis [Abstract]	Abstract	duration		aciu:SensitivityAnalysisActuarialAssumptionsAbstract
22	Percentage increase in actuarial assumption	Concept (Percent)	instant		ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption
23	Percentage decrease in actuarial assumption	Concept (Percent)	instant		ifrs-full:PercentageOfReasonablyPossibleDecreaseInActuarialAssumption
24	Defined benefit obligation	Concept (Monetary)	instant	credit	ifrs-full:LiabilityAssetOfDefinedBenefitPlans
25	Impact on the net defined benefit obligation	Concept (Monetary)	instant	credit	ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption
26	Impact on the net defined benefit obligation	Concept (Monetary)	instant	credit	ifrs-full:IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption

Model Structure
Network	091800 - Disclosure - Share-based compensation, Plans Outstanding (Details) (http://acimume.com/role/SharebasedCompensationPlansOutstandingDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Name
1	Share-based compensation [Abstract]	Abstract	duration	ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract
2	Number of equity-based instrument plans	Concept (Integer)	duration	aciu:NumberOfEquityBasedInstrumentPlans
3	Disclosure of terms and conditions of share-based payment arrangement [table]	Table	duration	ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
4	Types of share-based payment arrangements [axis]	Axis	duration	ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
5	Share-based payment arrangements [member]	Member	duration	ifrs-full:SharebasedPaymentArrangementsMember
6	Stock Option Plan A [Member]	Member	duration	aciu:StockOptionPlanAMember
7	Stock Option Plan B [Member]	Member	duration	aciu:StockOptionPlanBMember
8	Stock Option Plan C1 [Member]	Member	duration	aciu:StockOptionPlanC1Member
9	2016 Share Option and Incentive Plan [Member]	Member	duration	aciu:Two016ShareOptionAndIncentivePlanMember
10	Categories of related parties [axis]	Axis	duration	ifrs-full:CategoriesOfRelatedPartiesAxis
11	Entity's total for related parties [member]	Member	duration	ifrs-full:EntitysTotalForRelatedPartiesMember
12	Executives and Directors [Member]	Member	duration	ifrs-full:KeyManagementPersonnelOfEntityOrParentMember
13	Employees [Member]	Member	duration	aciu:EmployeesMember
14	Disclosure of terms and conditions of share-based payment arrangement [line items]	LineItems	duration	ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
15	Share-based plans outstanding [Abstract]	Abstract	duration	aciu:ShareBasedPlansOutstandingAbstract
16	Number of options awarded (in shares)	Concept (Decimal)	duration	ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
17	Vesting conditions	Concept (Duration)	duration	aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod
18	Contractual life of options	Concept (Duration)	duration	aciu:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement

Model Structure
Network	091802 - Disclosure - Share-based compensation, Weighted Average Exercise Prices (Details) (http://acimume.com/role/SharebasedCompensationWeightedAverageExercisePricesDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Name
1	Share-based compensation [Abstract]	Abstract	duration	ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract
2	Number and weighted average exercise prices of options under the share option programs [Abstract]	Abstract	duration	ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract
3	Number of Options [Abstract]	Abstract	duration	aciu:NumberOfOptionsAbstract
4	Outstanding at beginning of period (in shares)	Concept (Decimal)	instant	ifrs-full:NumberOfOutstandingShareOptions
5	Forfeited during the year (in shares)	Concept (Decimal)	duration	ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
6	Cancelled during the year (in shares)	Concept (Decimal)	duration	ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
7	Exercised during the year (in shares)	Concept (Decimal)	duration	ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
8	Granted during the year (in shares)	Concept (Decimal)	duration	ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
9	Outstanding at end of period (in shares)	Concept (Decimal)	instant	ifrs-full:NumberOfOutstandingShareOptions
10	Exercisable (in shares)	Concept (Decimal)	instant	ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
11	Weighted Average Exercise Price [Abstract]	Abstract	duration	aciu:WeightedAverageExercisePriceAbstract
12	Outstanding at beginning of period (in CHF per share)	Concept (Monetary)	instant	ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement
13	Forfeited during the year (in CHF per share)	Concept (Monetary)	duration	ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement
14	Cancelled during the year (in CHF per share)	Concept (Monetary)	duration	ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement
15	Exercised during the year (in CHF per share)	Concept (Monetary)	duration	ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement
16	Granted during the year (in CHF per share)	Concept (Monetary)	duration	ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement
17	Outstanding at end of period (in CHF per share)	Concept (Monetary)	instant	ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement
18	Exercisable (in CHF per share)	Concept (Monetary)	instant	ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement
19	Weighted Average Remaining Term (Years) [Abstract]	Abstract	duration	aciu:WeightedAverageRemainingAbstract
20	Weighted average remaining term (years)	Concept (Decimal)	instant	ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions
21	Exercisable	Concept (Decimal)	instant	aciu:WeightedAverageRemainingContractualLifeOfExercisableShareOptions

Model Structure
Network	091804 - Disclosure - Share-based compensation, Summary Information (Details) (http://acimume.com/role/SharebasedCompensationSummaryInformationDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Share-based compensation [Abstract]	Abstract	duration		ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract
2	Disclosure of terms and conditions of share-based payment arrangement [table]	Table	duration		ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
3	Categories of related parties [axis]	Axis	duration		ifrs-full:CategoriesOfRelatedPartiesAxis
4	Entity's total for related parties [member]	Member	duration		ifrs-full:EntitysTotalForRelatedPartiesMember
5	Former Chief Financial Officer [Member]	Member	duration		aciu:FormerChiefExecutiveFinancialOfficerMember
6	Range [axis]	Axis	duration		ifrs-full:RangeAxis
7	Ranges [member]	Member	duration		ifrs-full:RangesMember
8	Bottom of Range [Member]	Member	duration		ifrs-full:BottomOfRangeMember
9	Top of Range [Member]	Member	duration		ifrs-full:TopOfRangeMember
10	Disclosure of terms and conditions of share-based payment arrangement [line items]	LineItems	duration		ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
11	Number and weighted average exercise prices of options under the share option programs [Abstract]	Abstract	duration		ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsAbstract
12	Share-based compensation [Abstract]	Abstract	duration		aciu:ShareBasedPaymentArrangementAbstract
13	Exercise price for outstanding options (in CHF per share)	Concept (Monetary)	instant		ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement
14	Weighted average fair value, options granted (in CHF per share)	Concept (Monetary)	duration		ifrs-full:WeightedAverageSharePriceShareOptionsGranted
15	Fair values of options granted (in CHF per share)	Concept (Monetary)	duration		ifrs-full:ExercisePriceShareOptionsGranted
16	Weighted average share price of options granted (in CHF per share)	Concept (Monetary)	duration		ifrs-full:WeightedAverageSharePrice
17	Risk free interest rate	Concept (Percent)	duration		ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
18	Volatility rate	Concept (Percent)	duration		ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
19	Expected duration	Concept (Decimal)	duration		ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
20	Expiry period of options	Concept (Duration)	duration		aciu:MaximumTermOfOptionsGrantedForShareBasedPaymentArrangement
21	Weighted average share price of common share options exercised (in CHF per share)	Concept (Monetary)	duration		ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise
22	Expense charged against the income statement	Concept (Monetary)	duration	debit	ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
23	Incremental fair value amount	Concept (Monetary)	duration		ifrs-full:IncrementalFairValueGrantedModifiedSharebasedPaymentArrangements
24	Forfeited during the year (in shares)	Concept (Decimal)	duration		ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
25	Granted during the year (in shares)	Concept (Decimal)	duration		ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
26	Grant date fair value of the replacement award	Concept (Monetary)	instant	credit	ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted

Model Structure
Network	091806 - Disclosure - Share-based compensation, Non-vested Share Awards (Details) (http://acimume.com/role/SharebasedCompensationNonvestedShareAwardsDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Name
1	Share-based compensation [Abstract]	Abstract	duration	ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract
2	Disclosure of terms and conditions of share-based payment arrangement [table]	Table	duration	ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
3	Types of share-based payment arrangements [axis]	Axis	duration	ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
4	Share-based payment arrangements [member]	Member	duration	ifrs-full:SharebasedPaymentArrangementsMember
5	Non-vested Share Awards [Member]	Member	duration	aciu:RestrictedSharesAndRestrictedShareUnitsMember
6	Restricted Share Awards [Member]	Member	duration	aciu:RestrictedSharesMember
7	Restricted Stock Units [Member]	Member	duration	aciu:RestrictedStockUnitsMember
8	Categories of related parties [axis]	Axis	duration	ifrs-full:CategoriesOfRelatedPartiesAxis
9	Entity's total for related parties [member]	Member	duration	ifrs-full:EntitysTotalForRelatedPartiesMember
10	Directors [Member]	Member	duration	aciu:BoardOfDirectorsMember
11	Executives [Member]	Member	duration	aciu:ExecutiveManagementMember
12	Disclosure of terms and conditions of share-based payment arrangement [line items]	LineItems	duration	ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
13	Share-based payment arrangement [Abstract]	Abstract	duration	aciu:ShareBasedPaymentArrangementAbstract
14	Number of non-vested share awards granted (in shares)	Concept (Decimal)	duration	ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
15	Vesting conditions	Concept (Duration)	duration	aciu:VestingRequirementsForShareBasedPaymentArrangementAwardVestingPeriod
16	Contractual life of non-vested share awards	Concept (Duration)	duration	aciu:MaximumTermOfOtherEquityInstrumentsGrantedForShareBasedPaymentArrangement
17	Number of non-vested shares [Abstract]	Abstract	duration	aciu:NumberOfNonVestedSharesAbstract
18	Non-vested (in shares)	Concept (Decimal)	instant	ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
19	Forfeited during the year (in shares)	Concept (Decimal)	duration	ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
20	Cancelled during the year (in shares)	Concept (Decimal)	duration	ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement
21	Exercised during the year (in shares)	Concept (Decimal)	duration	ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
22	Granted during the year (in shares)	Concept (Decimal)	duration	ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
23	Non-vested (in shares)	Concept (Decimal)	instant	ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
24	Vested (in shares)	Concept (Decimal)	duration	aciu:NumberOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement
25	Weighted Average grant date fair value [Abstract]	Abstract	duration	aciu:WeightedAverageExercisePriceAbstract
26	Non-vested (in CHF per share)	Concept (Monetary)	instant	ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
27	Forfeited during the year (in CHF per share)	Concept (Monetary)	duration	ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
28	Cancelled during the year (in CHF per share)	Concept (Monetary)	duration	ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement
29	Exercised during the year (in CHF per share)	Concept (Monetary)	duration	ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
30	Granted during the year (in CHF per share)	Concept (Monetary)	duration	ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement
31	Non-vested (in CHF per share)	Concept (Monetary)	instant	ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
32	Vested (in CHF per share)	Concept (Monetary)	duration	aciu:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInShareBasedPaymentArrangement

Model Structure
Network	091900 - Disclosure - Commitments and contingencies (Details) (http://acimume.com/role/CommitmentsAndContingenciesDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Commitments and contingencies [Abstract]	Abstract	duration		aciu:CommitmentsAndContingenciesAbstract
2	Disclosure of information about commitments and contingencies [Table]	Table	duration		aciu:DisclosureOfInformationAboutCommitmentsAndContingenciesTable
3	Maturity [axis]	Axis	duration		ifrs-full:MaturityAxis
4	Aggregated time bands [member]	Member	duration		ifrs-full:AggregatedTimeBandsMember
5	Within One Year [Member]	Member	duration		ifrs-full:NotLaterThanOneYearMember
6	Between One and Three Years [Member]	Member	duration		ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember
7	Between Three and Five Years [Member]	Member	duration		ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember
8	More Than Five Years [Member]	Member	duration		ifrs-full:LaterThanFiveYearsMember
9	Disclosure of information about commitments and contingencies [Line Items]	LineItems	duration		aciu:DisclosureOfInformationAboutCommitmentsAndContingenciesLineItems
10	Commitments and contingencies [Abstract]	Abstract	duration		aciu:CommitmentsAbstract
11	Commitments	Concept (Monetary)	instant	credit	ifrs-full:Provisions
12	External research projects	Concept (Monetary)	instant	credit	aciu:ProvisionsResearchContracts
13	Notice period for cancellation of rental contract	Concept (Duration)	duration		aciu:RentalContractPeriodForNoticeOfCancellation
14	Lease expense	Concept (Monetary)	duration	debit	ifrs-full:RentalExpense
15	Rental contracts amount	Concept (Monetary)	instant	credit	ifrs-full:LeaseLiabilities
16	Royalty payment obligation	Concept (Monetary)	instant	credit	aciu:ProvisionRoyaltyObligation

Model Structure
Network	092000 - Disclosure - Earnings per share (Details) (http://acimume.com/role/EarningsPerShareDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Earnings per share [Abstract]	Abstract	duration		ifrs-full:EarningsPerShareAbstract
2	Net income / (loss) attributable to owners of the Company	Concept (Monetary)	duration	credit	ifrs-full:ProfitLoss
3	Earnings per share (EPS) [Abstract]	Abstract	duration		ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract
4	Basic, income / (loss) for the period attributable to equity holders (in CHF per share)	Concept (Per-Share)	duration		ifrs-full:BasicEarningsLossPerShare
5	Diluted, income / (loss) for the period attributable to equity holders (in CHF per share)	Concept (Per-Share)	duration		ifrs-full:DilutedEarningsLossPerShare
6	Weighted-average number of shares used to compute EPS basic (in shares)	Concept (Shares)	duration		ifrs-full:WeightedAverageShares
7	Weighted-average number of shares used to compute EPS fully diluted (in shares)	Concept (Shares)	duration		ifrs-full:AdjustedWeightedAverageShares
8	Antidilutive shares to be issued (in shares)	Concept (Shares)	duration		ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares
9	Weighted average number of equity awards outstanding (in shares)	Concept (Shares)	duration		aciu:WeightedAverageNumberOfEquityAwardsOutstanding

Model Structure
Network	092100 - Disclosure - Financial instruments and risk management (Details) (http://acimume.com/role/FinancialInstrumentsAndRiskManagementDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Financial instruments and risk management [Abstract]	Abstract	duration		ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract
2	Disclosure of nature and extent of risks arising from financial instruments [table]	Table	duration		ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable
3	Categories of financial assets [axis]	Axis	duration		ifrs-full:CategoriesOfFinancialAssetsAxis
4	Financial assets, category [member]	Member	duration		ifrs-full:FinancialAssetsCategoryMember
5	Other Current Receivables [Member]	Member	duration		aciu:OtherReceivablesMember
6	Cash and Cash Equivalents [Member]	Member	duration		aciu:CashOnHandAndCashEquivalentsMember
7	Categories of financial liabilities [axis]	Axis	duration		ifrs-full:CategoriesOfFinancialLiabilitiesAxis
8	Financial liabilities, category [member]	Member	duration		ifrs-full:FinancialLiabilitiesCategoryMember
9	Long-Term Financing Obligation [Member]	Member	duration		aciu:LongTermFinancialLiabilitiesMember
10	Trade and Other Payables [Member]	Member	duration		aciu:TradeAndOtherPayablesMember
11	Accrued Expenses [Member]	Member	duration		aciu:AccruedExpensesMember
12	Types of risks [axis]	Axis	duration		ifrs-full:TypesOfRisksAxis
13	Risks [member]	Member	duration		ifrs-full:TypesOfRisksMember
14	Foreign Currency Exchange Risk [Member]	Member	duration		ifrs-full:CurrencyRiskMember
15	Credit Risk [Member]	Member	duration		ifrs-full:CreditRiskMember
16	Liquidity Risk [Member]	Member	duration		ifrs-full:LiquidityRiskMember
17	Disclosure of nature and extent of risks arising from financial instruments [line items]	LineItems	duration		ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems
18	Financial assets and liabilities [Abstract]	Abstract	duration		aciu:FinancialAssetsAndLiabilitiesAbstract
19	Financial assets	Concept (Monetary)	instant	debit	ifrs-full:FinancialAssets
20	Financial liabilities	Concept (Monetary)	instant	credit	ifrs-full:FinancialLiabilities
21	Financial risks [Abstract]	Abstract	duration		aciu:FinancialRisksAbstract
22	Gain (loss) in finance income/(expense), net	Concept (Monetary)	duration	credit	ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
23	Number of banks holding cash and cash equivalents	Concept (Integer)	duration		aciu:NumberOfBanksHoldingDepositsCashAndCashEquivalents
24	Cash position rolling forecast period	Concept (Duration)	duration		aciu:LiquidityManagementRollingForecastPeriod
25	Percentage exchange rate strengthened	Concept (Percent)	instant		aciu:ClosingForeignExchangeRateIncrease
26	Percentage exchange rate weakened	Concept (Percent)	instant		aciu:ClosingForeignExchangeRateDecrease
27	Net loss for period decrease, result of foreign exchange rate increase	Concept (Monetary)	duration	credit	aciu:DecreaseInNetLossForeignExchangeRateIncrease
28	Net loss for period increase, result of foreign exchange rate decrease	Concept (Monetary)	duration	debit	aciu:IncreaseInNetLossForeignExchangeRateDecrease

Model Structure
Network	092300 - Disclosure - Post balance sheet events (Details) (http://acimume.com/role/PostBalanceSheetEventsDetails)
Table	(implied)

#	Label	Report Element Class	Period Type	Balance	Name
1	Post balance sheet events [Abstract]	Abstract	duration		aciu:PostBalanceSheetEventsAbstract
2	Disclosure of non-adjusting events after reporting period [table]	Table	duration		ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodTable
3	Non-adjusting events after reporting period [axis]	Axis	duration		ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
4	Non-adjusting events after reporting period [member]	Member	duration		ifrs-full:NonadjustingEventsMember
5	Subsequent Event [Member]	Member	duration		ifrs-full:MajorPurchasesOfAssetsMember
6	Disclosure of non-adjusting events after reporting period [line items]	LineItems	duration		ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems
7	Post balance sheet events [Abstract]	Abstract	duration		ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract
8	Additional lease space	Concept (xbrli:decimalItemType)	duration		aciu:AdditionalLeaseSpace
9	Purchase of lab equipment	Concept (Monetary)	duration	debit	aciu:PurchaseOfLabEquipment

Fact Tables

The colours used for the fact values are significant, and have the following meanings:

Reported facts that have been checked by consistency rules are in green
derived (imputed) facts are in blue
inconsistent facts in red
...and the rest (reported but unckecked) are either in gray (if some rule failed to execute) or black (if no rules exist for the fact's concept)

Fact Table
Network	000100 - Document - Document and Entity Information (http://acimume.com/role/DocumentAndEntityInformation)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Amendment Flag	false
2	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Current Fiscal Year End Date	--12-31
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Document Fiscal Period Focus	FY
4	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Document Fiscal Year Focus	2017
5	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Document Period End Date	2017-12-31
6	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Document Type	20-F
7	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Entity Central Index Key	0001651625
8	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Entity Common Stock, Shares Outstanding	57355188	xbrli:shares	INF
9	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Entity Current Reporting Status	Yes
10	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Entity Filer Category	Accelerated Filer
11	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Entity Registrant Name	AC Immune SA
12	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Entity Voluntary Filers	No
13	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Entity Well-known Seasoned Issuer	No

Fact Table
Network	010000 - Statement - Balance Sheets (http://acimume.com/role/BalanceSheets)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Current accrued income and grant receivables	889000	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Current accrued income and grant receivables	2799000	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Current receivables classified as other and value added and withholding taxes	517000	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Current receivables classified as other and value added and withholding taxes	918000	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Assets	156100000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Assets	132013000	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2014-12-31	null	Cash and cash equivalents	3306000	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2015-12-31	null	Cash and cash equivalents	76522000	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Cash and cash equivalents	152210000	iso4217:CHF	-3
10	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Cash and cash equivalents	124377000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Current accrued expenses and other current liabilities	5366000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Current accrued expenses and other current liabilities	8307000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Current assets	154894000	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Current assets	129534000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Current liabilities	9922000	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Current liabilities	9754000	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Current prepaid expenses	1278000	iso4217:CHF	-3
18	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Current prepaid expenses	1440000	iso4217:CHF	-3
19	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Deferred income classified as current	521000	iso4217:CHF	-3
20	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Deferred income classified as current	355000	iso4217:CHF	-3
21	0001651625 (http://www.sec.gov/CIK)	2014-12-31	null	Equity	23467000	iso4217:CHF	-3
22	0001651625 (http://www.sec.gov/CIK)	2015-12-31	null	Equity	71043000	iso4217:CHF	-3
23	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Equity	142380000	iso4217:CHF	-3
24	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Equity	116839000	iso4217:CHF	-3
25	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Equity and liabilities	156100000	iso4217:CHF	-3
26	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Equity and liabilities	132013000	iso4217:CHF	-3
27	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Issued capital	1135000	iso4217:CHF	-3
28	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Issued capital	1147000	iso4217:CHF	-3
29	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Liabilities	13720000	iso4217:CHF	-3
30	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Liabilities	15174000	iso4217:CHF	-3
31	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Non-current assets	1206000	iso4217:CHF	-3
32	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Non-current assets	2479000	iso4217:CHF	-3
33	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Non-current financial liabilities	0	iso4217:CHF	-3
34	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Non-current financial liabilities	395000	iso4217:CHF	-3
35	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Non-current financial liabilities	400000	iso4217:USD	-3
36	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Non-current interest payable	0	iso4217:CHF	-3
37	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Non-current interest payable	99000	iso4217:CHF	-3
38	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Non-current interest payable	100000	iso4217:USD	-3
39	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Non-current liabilities	3798000	iso4217:CHF	-3
40	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Non-current liabilities	5420000	iso4217:CHF	-3
41	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Non-current provisions for employee benefits	3798000	iso4217:CHF	-3
42	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Non-current provisions for employee benefits	4926000	iso4217:CHF	-3
43	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Deposits in escrow accounts	86000	iso4217:CHF	-3
44	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Deposits in escrow accounts	126000	iso4217:CHF	-3
45	0001651625 (http://www.sec.gov/CIK)	2015-12-31	null	Property, plant and equipment	500000	iso4217:CHF	-3
46	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Property, plant and equipment	1120000	iso4217:CHF	-3
47	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Property, plant and equipment	2353000	iso4217:CHF	-3
48	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Retained earnings	-46921000	iso4217:CHF	-3
49	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Retained earnings	-72607000	iso4217:CHF	-3
50	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Share premium	188166000	iso4217:CHF	-3
51	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Share premium	188299000	iso4217:CHF	-3
52	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Trade and other current payables	4035000	iso4217:CHF	-3
53	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Trade and other current payables	1092000	iso4217:CHF	-3

Fact Table
Network	020000 - Statement - Statements of Income / (Loss) (http://acimume.com/role/StatementsOfIncomeLoss)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Adjusted weighted average number of ordinary shares outstanding	46043198	xbrli:shares	0
2	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Adjusted weighted average number of ordinary shares outstanding	50096859	xbrli:shares	0
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Adjusted weighted average number of ordinary shares outstanding	57084295	xbrli:shares	0
4	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Basic earnings (loss) per share	0.47	iso4217:CHF/xbrli:shares	2
5	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Basic earnings (loss) per share	-0.14	iso4217:CHF/xbrli:shares	2
6	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Basic earnings (loss) per share	-0.46	iso4217:CHF/xbrli:shares	2
7	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Diluted earnings (loss) per share	0.44	iso4217:CHF/xbrli:shares	2
8	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Diluted earnings (loss) per share	-0.14	iso4217:CHF/xbrli:shares	2
9	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Diluted earnings (loss) per share	-0.46	iso4217:CHF/xbrli:shares	2
10	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Finance income / (expense), net	1591000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Finance income / (expense), net	3324000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Finance income / (expense), net	-4055000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Finance income (cost)	1646000	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Finance income (cost)	3360000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Finance income (cost)	-3872000	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Tax expense (income), continuing operations	0	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Tax expense (income), continuing operations	0	iso4217:CHF	-3
18	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Tax expense (income), continuing operations	0	iso4217:CHF	-3
19	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Interest expense	0	iso4217:CHF	-3
20	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Interest expense	7000	iso4217:CHF	-3
21	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Interest expense	147000	iso4217:CHF	-3
22	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Operating expense	20466000	iso4217:CHF	-3
23	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Operating expense	33670000	iso4217:CHF	-3
24	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Operating expense	42794000	iso4217:CHF	-3
25	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Net income / (loss) for the period	20270000	iso4217:CHF	-3
26	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Net income / (loss) for the period	-7096000	iso4217:CHF	-3
27	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Net income / (loss) for the period	-26411000	iso4217:CHF	-3
28	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Profit (loss) before tax	20270000	iso4217:CHF	-3
29	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Profit (loss) before tax	-7096000	iso4217:CHF	-3
30	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Profit (loss) before tax	-26411000	iso4217:CHF	-3
31	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Profit (loss) from operating activities	18624000	iso4217:CHF	-3
32	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Profit (loss) from operating activities	-10456000	iso4217:CHF	-3
33	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Profit (loss) from operating activities	-22539000	iso4217:CHF	-3
34	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Research and development expense	17049000	iso4217:CHF	-3
35	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Research and development expense	25774000	iso4217:CHF	-3
36	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Research and development expense	32663000	iso4217:CHF	-3
37	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Revenue	39090000	iso4217:CHF	-3
38	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Revenue	23214000	iso4217:CHF	-3
39	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Revenue	20255000	iso4217:CHF	-3
40	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Revenue from contracts with customers	39090000	iso4217:CHF	-3
41	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Revenue from contracts with customers	23214000	iso4217:CHF	-3
42	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Revenue from contracts with customers	20255000	iso4217:CHF	-3
43	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Interest income	55000	iso4217:CHF	-3
44	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Interest income	43000	iso4217:CHF	-3
45	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Interest income	330000	iso4217:CHF	-3
46	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Selling, general and administrative expense	3417000	iso4217:CHF	-3
47	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Selling, general and administrative expense	7896000	iso4217:CHF	-3
48	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Selling, general and administrative expense	10131000	iso4217:CHF	-3
49	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Weighted average number of ordinary shares outstanding	43412250	xbrli:shares	0
50	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Weighted average number of ordinary shares outstanding	50096859	xbrli:shares	0
51	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Weighted average number of ordinary shares outstanding	57084295	xbrli:shares	0

Fact Table
Network	030000 - Statement - Statements of Comprehensive Income / (Loss) (http://acimume.com/role/StatementsOfComprehensiveIncomeLoss)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Comprehensive income	19534000	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Comprehensive income	-7857000	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Comprehensive income	-27191000	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-736000	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-761000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-780000	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Net income / (loss) for the period	20270000	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Net income / (loss) for the period	-7096000	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Net income / (loss) for the period	-26411000	iso4217:CHF	-3

Fact Table
Network	030100 - Statement - Statements of Comprehensive Income / (Loss) (Parenthetical) (http://acimume.com/role/StatementsOfComprehensiveIncomeLossParenthetical)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Income tax relating to remeasurements of defined benefit plans of other comprehensive income	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Income tax relating to remeasurements of defined benefit plans of other comprehensive income	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Income tax relating to remeasurements of defined benefit plans of other comprehensive income	iso4217:CHF	-3

Fact Table
Network	040000 - Statement - Statements of Changes in Equity (http://acimume.com/role/StatementsOfChangesInEquity)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Equity [Member]	Issue of equity, extension preference shares, series E	13205000	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Issued capital [member]	Issue of equity, extension preference shares, series E	28000	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Retained earnings [member]	Issue of equity, extension preference shares, series E	0	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Share Premium [Member]	Issue of equity, extension preference shares, series E	13177000	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Equity [Member]	Issue of equity, preference shares, series E	29499000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Issued capital [member]	Issue of equity, preference shares, series E	62000	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Retained earnings [member]	Issue of equity, preference shares, series E	0	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Share Premium [Member]	Issue of equity, preference shares, series E	29437000	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Equity [Member]	Issue of Equity, Restricted Share Awards	0	iso4217:CHF	-3
10	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Issued capital [member]	Issue of Equity, Restricted Share Awards	0	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Retained earnings [member]	Issue of Equity, Restricted Share Awards	-74000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Share Premium [Member]	Issue of Equity, Restricted Share Awards	74000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Equity [Member]	Proceeds from issuing shares, net of underwriting fees	0	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Equity [Member]	Proceeds from issuing shares, net of underwriting fees	69388000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Issued capital [member]	Proceeds from issuing shares, net of underwriting fees	138000	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Retained earnings [member]	Proceeds from issuing shares, net of underwriting fees	0	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Share Premium [Member]	Proceeds from issuing shares, net of underwriting fees	69250000	iso4217:CHF	-3
18	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Equity [Member]	Proceeds from issuing shares, net of underwriting fees	0	iso4217:CHF	-3
19	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Equity [Member]	Comprehensive income	19534000	iso4217:CHF	-3
20	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Issued capital [member]	Comprehensive income	0	iso4217:CHF	-3
21	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Retained earnings [member]	Comprehensive income	19534000	iso4217:CHF	-3
22	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Share Premium [Member]	Comprehensive income	0	iso4217:CHF	-3
23	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Equity [Member]	Comprehensive income	-7857000	iso4217:CHF	-3
24	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Issued capital [member]	Comprehensive income	0	iso4217:CHF	-3
25	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Retained earnings [member]	Comprehensive income	-7857000	iso4217:CHF	-3
26	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Share Premium [Member]	Comprehensive income	0	iso4217:CHF	-3
27	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Equity [Member]	Comprehensive income	-27191000	iso4217:CHF	-3
28	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Issued capital [member]	Comprehensive income	0	iso4217:CHF	-3
29	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Retained earnings [member]	Comprehensive income	-27191000	iso4217:CHF	-3
30	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Share Premium [Member]	Comprehensive income	0	iso4217:CHF	-3
31	0001651625 (http://www.sec.gov/CIK)	2014-12-31	Equity [Member]	Equity	23467000	iso4217:CHF	-3
32	0001651625 (http://www.sec.gov/CIK)	2014-12-31	Issued capital [member]	Equity	854000	iso4217:CHF	-3
33	0001651625 (http://www.sec.gov/CIK)	2014-12-31	Retained earnings [member]	Equity	-60455000	iso4217:CHF	-3
34	0001651625 (http://www.sec.gov/CIK)	2014-12-31	Share Premium [Member]	Equity	83068000	iso4217:CHF	-3
35	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Equity [Member]	Equity	71043000	iso4217:CHF	-3
36	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Issued capital [member]	Equity	928000	iso4217:CHF	-3
37	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Retained earnings [member]	Equity	-40381000	iso4217:CHF	-3
38	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Share Premium [Member]	Equity	110496000	iso4217:CHF	-3
39	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Equity [Member]	Equity	142380000	iso4217:CHF	-3
40	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Issued capital [member]	Equity	1135000	iso4217:CHF	-3
41	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Retained earnings [member]	Equity	-46921000	iso4217:CHF	-3
42	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Share Premium [Member]	Equity	188166000	iso4217:CHF	-3
43	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Equity [Member]	Equity	116839000	iso4217:CHF	-3
44	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Issued capital [member]	Equity	1147000	iso4217:CHF	-3
45	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Retained earnings [member]	Equity	72607000	iso4217:CHF	-3
46	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Share Premium [Member]	Equity	188299000	iso4217:CHF	-3
47	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Equity [Member]	Increase (decrease) through exercise of options, equity	142000	iso4217:CHF	-3
48	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Issued capital [member]	Increase (decrease) through exercise of options, equity	12000	iso4217:CHF	-3
49	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Retained earnings [member]	Increase (decrease) through exercise of options, equity	0	iso4217:CHF	-3
50	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Share Premium [Member]	Increase (decrease) through exercise of options, equity	130000	iso4217:CHF	-3
51	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Equity [Member]	Increase (decrease) through exercise of options, equity	301000	iso4217:CHF	-3
52	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Issued capital [member]	Increase (decrease) through exercise of options, equity	41000	iso4217:CHF	-3
53	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Retained earnings [member]	Increase (decrease) through exercise of options, equity	0	iso4217:CHF	-3
54	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Share Premium [Member]	Increase (decrease) through exercise of options, equity	260000	iso4217:CHF	-3
55	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Equity [Member]	Increase (decrease) through exercise of options, equity	71000	iso4217:CHF	-3
56	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Issued capital [member]	Increase (decrease) through exercise of options, equity	12000	iso4217:CHF	-3
57	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Retained earnings [member]	Increase (decrease) through exercise of options, equity	0	iso4217:CHF	-3
58	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Share Premium [Member]	Increase (decrease) through exercise of options, equity	59000	iso4217:CHF	-3
59	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Equity [Member]	Increase (decrease) through share-based payment transactions, equity	540000	iso4217:CHF	-3
60	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Issued capital [member]	Increase (decrease) through share-based payment transactions, equity	0	iso4217:CHF	-3
61	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Retained earnings [member]	Increase (decrease) through share-based payment transactions, equity	540000	iso4217:CHF	-3
62	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Share Premium [Member]	Increase (decrease) through share-based payment transactions, equity	0	iso4217:CHF	-3
63	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Equity [Member]	Increase (decrease) through share-based payment transactions, equity	1317000	iso4217:CHF	-3
64	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Issued capital [member]	Increase (decrease) through share-based payment transactions, equity	0	iso4217:CHF	-3
65	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Retained earnings [member]	Increase (decrease) through share-based payment transactions, equity	1317000	iso4217:CHF	-3
66	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Share Premium [Member]	Increase (decrease) through share-based payment transactions, equity	0	iso4217:CHF	-3
67	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Equity [Member]	Increase (decrease) through share-based payment transactions, equity	1579000	iso4217:CHF	-3
68	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Issued capital [member]	Increase (decrease) through share-based payment transactions, equity	0	iso4217:CHF	-3
69	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Retained earnings [member]	Increase (decrease) through share-based payment transactions, equity	1579000	iso4217:CHF	-3
70	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Share Premium [Member]	Increase (decrease) through share-based payment transactions, equity	0	iso4217:CHF	-3
71	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Equity [Member]	Other comprehensive income	-736000	iso4217:CHF	-3
72	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Issued capital [member]	Other comprehensive income	0	iso4217:CHF	-3
73	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Retained earnings [member]	Other comprehensive income	-736000	iso4217:CHF	-3
74	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Share Premium [Member]	Other comprehensive income	0	iso4217:CHF	-3
75	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Equity [Member]	Other comprehensive income	-761000	iso4217:CHF	-3
76	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Issued capital [member]	Other comprehensive income	0	iso4217:CHF	-3
77	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Retained earnings [member]	Other comprehensive income	-761000	iso4217:CHF	-3
78	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Share Premium [Member]	Other comprehensive income	0	iso4217:CHF	-3
79	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Equity [Member]	Other comprehensive income	-780000	iso4217:CHF	-3
80	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Issued capital [member]	Other comprehensive income	0	iso4217:CHF	-3
81	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Retained earnings [member]	Other comprehensive income	-780000	iso4217:CHF	-3
82	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Share Premium [Member]	Other comprehensive income	0	iso4217:CHF	-3
83	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Equity [Member]	Net income / (loss) for the period	20270000	iso4217:CHF	-3
84	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Issued capital [member]	Net income / (loss) for the period	0	iso4217:CHF	-3
85	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Retained earnings [member]	Net income / (loss) for the period	20270000	iso4217:CHF	-3
86	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Share Premium [Member]	Net income / (loss) for the period	0	iso4217:CHF	-3
87	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Equity [Member]	Net income / (loss) for the period	-7096000	iso4217:CHF	-3
88	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Issued capital [member]	Net income / (loss) for the period	0	iso4217:CHF	-3
89	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Retained earnings [member]	Net income / (loss) for the period	-7096000	iso4217:CHF	-3
90	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Share Premium [Member]	Net income / (loss) for the period	0	iso4217:CHF	-3
91	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Equity [Member]	Net income / (loss) for the period	-26411000	iso4217:CHF	-3
92	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Issued capital [member]	Net income / (loss) for the period	0	iso4217:CHF	-3
93	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Retained earnings [member]	Net income / (loss) for the period	-26411000	iso4217:CHF	-3
94	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Share Premium [Member]	Net income / (loss) for the period	0	iso4217:CHF	-3
95	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Equity [Member]	Share issue related cost	2139000	iso4217:CHF	-3
96	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Issued capital [member]	Share issue related cost	0	iso4217:CHF	-3
97	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Retained earnings [member]	Share issue related cost	0	iso4217:CHF	-3
98	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Share Premium [Member]	Share issue related cost	2139000	iso4217:CHF	-3
99	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Equity [Member]	Share issue related cost	5017000	iso4217:CHF	-3
100	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Issued capital [member]	Share issue related cost	0	iso4217:CHF	-3
101	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Retained earnings [member]	Share issue related cost	0	iso4217:CHF	-3
102	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Share Premium [Member]	Share issue related cost	5017000	iso4217:CHF	-3

Fact Table
Network	050000 - Statement - Statements of Cash Flows (http://acimume.com/role/StatementsOfCashFlows)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Adjustments for Accrued Interest Payable	0	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Adjustments for Accrued Interest Payable	0	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Adjustments for Accrued Interest Payable	99000	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Adjustments for decrease (increase) in accrued income	6000	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Adjustments for decrease (increase) in accrued income	-842000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Adjustments for decrease (increase) in accrued income	-1910000	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Adjustments for decrease (increase) in prepaid expense	2135000	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Adjustments for decrease (increase) in prepaid expense	494000	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Adjustments for decrease (increase) in prepaid expense	162000	iso4217:CHF	-3
10	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Adjustments for increase (decrease) in accrued expenses	-1707000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Adjustments for increase (decrease) in accrued expenses	-1564000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Adjustments for increase (decrease) in accrued expenses	-2940000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Adjustments for Increase (Decrease) Long-term Financial Liabilities	0	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Adjustments for Increase (Decrease) Long-term Financial Liabilities	0	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Adjustments for Increase (Decrease) Long-term Financial Liabilities	-204000	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Cash Advances for Rent Deposit	0	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Cash Advances for Rent Deposit	0	iso4217:CHF	-3
18	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Cash Advances for Rent Deposit	40000	iso4217:CHF	-3
19	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Proceeds from issuing shares, net of underwriting fees	0	iso4217:CHF	-3
20	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Proceeds from issuing shares, net of underwriting fees	69388000	iso4217:CHF	-3
21	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Proceeds from issuing shares, net of underwriting fees	0	iso4217:CHF	-3
22	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Proceeds from loan repayments	55000	iso4217:CHF	-3
23	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Proceeds from loan repayments	0	iso4217:CHF	-3
24	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Proceeds from loan repayments	0	iso4217:CHF	-3
25	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Adjustments for decrease (increase) in other operating receivables	25666000	iso4217:CHF	-3
26	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Adjustments for decrease (increase) in other operating receivables	-248000	iso4217:CHF	-3
27	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Adjustments for decrease (increase) in other operating receivables	-401000	iso4217:CHF	-3
28	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Adjustments for depreciation expense	287000	iso4217:CHF	-3
29	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Adjustments for depreciation expense	278000	iso4217:CHF	-3
30	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Adjustments for depreciation expense	580000	iso4217:CHF	-3
31	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Adjustments for finance income (cost)	1646000	iso4217:CHF	-3
32	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Adjustments for finance income (cost)	3360000	iso4217:CHF	-3
33	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Adjustments for finance income (cost)	-3872000	iso4217:CHF	-3
34	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Adjustments for increase (decrease) in deferred income	-160000	iso4217:CHF	-3
35	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Adjustments for increase (decrease) in deferred income	476000	iso4217:CHF	-3
36	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Adjustments for increase (decrease) in deferred income	-156000	iso4217:CHF	-3
37	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Adjustments for increase (decrease) in employee benefit liabilities	-359000	iso4217:CHF	-3
38	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Adjustments for increase (decrease) in employee benefit liabilities	250000	iso4217:CHF	-3
39	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Adjustments for increase (decrease) in employee benefit liabilities	348000	iso4217:CHF	-3
40	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Adjustments for increase (decrease) in trade accounts payable	-141000	iso4217:CHF	-3
41	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Adjustments for increase (decrease) in trade accounts payable	2592000	iso4217:CHF	-3
42	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Adjustments for increase (decrease) in trade accounts payable	-2853000	iso4217:CHF	-3
43	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Adjustments for share-based payments	540000	iso4217:CHF	-3
44	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Adjustments for share-based payments	1317000	iso4217:CHF	-3
45	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Adjustments for share-based payments	1579000	iso4217:CHF	-3
46	0001651625 (http://www.sec.gov/CIK)	2014-12-31	null	Cash and cash equivalents	3306000	iso4217:CHF	-3
47	0001651625 (http://www.sec.gov/CIK)	2015-12-31	null	Cash and cash equivalents	76522000	iso4217:CHF	-3
48	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Cash and cash equivalents	152210000	iso4217:CHF	-3
49	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Cash and cash equivalents	124377000	iso4217:CHF	-3
50	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Cash flows from (used in) financing activities	27778000	iso4217:CHF	-3
51	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Cash flows from (used in) financing activities	78790000	iso4217:CHF	-3
52	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Cash flows from (used in) financing activities	271000	iso4217:CHF	-3
53	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Cash flows from (used in) investing activities	-244000	iso4217:CHF	-3
54	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Cash flows from (used in) investing activities	-899000	iso4217:CHF	-3
55	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Cash flows from (used in) investing activities	-1842000	iso4217:CHF	-3
56	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Cash flows from (used in) operating activities	44084000	iso4217:CHF	-3
57	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Cash flows from (used in) operating activities	-5646000	iso4217:CHF	-3
58	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Cash flows from (used in) operating activities	-22094000	iso4217:CHF	-3
59	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Cash flows from (used in) operations	44035000	iso4217:CHF	-3
60	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Cash flows from (used in) operations	-5563000	iso4217:CHF	-3
61	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Cash flows from (used in) operations	-22271000	iso4217:CHF	-3
62	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Effect of exchange rate changes on cash and cash equivalents	1598000	iso4217:CHF	-3
63	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Effect of exchange rate changes on cash and cash equivalents	3443000	iso4217:CHF	-3
64	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Effect of exchange rate changes on cash and cash equivalents	-4168000	iso4217:CHF	-3
65	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Finance costs paid, classified as operating activities	6000	iso4217:CHF	-3
66	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Finance costs paid, classified as operating activities	126000	iso4217:CHF	-3
67	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Finance costs paid, classified as operating activities	153000	iso4217:CHF	-3
68	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Finance income received, classified as operating activities	55000	iso4217:CHF	-3
69	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Finance income received, classified as operating activities	43000	iso4217:CHF	-3
70	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Finance income received, classified as operating activities	330000	iso4217:CHF	-3
71	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Increase (decrease) in cash and cash equivalents	71618000	iso4217:CHF	-3
72	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Increase (decrease) in cash and cash equivalents	72245000	iso4217:CHF	-3
73	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Increase (decrease) in cash and cash equivalents	-23665000	iso4217:CHF	-3
74	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Payments for share issue costs	1859000	iso4217:CHF	-3
75	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Payments for share issue costs	4105000	iso4217:CHF	-3
76	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Payments for share issue costs	0	iso4217:CHF	-3
77	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Proceeds from long-term debt	0	iso4217:CHF	-3
78	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Proceeds from long-term debt	0	iso4217:CHF	-3
79	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Proceeds from long-term debt	200000	iso4217:CHF	-3
80	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Proceeds from exercise of options	83000	iso4217:CHF	-3
81	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Proceeds from exercise of options	301000	iso4217:CHF	-3
82	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Proceeds from exercise of options	71000	iso4217:CHF	-3
83	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Private placement extension financing	29499000	iso4217:CHF	-3
84	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Private placement extension financing	13206000	iso4217:CHF	-3
85	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Private placement extension financing	0	iso4217:CHF	-3
86	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Net income / (loss) for the period	20270000	iso4217:CHF	-3
87	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Net income / (loss) for the period	-7096000	iso4217:CHF	-3
88	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Net income / (loss) for the period	-26411000	iso4217:CHF	-3
89	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Purchase of property, plant and equipment, classified as investing activities	244000	iso4217:CHF	-3
90	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Purchase of property, plant and equipment, classified as investing activities	899000	iso4217:CHF	-3
91	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Purchase of property, plant and equipment, classified as investing activities	1802000	iso4217:CHF	-3

Fact Table
Network	050100 - Statement - Statements of Cash Flows (Parenthetical) (http://acimume.com/role/StatementsOfCashFlowsParenthetical)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value		Unit	Rounding	Parenthetical Explanations
1	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Underwriting fees, in noncash financing activities	5100000		iso4217:CHF	-5

Fact Table
Network	060100 - Disclosure - General information (http://acimume.com/role/GeneralInformation)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of general information about the entity explanatory [Text Block]

1.	General information

AC Immune SA (the “Company,” or “AC Immune,” “ACI,” “we,” “our,” “ours,” “us”) is a clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. Misfolded proteins are generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer’s disease, or AD, and Parkinson’s disease, or PD, with common mechanisms and drug targets, such as Abeta, Tau and alpha-synuclein. Our corporate strategy is founded upon a three-pillar approach that targets Alzheimer’s disease, non-Alzheimer’s neurodegenerative diseases including neuro-orphan indications and diagnostics. Our lead product candidate is crenezumab, a humanized, monoclonal, conformation-specific anti-Abeta antibody that we developed using our proprietary SupraAntigen platform. The two Phase 3 clinical studies for crenezumab were commenced in early 2016 and in February 2017, respectively. We use our two unique proprietary platform technologies, SupraAntigen (conformation-specific biologics) and Morphomer (conformation-specific small molecules), to discover, design and develop medicines and diagnostics to target misfolded proteins.

The Company was initially incorporated as a limited liability company on February 13, 2003 in Basel and effective August 25, 2003 was transitioned into a stock company. The Company’s corporate headquarters are located at EPFL Innovation Park Building B, Ecublens/Lausanne, Vaud, Switzerland.

Fact Table
Network	060200 - Disclosure - Basis of preparation (http://acimume.com/role/BasisOfPreparation)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of basis of preparation of financial statements [text block]

2.	Basis of preparation

Going concern

The financial statements have been prepared on the basis that the Company will continue as a going concern after considering the Company’s cash position of CHF 124.4 million as of December 31, 2017. The Company received CHF 14 million in 2017 for the clinical milestone related to the collaboration with Genentech on the first dosing in a Phase 2 clinical trial for Alzheimer’s Disease (AD) with an anti-Tau monoclonal antibody, CHF 14 million in 2016 for the clinical milestone related to the collaboration with Genentech on the anti-Tau antibody program and CHF 4.9 million in 2016 for the clinical milestone related to ACI-35 pursuant to its collaboration with Janssen. This total also reflects the $75.9 million (CHF 74.5 million) in gross proceeds raised in the initial public offering (“IPO”) in September 2016 and the $13.5 million (CHF 13.2 million) the Company raised in the Series E Private Placement Extension financing in April 2016.

To date, the Company has financed its cash requirements primarily from its initial public offering, share issuances and revenues from collaboration agreements. The Company is a clinical stage company and is exposed to all the risks inherent to establishing a business. Inherent to the Company’s business are various risks and uncertainties, including the substantial uncertainty as to whether current projects will succeed. The Company’s success may depend in part upon its ability to (i) establish and maintain a strong patent position and protection, (ii) enter into collaborations with partners in the biotech and pharmaceutical industry, (iii) successfully move its product candidates through clinical development, (iv) attract and retain key personnel, and (v) acquire capital to support its operations.

Statement of compliance

The financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). These financial statements have been approved for issue by the Board of Directors on March 20, 2018.

Basis of measurement

The financial statements have been prepared under the historical cost convention except for items that are required to be accounted for at fair value.

Functional currency

The financial statements of the Company are presented in Swiss Francs (CHF), which is also the functional currency of the Company. All financial information presented in Swiss Francs (except for share capital and earnings per share data) has been rounded to the nearest thousand CHF (CHF thousands), unless otherwise indicated. The Company also has transactions denominated in U.S. Dollars ($) and Euros (EUR) that are translated to CHF using prevailing exchange rates at the date of transaction or as of the balance sheet date.

Fact Table
Network	060300 - Disclosure - Summary of significant accounting policies (http://acimume.com/role/SummaryOfSignificantAccountingPolicies)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of significant accounting policies [text block]

3.	Summary of significant accounting policies

The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Current vs. non-current classification

The Company presents assets and liabilities in the balance sheet based on current/non-current classification. The Company classifies all amounts to be realized or settled within twelve months after the reporting period to be current and all other amounts to be non-current.

Foreign currency transactions

Foreign currency transactions are translated into the functional currency Swiss Francs (CHF) using prevailing exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into CHF at rates of exchange prevailing at reporting date. Any gains or losses from these translations are included in the statement of income in the period in which they arise.

Revenue recognition

Revenue includes upfront fees, milestone payments as well as revenue from research and development agreements associated with collaborations with third parties and grants from public institutions and foundations.

License of intellectual property

Revenue from non-refundable, upfront license payments and performance milestones where the Company has continuing involvement is recognized over the estimated performance or agreement period, depending on the terms of the agreement. The recognition of revenue is prospectively changed for subsequent changes in the development or agreement period.

For collaboration agreements on product candidates (i) that are in clinical development, (ii) where the upfront payment reflects a payment for past investments the Company has made in the development of the product candidate, access to the product candidate, the associated intellectual property and our knowledge, and, (iii) where there is no further performance commitment, the Company recognizes the fair value of the upfront payment at the time of entering into the collaboration agreement. For collaboration agreements (i) in clinical development but where conditions (ii) and (iii) are not met, the Company recognizes revenue from upfront payments under our collaboration agreements pro-rata over the term of the estimated period of performance under each agreement.

For collaboration agreements, in addition to receiving upfront payments, the Company is also entitled to milestone and other contingent payments upon achieving pre-defined objectives.

Milestone payments

Revenue from milestones, if they are non-refundable and deemed substantive, is recognized upon successful accomplishment of the milestones. To the extent that non-substantive milestones are achieved and the Company has remaining performance obligations, milestones are deferred and recognized as revenue over the estimated remaining period of performance.

Research and Development Services

The Company has certain arrangements with our collaboration partners that include contracting our full-time employees for research and development programs. These revenues are recorded in contract revenue as the services are performed.

Research and development expenditure

Given the stage of development of the Company’s products, all research expenditure is recognized as expense when incurred. Research and development expenditures include:

the cost of acquiring, developing and manufacturing active pharmaceutical ingredients for product candidates that have not received regulatory approval, clinical trial materials and other research and development materials;

fees and expenses incurred under agreements with contract research organizations, investigative sites, and other entities in connection with the conduct of clinical trials and preclinical studies and related services, such as administrative, data management, and laboratory services;

fees and costs related to regulatory filings and activities;

costs associated with pre-clinical and clinical activities; and

employee-related expenses, including salaries and bonuses, benefits, travel and stock-based compensation expense

For external research contracts the “stage of completion” method is used to estimate the amount of accrued expense related to the research projects for its clinical studies. The Company estimates its accrued expenses as of the balance sheet date in the financial statement based on facts and circumstances known at the time.

Registration costs for patents are part of the expenditure for research and development projects. Therefore, registration costs for patents are expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization.

Property, plant and equipment

Equipment is shown at historical acquisition cost, less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures that are directly attributable to the acquisition of the property, plant and equipment. Depreciation is calculated using a straight-line method to write off the cost of each asset to its residual value over its estimated useful life as follows:

IT equipment	3 years
Laboratory equipment	5 years
Leasehold improvements / furniture	5 years

The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date. Where an asset’s carrying amount is greater than its estimated recoverable amount, it is written down to its recoverable amount.

Gains and losses on disposals are determined by comparing the disposal proceeds with the carrying amount and are included in the Statements of Income / (Loss).

Financial assets and liabilities

The Company’s financial assets and liabilities are comprised of receivables, cash and cash equivalents, trade payables and a long-term financing obligation. The carrying amount for these financial assets and liabilities approximates fair value.

Receivables

Receivables are non-derivative financial assets with fixed payments that are not quoted in an active market. They arise when the Company provides money, goods or services directly to a debtor with no intention of trading the receivable. They are included in current assets, except for those with maturities greater than 12 months after the balance sheet date, which are classified as long-term assets. Receivables are recognized at their billing value. An allowance for doubtful accounts is recorded for potential estimated losses when there is objective evidence of the debtor’s inability to make required payments.

Cash and cash equivalents

Cash and cash equivalents include deposits held with external financial institutions and cash on hand. All cash and cash equivalents are either in cash or in deposits with less than 3 months’ duration.

The Company assesses at each period whether there is objective evidence that financial assets are impaired. Recognized impairment losses would be immediately recognized in the Statement of Income / (Loss).

Trade payables

Trade payables are recognized initially at fair value, which represents cost incurred.

Long-term financing obligation

The Company’s long-term financing obligation is measured as of the period end date based on the repayment terms when originated.

Share capital and Initial Public Offering

Ordinary (Common) Shares are classified as equity, as were all Preferred Shares previously outstanding prior to the IPO. Expenses directly attributable to the issuance of new shares are shown in equity as a deduction, net of tax, from the proceeds.

Preferred Shares

AC Immune had five classes (Class A, B, C, D and E) of Preferred Shares outstanding as of December 31, 2015. These Preferred Shares remained outstanding until the Company completed an IPO in September 2016 and at that time the Preferred Shares were converted to Common Shares on a one-for-one basis. The Preferred Shares were a class of shares that AC Immune SA issued in connection with five separate capital increases and conveyed voting rights and certain other rights to their holders.

The holders of Preferred Shares owned 80.1% of the total amount of shares outstanding (assuming conversion of the Preferred Shares into Common Shares on a one-for-one basis) as of December 31, 2015 and the Company’s Board of Directors were predominantly the holders of Preferred Shares. The Preferred Shares had been the primary source of equity financing for the Company for more than 13 years until the Company completed an IPO in September 2016, at which point all Preferred Shares were converted to Common Shares. The Preferred Shares did not have mandatory redemption features; however, the Shareholders’ Agreement provided for conversion of Preferred Shares into Common Shares as a result of an IPO. The redemption of the Preferred Shares was authorized by the Company’s Board of Directors.

The voting rights associated with Preferred Shares were the same as for Common Shares. Each Preferred Share entitled the holder to one vote. No dividends were paid on the Preferred Shares and the holders of Preferred Shares were not entitled to any dividends unless dividends are paid on the Common Shares.

The Preferred Shares had a liquidation preference wherein, in the event of a change of control or a liquidation of the Company, the holders of Preferred Shares were entitled to receive, prior and in preference to the holders of Common Shares, the amount corresponding to the price paid for each Preferred Share. Thereafter, all holders of Preferred Shares participated with the holders of Common Shares on an as-if-converted basis in any remaining proceeds.

On October 23, 2015, AC Immune completed a 250-for-1 stock split. The split was applied to all of AC Immune’s outstanding common shares, preferred shares (Series A, B, C, D and E) and vested and unvested options. The stock split impacted earnings per share (“EPS”). To facilitate a comparison of EPS figures, the 2015 reported EPS figures were adjusted to reflect the stock split. 2015 disclosures in notes 9 (share capital), 18 (share-based compensation) and 20 (earnings per share) have all been prepared taking into consideration the 250-for-1 stock split.

On April 15, 2016, AC Immune completed a private placement of Series E preferred shares, each with a nominal value of CHF 0.02 per share (the “Series E Private Placement Extension”). An aggregate 1,401,792 Series E preferred shares were issued at a price of $9.6384 per preferred share to certain strategic investors, individuals and existing shareholder in the Series E Private Placement Extension for an aggregate subscription amount of approximately $13.5 million. The Series E preferred shares had substantially the same terms as the Series A, B, C and D preferred shares and were accounted for as equity on AC Immune’s balance sheet and subsequently converted to Common Shares as a result of the IPO.

Initial Public Offering (IPO)

On September 22, 2016, AC Immune successfully priced a 6.0 million common share IPO at $11.00 per share. On the same day, the underwriters exercised the overallotment option which resulted in a further 900,000 common shares being placed in the market and took the total number of shares offered to investors to 6.9 million common shares. The gross proceeds received were $75.9 million (CHF 74.5 million) while the proceeds net of underwriting fees amounted to $70.6 million (CHF 69.3 million).

The IPO resulted in an increase of CHF 64.2 million in the share premium of AC Immune excluding the effect of transaction costs associated with the IPO related to the issuance of new shares. Transaction costs associated with the IPO and related to the issuance of new shares were charged directly against the share premium account thereby reducing the total equity reported.

Employee benefits

Post-employment benefits

The Company operates the mandatory pension schemes for its employees in Switzerland. The schemes are generally funded through payments to insurance companies or trustee-administered funds. The Company has a pension plan designed to pay pensions based on accumulated contributions on individual savings accounts. However, this plan is classified as a defined benefit plan under IAS 19.

The net defined benefit liability is the present value of the defined benefit obligation at the balance sheet date minus the fair value of plan assets. The defined benefit obligation is in all material cases calculated annually by independent actuaries using the projected unit credit method, which reflects services rendered by employees to the date of valuation, incorporates assumptions concerning employees’ projected salaries, pension increases as well as discount rates of highly liquid corporate bonds which have terms to maturity approximating the terms of the related liability.

Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest), are recognized immediately in Other Comprehensive Income. Past service costs, including curtailment gains or losses, are recognized immediately in general and administrative expenses within the operating results. Settlement gains or losses are recognized in general and administrative expenses within the operating results. The Company determines the net interest expense (income) on the net defined benefit liability for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period or in case of any significant events between measurement dates to the then-net defined benefit liability, taking into account any changes in the net defined benefit liability during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in the statement of income.

Share-based compensation

The Company operates an equity-settled, share-based compensation plan. The fair value of the employee services received in exchange for the grant of equity based awards is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value of the instruments granted, excluding the impact of any non-market vesting conditions. Non-market vesting conditions are included in assumptions about the number of instruments that are expected to become exercisable. At each balance sheet date, the Company revises its estimates of the number of instruments that are expected to become exercisable. It recognizes the impact of the revision of original estimates, if any, prospectively in the income statement, and a corresponding adjustment to equity over the remaining vesting period.

Stock options granted under the Company’s stock option plans A, B, C and the 2016 Stock Option and Incentive Plan are valued using the Black-Scholes option pricing model (see Note 18). This valuation model as well as parameters used such as expected volatility and expected term of the stock options are partially based on management’s estimates.

The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised.

We estimate the fair value of non-vested stock awards (restricted shares and restricted share units) using a reasonable estimate of market value of the common stock on the date of the award. We classify our share-based payments as equity-classified awards as they are settled in shares of our common stock. We measure equity-classified awards at their grant date fair value and do not subsequently remeasure them. Compensation costs related to equity-classified awards are equal to the fair value of the award at grant-date amortized over the vesting period of the award using the graded method. We reclassify that portion of vested awards to share premium as the awards vest.

Provisions

Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events where it is more likely than not that an outflow of resources will be required to settle the obligation, and a reliable estimate of the amount can be made.

Taxation

Current income tax assets and liabilities for the period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the tax amounts are those that are enacted or substantively enacted, at the reporting date in accordance with the fiscal regulations of the respective country where the Company operates and generates taxable income. Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. If required, deferred taxation is provided in full using the liability method, on all temporary differences at the reporting dates. It is calculated at the tax rates that are expected to apply to the period when it is anticipated the liabilities will be settled, and it is based on tax rates (and laws) that have been enacted or substantively enacted at the reporting date.

Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Although the Company has substantial tax loss carryforwards, historically, due to the fact that the Company had limited certainty on the achievement of key milestones, it has not recognized any deferred tax assets.

Earnings per share

The Company presents basic earnings per share for each period in the financial statements. The earnings per share is calculated by dividing the earnings of the period by the weighted average number of shares (common and preferred) outstanding during the period. Diluted earnings per share reflect the potential dilution that could occur if dilutive securities such as share options were vested or exercised into common shares or resulted in the issuance of common shares that would participate in net income. Anti-dilutive shares are excluded from basic and dilutive earnings per share calculation.

Critical judgments and accounting estimates

The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses.

The areas where AC Immune has had to make judgments, estimates and assumptions relate to (i) revenue recognition on collaboration and licensing agreements, (ii) clinical development accruals, (iii) net employee defined benefit liability, (iv) income taxes and (v) share-based compensation. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Income taxes

As disclosed in Note 16, the Company has tax losses that can generally be carried forward for a period of 7 years from the period the loss was incurred. These tax losses represent potential value to the Company to the extent that the Company is able to create taxable profits before the expiry period of these tax losses. The Company has not recorded any deferred tax assets in relation to these tax losses.

Preferred shares

Significant judgment was required in determining the classification of the Preferred Shares issued by the Company as either equity or liabilities. The Preferred shareholders received certain preference rights that represented a significant proportion of the net assets of the Company in the case of liquidation or certain exit events, the occurrence of which was outside the control of the Company. These Preferred Shares remained outstanding until the Company completed an IPO in September 2016 and at that time the Preferred Shares were converted from Preferred Shares to Common Shares on a one-for-one basis.

Segment reporting

The Company has one segment. The Company currently focuses all of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins.

The Company is managed and operated as one business. A single management team that reports to the chief operating decision maker comprehensively manages the entire business. Accordingly, the Company views its business and manages its operations as one reportable segment. Non-current assets are located in and revenue is attributable to the Company’s country of domicile, Switzerland.

Accounting pronouncements – not yet adopted

IFRS 9 Financial Instruments will supersede IAS 39 Financial Instruments: Recognition and Measurement and is effective for annual periods beginning on or after January 1, 2018. IFRS 9 covers classification and measurement of financial assets and financial liabilities, impairment of financial assets and hedge accounting. The Company expects to adopt this standard on January 1, 2018, and after completing its assessment of the standard, AC Immune does not anticipate IFRS 9 to have a material impact on the financial statements.

IFRS 16 Leases provides a new model for lessee accounting in which all leases, other than short-term and small-ticket-item leases, will be accounted for by the recognition on the balance sheet of a right-to-use asset and a lease liability, and the subsequent amortization of the right-to-use asset over the lease term. IFRS 16 will be effective for annual periods beginning on or after January 1, 2019 with early adoption permitted. AC Immune is still assessing the impact of this standard on its financial statements.

The Company has completed its analysis of the impact of IFRS 15 Revenue from Contracts with Customers, which amends revenue recognition requirements and establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The standard replaces IAS 18 Revenue and IAS 11 Construction Contracts and Related Interpretations. The new standard, as amended, becomes effective for the Company in the first quarter of fiscal year 2018, but allows the Company to adopt early. The Company will adopt this accounting standard in the first quarter of fiscal year 2018.

The Company will adopt this standard using the modified retrospective method. Under this method, the cumulative effect of adopting the standard will be recorded to retained earnings on January 1, 2018. We have completed our assessment of the effect of this adoption, including a detailed review of all of our contracts to identify potential differences in accounting as a result of the new standard and use of the practical expedient regarding contract modifications. The new standard will result in additional revenue-related disclosures in the footnotes to our financial statements. Adoption of this standard will also require changes to certain business processes which are in place to ensure our compliance. Based on our analysis, we do not anticipate a material impact on our total revenues or costs.

Fact Table
Network	060400 - Disclosure - Property, plant and equipment (http://acimume.com/role/PropertyPlantAndEquipment)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of property, plant and equipment [text block]

4.	Property, plant and equipment

	As of December 31, 2017
	Furniture			Computers/IT			Lab Equipment			Leasehold Improvements			Total
Acquisition Cost:
Balance at the end of the previous year		81			298			2,792			103			3,274
Acquisitions		4			271			1,369			169			1,813
Balance at end		85			569			4,161			272			5,087

Accumulated depreciation:
Balance at the end of the previous year		(45	)		(172	)		(1,858	)		(79	)		(2,154	)
Depreciation expense		(14	)		(87	)		(453	)		(26	)		(580	)
Balance at end		(59	)		(259	)		(2,311	)		(105	)		(2,734	)

Carrying Amount:
December 31, 2016		36			126			934			24			1,120
December 31, 2017		26			310			1,850			167			2,353

	As of December 31, 2016
	Furniture			Computers/IT			Lab Equipment			Leasehold Improvements			Total
Acquisition Cost:
Balance at the end of the previous year		43			172			2,058			103			2,376
Acquisitions		38			126			734			-			898
Balance at end		81			298			2,792			103			3,274

Accumulated depreciation:
Balance at the end of the previous year		(36	)		(138	)		(1,629	)		(73	)		(1,876	)
Depreciation expense		(9	)		(34	)		(229	)		(6	)		(278	)
Balance at end		(45	)		(172	)		(1,858	)		(79	)		(2,154	)

Carrying Amount:
December 31, 2015		7			34			429			30			500
December 31, 2016		36			126			934			24			1,120

For the years ended December 31, 2017, 2016 and 2015, the Company incurred CHF 580 thousand, 278 thousand and 287 thousand in depreciation expense, respectively.

Fact Table
Network	060500 - Disclosure - Financial Assets (http://acimume.com/role/FinancialAssets)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of restricted cash and cash equivalents [text block]

5.	Financial Assets

AC Immune has two deposits in escrow accounts totaling CHF 126 thousand associated with the lease of the Company’s premises as of December 31, 2017 and CHF 86 thousand as of December 31, 2016.

Fact Table
Network	060600 - Disclosure - Prepaid expenses and accrued income (http://acimume.com/role/PrepaidExpensesAndAccruedIncome)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of prepaid expenses and accrued income [Text Block]

6.	Prepaid expenses and accrued income

	For the Years Ended December 31,
in CHF thousands	2017	2016
Prepaid expenses	1,440	1,278
Accrued income	2,799	889
Total	4,239	2,167

The prepaid expenses relate mainly to research contracts with down-payments at contract signature and the related activities will start or continue into 2018.

Accrued income consists of CHF 1.5 million as of December 31, 2017 associated with our Biogen collaboration and CHF 1.2 million associated with our Janssen collaboration (see Note 13). CHF 0.9 million was accrued as of December 31, 2016 and subsequently invoiced in 2017.

Fact Table
Network	060700 - Disclosure - Other current receivables (http://acimume.com/role/OtherCurrentReceivables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of other current receivables [Text Block]

7.	Other current receivables

	For the Years Ended December 31,
in CHF thousands	2017		2016
Other receivables		691		182
Swiss VAT		112		320
Withholding tax		115		15
Total		918		517

The maturity of these assets is less than three months. The Company considers the counterparty risk as low and the carrying amount of these receivables is considered to correspond to their fair value.

Fact Table
Network	060800 - Disclosure - Cash and cash equivalents (http://acimume.com/role/CashAndCashEquivalents)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of cash and cash equivalents [text block]

8.	Cash and cash equivalents

	For the Years Ended December 31,
in CHF thousands	2017		2016
Cash		124,377		152,210
Total		124,377		152,210

By Currency
CHF		103,272		41,322
EUR		3,658		6,727
USD		17,447		104,161
Total		124,377		152,210

At the balance sheet dates, Company funds were held in CHF, EUR and USD currencies. As of December 31, 2017, funds in EUR and USD were translated into CHF at a rate of 1.169 and 0.976, respectively.

Fact Table
Network	060900 - Disclosure - Share capital (http://acimume.com/role/ShareCapital)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of share capital, reserves and other equity interest [text block]

9.	Share capital

As of December 31, 2017 and 2016, the issued share capital amounted to CHF 1,147,104 and CHF 1,135,468 respectively and comprised of Common Shares of 57,355,188 and 56,773,392, respectively.

The table below summarizes the Company’s capital structure:

	For the Years Ended December 31,
	2017		2016
	Number	CHF	Number	CHF
Common shares with a nominal value of CHF 0.02 each	57,355,188	1,147,104	56,773,392	1,135,468
Total	57,355,188	1,147,104	56,773,392	1,135,468

The Common Shares nominal values of CHF 0.02 per share are fully paid in.

The changes in common shares outstanding for the year ended December 31, 2017 represent 4,023 Restricted Shares issued, 5,998 Restricted Share Units which vested and 571,775 share options that were exercised.

On April 15, 2016, AC Immune completed a private placement of Series E preferred shares, each with a nominal value of CHF 0.02 per share (the “Series E Private Placement Extension”). An aggregate 1,401,792 Series E preferred shares were issued at a price of $9.6384 per preferred share to certain strategic investors, individuals and existing shareholder in the Series E Private Placement Extension for an aggregate subscription amount of approximately $13.5 million. As previously referenced in Note 3 in the summary of significant accounting policies, all outstanding Preferred Shares were converted to common shares as a result of the IPO completed in September 2016.

The changes in common shares outstanding for the year ended December 31, 2016 represent (i) 6.9 million common shares issued as a result of the Company’s 2016 IPO, (ii) 38,577,042 additional common shares as a result the conversion of all outstanding preferred shares (including the 1.4 million preferred Series E shares issued in April 2016) on a one-for-one basis as a result of the Company’s 2016 IPO and (iii) 2,069,100 share options exercised during 2016.

Fact Table
Network	061000 - Disclosure - Trade payables and accrued liabilities (http://acimume.com/role/TradePayablesAndAccruedLiabilities)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of trade and other payables [text block]

10.	Trade payables and accrued liabilities

	For the Years Ended December 31,
in CHF thousands	2017		2016
Trade payables and other payables		1,092		4,035
Accrued research and development costs		5,430		3,265
Accrued payroll expenses		2,420		1,419
Other accrued expenses		457		682
Deferred income		355		521
Total		9,754		9,922

An accrual of CHF 1.1 million and CHF 1.0 million was recognized for performance-related remuneration relating to 2017 and 2016, respectively.

Fact Table
Network	061100 - Disclosure - Deferred income (http://acimume.com/role/DeferredIncome)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Deferred income

11.	Deferred income

For the year ended December 31, 2017, the Company has recorded CHF 0.4 million in deferred income in relation to research funding commitments from Biogen. For the year ended December 31, 2016, we received a research contribution from Biogen for research collaboration of $1.5 million (CHF 1.5 million) for the alpha-synuclein and TDP-43 PET imaging programs. As of December 31, 2016, the remaining CHF 521 thousand was recorded as a current liability in deferred income and was recognized as revenue in 2017 as remaining performance obligations were completed.

Fact Table
Network	061200 - Disclosure - Long term financing obligation (http://acimume.com/role/LongTermFinancingObligation)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of Long term financing obligation [Text Block]

12.	Long term financing obligation

On January 4, 2016 and September 13, 2016 for fiscal years 2016 and 2017, respectively, AC Immune obtained separate funding commitment notices from the LuMind Research Down Syndrome Foundation (“LuMind”) totaling $200 thousand in each instance. Per the Research Grant Agreement, the terms stipulate that AC Immune has an obligation to reimburse LuMind for an amount equal to 125% of the then funding commitment made by LuMind to AC Immune. AC Immune has accordingly recorded a long-term financing obligation for the total $400 thousand (CHF 395 thousand) committed and a corresponding interest accrual of $100 thousand (CHF 99 thousand).

Fact Table
Network	061300 - Disclosure - Revenues (http://acimume.com/role/Revenues)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of revenue [text block]

13.

Revenues

	For the Years Ended December 31,
in CHF thousands	2017	2016	2015
Contract revenue	20,255	23,214	39,090
Total	20,255	23,214	39,090

Anti-Abeta antibody in AD - Collaboration agreement of 2006 with Genentech

In November 2006, AC Immune signed an exclusive, worldwide licensing agreement for crenezumab, our humanized monoclonal antibody targeting misfolded Abeta. Genentech commenced Phase 3 clinical studies for crenezumab in the first quarter of 2016. In February 2017, Genentech started a second Phase 3 clinical trial. If crenezumab receives regulatory approval, we will be entitled to receive royalties that are tied to annual sales volumes with different royalty rates applicable in the U.S. and Europe. These percentage rates range from net high single digits to the mid-teens.

Under the agreement with Genentech, we may become eligible to receive payments totaling up to approximately $340 million, excluding royalties. As of December 31, 2017 we have received total payments of $65 million (CHF 70.1 million).

We recognized the Phase 3 July 2015 payment as revenue in our 2015 fiscal year since there was no further performance requirement to be met by the Company. The agreement provides for a second therapeutic product based on the same intellectual property and anti-Abeta antibody compound as well as an anti-Abeta diagnostic product. Genentech may terminate the agreement at any time by providing three months’ notice to us. In such event all costs incurred are still refundable.

Anti-Tau antibody in AD – Collaboration agreement of 2012 with Genentech

In June 2012, we entered into a second partnership with Genentech to commercialize our anti-Tau antibodies for use as immunotherapeutics. The value of this exclusive, worldwide alliance is potentially greater than CHF 400 million and includes upfront and milestone payments. In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the mid-single digits to high single digits. The agreement also provides for collaboration on two additional indications built on the same anti-Tau antibody program as well as a potential anti-Tau diagnostic product.

To date, we have received payments totaling CHF 59 million, including a CHF 14 million milestone payment recognized and payment received in the fourth quarter of 2017 associated with the first patient dosing in a Phase 2 clinical trial for Alzheimer’s Disease with an anti-Tau monoclonal body known as RO7105705, a CHF 14 million milestone payment recognized in the second quarter of 2016 and received in July 2016, associated with the recent announcement of the commencement of the Phase 1 clinical study of the lead anti-Tau antibody candidate and a CHF 14 million milestone payment received in 2015 in connection with the ED-GO decision.

Genentech may terminate the agreement at any time by providing three months’ notice to us. In such event all costs incurred are still refundable.

Tau Vaccine in AD – Collaboration agreement of 2014 with Janssen Pharmaceuticals

In December 2014, we entered into a partnership with Janssen Pharmaceuticals, a Johnson & Johnson company, to develop and commercialize therapeutic anti-Tau vaccines for the treatment of AD and potentially other Tauopathies. The partnership includes a worldwide exclusive license and research collaboration. We and Janssen will co-develop the lead therapeutic vaccine, ACI-35, through Phase 1b completion. From Phase 2 and onward, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of ACI-35. ACI-35 is an active therapeutic vaccine stimulating the patient’s immune system to produce a polyclonal antibody response against phosphorylated Tau protein.

The agreement also allows for the collaboration to be expanded to a second indication based on the same anti-Tau vaccine program and intellectual property related to this program.

We received an upfront payment of CHF 25.9 million which we recognized in 2014 and are eligible to receive development, regulatory and commercialization milestone payments for AD and a potential second indication outside of AD. Additionally, we will receive royalties on sales at a percentage rate ranging from the low double digits to mid-teens. The two companies have entered into a three-year joint research collaboration, which was subsequently amended to five years, to further characterize and develop novel vaccine therapies for the treatment of Tauopathies.

The recognition of the upfront payment from Janssen was recorded at the time of receipt as the Company determined that the license granted to Janssen was a separate, non-contingent deliverable under the agreement. The Company determined the license had stand-alone value based on Janssen’s ability to create value from the license without our research and development support services due their extensive experience in vaccine development and production which would allow them to complete the phase 1b clinical trials.

In 2016, we received payments of CHF 1.5 million for pre-payment of research and external research costs. Pursuant to the terms of the collaboration agreement, there is a performance obligation until the end of the year. As a result, we recognized the proceeds from the milestone payment over a 12-month period on a straight-line basis. In May 2016, we received a CHF 4.9 million payment for reaching a clinical milestone in the Phase 1b study. As we met all performance obligations on reaching the milestone, we have recognized related revenue.

In July 2017, AC Immune and Janssen entered into a Second Amendment to the December 2014 License, Development and Commercialization Agreement. The Amendment allows for the alignment of certain payment provisions with the new Development Plan and Research Plan activities. ACI and Janssen will jointly share R&D costs until the completion of the first Phase 2 or first Phase 3 trial begins. Under the terms of the agreement, Janssen may terminate the agreement at any time after completion of the Phase 1b clinical study by providing 90 days’ notice to us.

Tau-PET imaging agent in AD – License and Collaboration agreement of 2014 with Piramal Imaging

In May 2014, AC Immune SA entered into an LCA, our first diagnostic partnership with Piramal Imaging (“Piramal”), a division of Piramal Enterprises, Ltd. The LCA with Piramal is an exclusive, worldwide licensing agreement for the research, development and commercialization of the Company’s Tau protein positron emission tomography (PET) tracers supporting the diagnosis and clinical management of AD and potential Tau-related disorders and includes upfront and sales milestone payments totaling up to EUR 157 million, plus royalties on sales at a percentage rate ranging from mid-single digits to low double digits.

The upfront payment of EUR 500 thousand received from this collaboration was deferred over a period of 12 months which was the joint Research Collaboration period. As such, the residual balance in deferred revenue related to this collaboration at December 31, 2014, was fully recognized until May 2015.

In March 2017, we invoiced Piramal for a CHF 1.1 million milestone related to the initiation of “Part B” of the first-in-man Phase 1 clinical trial for PSP (Progressive Supranuclear Palsy). As we met all performance obligations on reaching the milestone, we have recognized this milestone as revenue in the first quarter of fiscal 2017 and received payment in Q4 2017. We are also entitled to further clinical milestones totaling EUR 6 million should the compound make it through to Phase 3 clinical studies and are further entitled to potential regulatory, commercialization and sales based milestones totaling EUR 150 million.

Piramal may terminate the LCA agreement by providing three months’ notice to the Company.

Alpha-synuclein and TDP-43 PET tracer in AD – Collaboration agreement of 2016 with Biogen

On April 13, 2016, AC Immune entered into a non-exclusive research collaboration agreement with Biogen International GmbH, or Biogen. Under the agreement, we and Biogen have agreed to collaborate in the research and early clinical development of our alpha-synuclein PET Tracer program for Parkinson’s disease and other synucleinopathies, and a second program for the identification, research and development of novel PET ligands against TDP-43, a protein recently linked to neurodegeneration in diseases such as amyotrophic lateral sclerosis. In addition, we have agreed to share the costs of the collaboration, with Biogen primarily funding the majority of research costs, subject to a cap, which includes an upfront technology access fee and funding towards research and development personnel. We will own all intellectual property rights to any invention relating to alpha-synuclein or TDP-43 PET tracers.

In April 2017, we began the second year of our collaboration and have recognized CHF 3.4 million for research contribution and collaboration services. We have also recognized the remaining CHF 0.5 million related to the technology access fee bill in April 2016 which was amortized over a 12-month period.

As of December 31, 2017, CHF 355 thousand is recorded as a current liability in deferred income and is expected to be recognized as revenue in 2018 as remaining performance obligations are completed.

Recombinant protein therapeutic candidate – Collaboration with Essex Bio-Technology Limited

On May 19, 2017, we entered into a Research Project Agreement with Essex Bio-Technology Limited, or Essex, to develop a recombinant protein therapeutic candidate acting on a unique neuroprotective mechanism for treatment of neurological diseases, such as Alzheimer’s disease and frontotemporal dementia. Essex will provide joint research commitment as well as financial support to AC Immune for the pre-IND development of the biological agent.

As part of this agreement, the parties have agreed to an initial two year Research Plan, which intends to develop a basic Fibroblast Growth Factor ("bFGF") as a therapeutic for the treatment of neurodegenerative diseases and to generate novel antibody therapeutics.

Under the terms of the agreement, Essex will provide support to AC Immune until the selection of a collaboration product by the Joint Steering Committee, up to a maximum of CHF 750 thousand per year. The Company recognized CHF 78 thousand for the year ended December 31, 2017.

Continuation of 2015 Grant from the Michael J. Fox Foundation

On September 16, 2017, AC Immune formally signed a one year grant continuation with the Michael J. Fox Foundation for Parkinson’s Disease research. This grant provides funds for the development of Positron Emission Tomography (PET) tracers for the alpha-synuclein protein, to support the early diagnosis and clinical management of Parkinson’s disease. The Company recognized CHF 95 thousand for research services performed for the year ended December 31, 2017.

Fact Table
Network	061400 - Disclosure - Expenses by category (http://acimume.com/role/ExpensesByCategory)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of expenses [text block]

14.	Expenses by category

Research and Development

	For the Years Ended December 31,
in CHF thousands	2017		2016		2015
Operating expenses		23,822		18,767		10,763
Payroll expenses		8,552		6,450		5,879
Share-based compensation		289		557		407
Total research and development expenses		32,663		25,774		17,049

General and Administrative

	For the Years Ended December 31,
in CHF thousands	2017		2016		2015
Operating expenses		3,857		3,168		1,377
Payroll expenses		4,984		3,969		1,908
Share-based compensation		1,290		759		132
Total general and administrative expenses		10,131		7,896		3,417

Financial Result, net

	For the Years Ended December 31,
in CHF thousands	2017			2016			2015
Interest income/ (expense)		184			36			55
Foreign currency remeasurement gain/(loss), net		(4,049	)		3,443			1,598
Other finance income/(expense)		(7	)		(119	)		(7	)
Finance result, net		(3,872	)		3,360			1,646

Fact Table
Network	061500 - Disclosure - Related-party transactions (http://acimume.com/role/RelatedpartyTransactions)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of related party [text block]

15.	Related-party transactions

Key management including the Board of Directors (five individuals excluding the CEO) and the Executive Management (four individuals) compensation was:

	For the Years Ended December 31,
in CHF thousands	2017		2016		2015
Short-term employee benefits		2,463		2,251		1,776
Post-employment benefits		166		154		124
Share-based compensation		1,267		832		8
Total		3,896		3,237		1,908

In April 2017, Joerg Hornstein was named the Chief Financial Officer and a member of the Executive Management. He replaced the former CFO whose tenure ended in November 2016.

Friedrich von Bohlen and Peter Bollmann joined the Board of Directors of AC Immune in October and December 2015, respectively. Friedrich von Bohlen replaced Christof Hettich who stepped down from the Board in August 2015. Hans-Beat Guertler resigned from the board in December 2015. His position was assumed by Peter Bollmann. In November 2016, Mr. Thomas Graney joined the Board of Directors of AC Immune, replacing Mathias Hothum as his term expired.

Short-term employee benefits comprise of salaries, bonuses, social security and expense allowances.

257,916, 98,500, and 45,000 options were granted in 2017, 2016 and 2015, respectively, to the Executive Management of the Company. No options were granted in 2017, 2016, and 2015, respectively, to the Directors of the Company. In connection with his departure in the fourth quarter of 2016, the former Chief Financial Officer forfeited his initial 2016 grant (included in the aggregate 2016 total above), and in its place was awarded 49,250 options. The fourth quarter 2016 grant date fair value of the replacement award was CHF 674 thousand.

The Company granted 4,023 Restricted Shares as part of a Restricted Share Award to one of our Directors in accordance with our 2016 Stock Option and Incentive Plan in 2017. No such awards were issued in 2016 and 2015.

In the third quarter of fiscal 2017, the Company granted 125,332 Restricted Share Units to certain members of the Board of Directors and Executive Management. No such awards were issued in 2016 and 2015.

Fact Table
Network	061600 - Disclosure - Income taxes (http://acimume.com/role/IncomeTaxes)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Income taxes

16.	Income taxes

The Company recognized no income tax expense or deferred tax asset or liability positions for the years ended December 31, 2017, 2016, and 2015.

The income tax expense for each year can be reconciled to Income / (loss) before tax as follows:

	For the Years Ended December 31,
in CHF thousands	2017			2016			2015
Income / (loss) before income tax		(26,411	)		(7,096	)		20,270
Tax expense / (benefit) calculated at the statutory rate of 20.5% (21% for 2016 and 22% for 2015)		(5,420	)		(1,504	)		4,566
Effect of Swiss Tax Holidays		-			-			-
Permanent differences		40			(166	)		-
Effect of unrecognized carry forward tax loss		-			-			(4,566	)
Effect of unused tax losses and tax offsets not recognized as deferred tax assets		5,380			1,670			-
Effective income tax rate benefit / (expense)		-			-			-

The tax rate used for the 2017 reconciliations above is the corporate tax rate of 20.5% (21%: 2016 and 22% : 2015) payable by corporate entities in the Canton of Vaud, Switzerland on taxable profits under tax law in that jurisdiction.

In 2015, AC Immune was able to apply tax loss carryforwards to reduce its effective tax rate to zero.

	For the Years Ended December 31,
in CHF thousands	2017		2016		2015
Unrecognized deductible temporary differences, unused tax losses and unused tax credits
Deductible temporary differences, unused tax losses and unused tax credits for which no deferred tax assets have been recognized are attributable to the following:
- Tax losses		62,575		36,707		29,079
- Deductible temporary differences related to the retirement benefit plan		4,926		3,798		2,787

Total		67,501		40,505		31,866

Deductible temporary differences related to the retirement benefit plan do not expire. Tax losses expiry dates are shown in the table below:

in CHF thousands	2017		2016		2015
Tax losses split by expiry date
December 31, 2017		-		-		-
December 31, 2018		2,175		2,175		2,175
December 31, 2019		16,566		16,566		16,566
December 31, 2020		10,338		10,338		10,388
December 31, 2021		-		-		-
December 31, 2022		-		-		-
December 31, 2023		7,628		7,628		-
December 31, 2024		25,868		-		-
Total		62,575		36,707		29,079

The tax losses available for future offset against taxable profits have increased by CHF 25.9 million from 2016, representing the amount of tax losses that are additionally available as an offset, subject to expiration as disclosed in the table above, against future taxable income.

Consistent with prior years, the Company has not recorded any deferred tax assets in relation to the past tax losses available for offset against future profits as the recognition criteria have not been met at the balance sheet date.

Fact Table
Network	061700 - Disclosure - Retirement benefit plan (http://acimume.com/role/RetirementBenefitPlan)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of employee benefits [text block]

17.	Retirement benefit plan

The Company participates in a collective foundation covering all of its employees including its executive officers. In addition to retirement benefits, the plan provides death or long-term disability benefits.

Contributions paid to the plan are computed as a percentage of salary, adjusted for the age of the employee and shared approximately 47% and 53% by employee and employer, respectively.

This plan is governed by the Swiss Law on Occupational Retirement, Survivors and Disability Pension Plans (BVG), which requires contributions to be made to a separately administered fund. The fund has the legal form of a foundation and it is governed by the board of trustees, which consists of an equal number of employer’s and employee’s representatives. The board of trustees is responsible for the administration of the plan assets and for the definition of the investment strategy.

The collective foundation is governed by a foundation board. The board is made up of an equal number of employee and employer representatives of the different affiliated companies. The Company has no direct influence on the investment strategy of the foundation board.

The assets are invested by the pension plan, to which many companies contribute, in a diversified portfolio that respects the requirements of the Swiss BVG. Therefore disaggregation of the pension assets and presentation of plan assets in classes that distinguish the nature and risks of those assets is not possible. Under the Plan, both the Company and the employee share the costs equally. The structure of the plan and the legal provisions of the BVG mean that the employer is exposed to actuarial risks. The main risks are investment risk, interest risk, disability risk and the life expectancy of pensioners. Through our affiliation with the pension plan, the Company has minimized these risks, since they are shared between a much greater number of participants. On leaving the Company, a departing employee’s retirement savings are transferred to the pension institution of the new employer or to a vested benefits institution. This transfer mechanism may result in pension payments varying considerably from year to year.

The pension plan is exposed to Swiss inflation, interest rate risks and changes in the life expectancy for pensioners.

For accounting purposes under IFRS, the plan is treated as a defined benefit plan. Liabilities are calculated annually by an independent actuary. Plan assets have been estimated at their fair market value and liabilities have been calculated according to the “Projected Unit Credit” method.

The following table sets forth the status of the defined benefit pension plan and the amount that should be recognized in the balance sheet:

	For the Years Ended December 31,
in CHF thousands	2017		2016		2015
Defined benefit obligation	(14,278	)	(11,596	)		(9,439	)
Fair value of plan assets	9,352		7,798			6,652
Total liability	(4,926	)	(3,798	)		(2,787	)

The following amounts have been recorded as net pension cost in the statement of income:

	For the Years Ended December 31,
in CHF thousands	2017			2016			2015
Service cost		912			742			641
Interest cost		81			75			101
Interest income		(55	)		(56	)		(76	)
Impact of plan amendment		-			-			(584	)
Net pension cost		938			761			82

The changes in defined benefit obligation, fair value of plan assets and unrecognized (gains) / losses are as follows:

A.	Change in defined benefit obligation

in CHF thousands	2017			2016			2015
Defined benefit obligation as of January 1		(11,596	)		(9,439	)		(8,091	)
Service cost		(912	)		(742	)		(641	)
Interest cost		(81	)		(75	)		(101	)
Change in demographic assumptions		—			(389	)		—
Change in financial assumptions		—			(26	)		(591	)
Other actuarial gains / (losses)		(735	)		(378	)		(176	)
Plan amendment		—			—			584
Benefit payments		(426	)		(111	)		(48	)
Employees’ contributions		(528	)		(436	)		(375	)
Defined benefit obligation as of December 31		(14,278	)		(11,596	)		(9,439	)

B.	Change in fair value of plan assets

in CHF thousands	2017			2016		2015
Fair value of plan assets as of January 1		7,798			6,652		5,681
Interest income		55			56		76
Employees’ contributions		528			436		375
Employer’s contributions		590			511		441
Benefits payments		426			111		48
Plan assets gains/(losses)		(45	)		32		31
Fair value of plan assets as of December 31		9,352			7,798		6,652

Employer’s contribution to the pension plan for the financial year 2018 are estimated to be CHF 630 thousand.

C.	Change in net defined benefit liability

in CHF thousands	2017			2016			2015
Net defined benefit liabilities as of January 1		3,798			2,787			2,410
Net pension cost through statement of income		938			761			82
Re-measurement through other comprehensive income		780			761			736
Employer’s contribution		(590	)		(511	)		(441	)
Net defined benefit liabilities as of December 31		4,926			3,798			2,787

The fair value of the plan assets is the cash surrender value of the insurance with AXA. The investment strategy defined by the board of trustees follows a conservative profile.

The plan assets are primarily held within instruments with quoted market prices in an active market, with the exception of real estate and mortgages.

The weighted average duration of the defined benefit obligation is 20.5 years as of December 31, 2017.

The actuarial assumptions used for the calculation of the pension cost and the defined benefit obligation of the defined benefit pension plan for the year 2017, 2016 and 2015 are as follows:

	For the Years Ended December 31,
	2017			2016			2015
Discount rate		0.70	%		0.70	%		1.25	%
Rate of future increase in compensations		1.50	%		1.50	%		1.50	%
Rate of future increase in current pensions		0.50	%		0.50	%		0.50	%
Mortality and disability rates	BVG 2015G			BVG 2015G			BVG 2010G

In defining the benefits, the minimum requirements of the Swiss Law on Occupational Retirement, Survivors and Disability Pension Plans (BVG) and its implementing provisions must be observed. The BVG defines the minimum pensionable salary and the minimum retirement credits.

A quantitative sensitivity analysis for significant assumption as of December 31, 2017 is as shown below:

		Discount rate				Future salary increase					Future pension cost
Assumptions		+0.5% increase	-0.5% decrease			+0.5% increase			-0.5% decrease		+0.5% increase			-0.5% decrease
	in CHF thousands
Defined benefit obligation		12,707		15,849			14,449			14,121		14,989			13,564
Impact on the net defined benefit obligation		1,571		(1,571	)		(171	)		157		(711	)		714

The sensitivity analyses above is subject to limitations and has been determined based on a method that extrapolates the impact on net defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period.

Fact Table
Network	061800 - Disclosure - Share-based compensation (http://acimume.com/role/SharebasedCompensation)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of share-based payment arrangements [text block]

18.	Share-based compensation

Through the year ended December 31, 2017, the Company has issued equity-based instruments under four different plans that existed in 2017 as outlined in the table below.

The Company’s 2016 Share Option and Incentive Plan (“Plan”) was approved by the shareholders at the Ordinary Shareholder’s meeting in November 2016. The 2016 Plan authorizes the grant of incentive and non-qualified share options, share appreciation rights, restricted share awards, restricted share units, unrestricted share awards, performance share awards, performance-based awards to covered employees and dividend equivalent rights.

The following table summarizes equity settled share option grants since inception under each plan:

PLAN	Number of options awarded (since inception)	Vesting conditions	Contractual life of options
Share option plan A	362,750	At grant	15.5 years
Share option plan B	819,000	At grant	10.5 years
Share option plan C1	6,775,250	4 years’ service from grant date	10 years
2016 Share Option and Incentive Plan:
Executives and Directors	257,916	4 years’ service from the date of grant, quarterly	10 years
Employees	18,850	4 years’ service from the date of grant, annually	10 years

The number and weighted average exercise prices (in CHF) of options under the share option programs for Plans A, B, C1 and 2016 are as follows:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Term (Years)
Outstanding at January 1, 2015		4,006,500			0.21668		4.5
Forfeited during the year		(23,250	)		0.14548		-
Cancelled during the year		(15,250	)		0.14548		-
Exercised during the year		(594,250	)		0.14548		-
Granted during the year		223,250			0.14548		-
Outstanding at December 31, 2015		3,597,000			0.14548		3.6
Exercisable at December 31, 2015		3,032,500			0.14548		3.4
Outstanding at January 1, 2016		3,597,000			0.14548		3.6
Forfeited during the year		(106,000	)		0.14548		-
Cancelled during the year		(19,250	)		0.14548		-
Exercised during the year		(2,069,100	)		0.14548		-
Granted during the year		285,250			0.14548		-
Outstanding at December 31, 2016		1,687,900			0.14548		5.6
Exercisable at December 31, 2016		1,284,525			0.14548		6.5
Outstanding at January 1, 2017		1,687,900			0.14548		5.6
Forfeited during the year		(1,750	)		0.14548		-
Cancelled during the year		(31,250	)		0.14548		-
Exercised during the year		(571,775	)		0.14548		-
Granted during the year		276,766			9.70		-
Outstanding at December 31, 2017		1,359,891			2.09		5.8
Exercisable at December 31, 2017		900,474			0.39		4.3

The weighted average exercise price for options granted in 2017, 2016 and 2015 is CHF 9.70, CHF .14548 and CHF .14548, respectively. The range of exercise prices for outstanding options was CHF 0.14548 to CHF 12.00 as of December 31, 2017 and 0.14548 as of December 31, 2016 and 2015.

The weighted average fair values of the options granted in 2017, 2016 and 2015 are CHF 7.29, CHF 5.85, and CHF 1.77, respectively. These fair values of options granted have been determined using the Black-Scholes option pricing model and an exercise price ranging from CHF 9.53 to CHF 12.00 in 2017 (2016 and 2015: CHF 0.14548), a weighted average share price of CHF 8.77 (2016: CHF 5.96 and 2015: CHF 1.91), a risk-free interest rate of 0% (2016 and 2015: 0%) and a volatility of 80% (2016: 80% and 2015: 50%) with an expected duration of 6 years (2016 and 2015: 6 years). All options expire 10 years from the grant date unless otherwise noted.

Prior to the IPO, the exercise price was set by the Board of Directors. The volatility is based on the historical trend of an appropriate sample of companies operating in the biotech and pharmaceutical industry. The risk-free interest rate is based on the CHF swap rate for the expected life of the option. The weighted average share price of common share options exercised in 2017 is CHF 10.53 (2016: CHF 6.22 and 2015: CHF 1.91).

The expense charged against the income statement for the financial year 2017 amounts to CHF 1,579 thousand (2016: CHF 1,317 thousand and 2015: 540 thousand). The expense is revised by the Company based on the number of instruments that are expected to become exercisable. The 2016 expense also reflects a share based option award that was modified in 2016 to amend the option grant’s contractual life and the issuance of a replacement award. An incremental fair value of CHF 238 thousand was immediately recognized in 2016 as a result of the modification of the share options contractual life. Additionally, in connection with former CFO departure in the fourth quarter of 2016, the former Chief Financial Officer forfeited his initial 2016 grant (included in the aggregate 2016 total of 98,500), and in its place was awarded 49,250 options, which has been accounted for as a new award granted on the date of forfeiture of the original award. The fourth quarter 2016 grant date fair value of the replacement award was CHF 674 thousand. The fair value of the modified award was measured using the Black-Scholes option pricing model with similar assumptions to the 2016 option, except for a currently quoted common share price as of the date of the modification.

The following table summarizes non-vested share awards (restricted share and restricted share units) during the year ended December 31, 2017 (no such awards were granted in 2016 and 2015, respectively):

Grantee Type	Number of non-vested share awards granted	Vesting conditions	Contractual life of non-vested share awards
Restricted Share Units
Directors	29,375	1 year service from date of grant, annually	10 years
Executives	95,957	4 years’ service from the date of grant, quarterly	10 years
Restricted Share Awards	4,023	2.75 years’ service from date of grant, quarterly	10 years

	Number of non-vested shares		Weighted average grant date fair value
Non-vested at January 1, 2017		-		-
Forfeited during the year		-		-
Cancelled during the year		-		-
Exercised during the year		-		-
Granted during the year		129,355		9.62
Non-vested at December 31, 2017		122,014		9.59
Vested at December 31, 2017		7,341		10.06

The weighted average grant date fair value of the restricted share awards granted (restricted shares and restricted share units) in 2017 was CHF 9.62. No RSAs or RSUs were granted in 2016 and 2015. The weighted average grant date fair values of the non-vested share awards granted (restricted shares and restricted share units) in 2017, 2016 and 2015 are CHF 9.59, 0 and 0, respectively. These fair values of non-vested share awards granted have been determined using a reasonable estimate of market value of the common stock on the date of the award.

Fact Table
Network	061900 - Disclosure - Commitments and contingencies (http://acimume.com/role/CommitmentsAndContingencies)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of commitments and contingent liabilities [text block]

19.	Commitments and contingencies

	For the Years Ended December 31,
in CHF thousands	2017		2016
Within one year		9,686		9,175
Between one and three years		2,546		1,624
Between three and five years		140		-
More than five years		-		-
Total		12,372		10,799

The Company has research contracts with several external service providers. As of December 31, 2017 external research projects for CHF 9.4 million were committed for 2018. Rental contract for laboratory and offices space at the EPFL Innovation Park in Ecublens/Lausanne can be cancelled within a 6 month notice period. Lease expense in 2017 was CHF 0.5 million. As of December 31, 2017, rental contracts for CHF 0.2 million were committed for 2018.

The Company has a contractual obligation that requires the payment of royalties to a third party, which is associated with the achievement of program milestones. As of December 31, 2017, the Company’s contractual obligation associated with this agreement was CHF 0.4 million.

Fact Table
Network	062000 - Disclosure - Earnings per share (http://acimume.com/role/EarningsPerShare)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of earnings per share [text block]

20.	Earnings per share

	For the Years Ended December 31,
in CHF thousands except for share and per share data	2017			2016			2015
Net income / (loss) attributable to owners of the Company		(26,411	)		(7,096	)		20,270
Earnings per share (EPS):
Basic, income / (loss) for the period attributable to equity holders		(0.46	)		(0.14	)		0.47
Diluted, income / (loss) for the period attributable to equity holders		(0.46	)		(0.14	)		0.44
Weighted-average number of shares used to compute EPS basic		57,084,295			50,096,859			43,412,250
Weighted-average number of shares used to compute EPS fully diluted		57,084,295			50,096,859			46,043,198

For the years ended December 31, 2017, 2016 and 2015 basic and diluted earnings per share is based on the weighted average number of shares issued and outstanding. Weighted-average dilutive shares outstanding excludes antidilutive shares to be issued that totaled 1,463,056 and 1,687,900 from the computation of diluted income (loss) per common share for the years-ended December 31, 2017 and 2016, respectively. The weighted average number of equity awards outstanding for the years ended December 31, 2017 and 2016 was 1,582,612 and 2,784,245, respectively.

Fact Table
Network	062100 - Disclosure - Financial instruments and risk management (http://acimume.com/role/FinancialInstrumentsAndRiskManagement)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of financial risk management [text block]

21.	Financial instruments and risk management

The Company’s activities expose it to the following financial risks: market risk (currency risk), credit risk and liquidity risk. The Company’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Company’s financial performance.

The following table shows the carrying amounts of financial assets and financial liabilities:

	For the Years Ended December 31,
in CHF thousands	2017		2016
Financial assets
Other current receivables		918		517
Cash and cash equivalents		124,377		152,210
Total financial assets		125,295		152,727

Financial liabilities
Long-term financing obligation		395		-
Trade and other payables		1,092		4,035
Accrued expenses		8,307		5,366
Total financial liabilities		9,794		9,401

Foreign exchange risk

The Company is exposed to foreign exchange risk arising from currency exposures, primarily with respect to the EUR, USD and to a lesser extent to GBP, DKK and SEK. The currency exposure is not hedged. However, the Company has a policy of matching its cash holdings to the currency structure of its expenses, which means that the Company holds predominately CHF, EUR and USD (see also Note 8). In the Company’s income statements for the years ended December 31, 2017, 2016 and 2015 a loss of 4.2 million and a gain of CHF 3.4 million and CHF 1.6 million, respectively, is recognized in the financial statement line item “Finance Income/(expense), net.”

Credit risk

The majority of the cash and cash equivalents is held within one bank. However, the credit risk on liquid funds is limited because the counterparty is a bank with a high credit-rating assigned by international credit-rating agencies. The maximum amount of credit risk is the carrying amount of the financial assets. Trade and other receivables are fully performing, not past due and not impaired (see Note 6).

Liquidity risk

Inherent in the Company’s business are various risks and uncertainties, including its limited operating history and the high uncertainty that new therapeutic concepts will succeed. AC Immune’s success may depend in part upon its ability to (i) establish and maintain a strong patent position and protection, (ii) enter into collaborations with partners in the biotech and pharmaceutical industry, (iii) acquire and keep key personnel employed, and (iv) acquire additional capital to support its operations.

The Company’s approach of managing liquidity is to ensure sufficient cash to meet its liabilities when due. Therefore, management closely monitors the cash position on rolling forecasts based on expected cash flow to enable the Company to finance its operations for at least 18 months.

Based on the current cash position, the Company is well financed through the second quarter of 2019.

Foreign currency

The Company undertakes certain transactions denominated in foreign currencies. Hence, exposure to exchange rate fluctuations arises. Exchange rate exposures are managed by matching its cash holdings to the currency structure of its expenses.

As of December 31, 2017, if the CHF had strengthened/weakened by 10% against the EUR and the USD with all other variables held constant, the net loss for the period would have been lower/higher by CHF 2.1 million (2016: CHF 10.9 million), mainly as a result of foreign exchange gains/losses on predominantly EUR/USD denominated cash and cash equivalents.

Interest rates

The Company is not materially exposed to any interest rates fluctuations.

Fact Table
Network	062200 - Disclosure - Capital risk management (http://acimume.com/role/CapitalRiskManagement)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of objectives, policies and processes for managing capital [text block]

22.	Capital risk management

The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern and to preserve the capital on the required statutory level in order to succeed in developing a cure against AD.

Fact Table
Network	062300 - Disclosure - Post balance sheet events (http://acimume.com/role/PostBalanceSheetEvents)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of events after reporting period [text block]

23.	Post balance sheet events

On February 2, 2018, we entered into an additional lease with the EPFL Innovation Park to expand our premises by more than 4,300 square feet effective March 1, 2018. As part of this expansion, the Company agreed to purchase CHF 750 thousand of the previous tenant’s lab equipment.

Fact Table
Network	070300 - Disclosure - Summary of significant accounting policies (Policies) (http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPolicies)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Description of accounting policy for accounting judgments and estimates [Policy Text Block]

Critical judgments and accounting estimates

Income taxes

Preferred shares

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Description of accounting policy for classification of assets and liabilities [Policy Text Block]

Current vs. non-current classification

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of accounting policy for changes in accounting policies not yet adopted [Policy Text Block]

Accounting pronouncements – not yet adopted

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Financial assets and liabilities [Policy Text Block]

Financial assets and liabilities

Receivables

Cash and cash equivalents

Trade payables

Trade payables are recognized initially at fair value, which represents cost incurred.

Long-term financing obligation

The Company’s long-term financing obligation is measured as of the period end date based on the repayment terms when originated.

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Description of accounting policy for earnings per share [text block]

Earnings per share

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Description of accounting policy for employee benefits [text block]

Employee benefits

Post-employment benefits

Share-based compensation

The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised.

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Description of accounting policy for foreign currency translation [text block]

Foreign currency transactions

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Description of accounting policy for income tax [text block]

Taxation

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Description of accounting policy for issued capital [text block]

Share capital and Initial Public Offering

Preferred Shares

Initial Public Offering (IPO)

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Description of accounting policy for property, plant and equipment [text block]

Property, plant and equipment

IT equipment	3 years
Laboratory equipment	5 years
Leasehold improvements / furniture	5 years

Gains and losses on disposals are determined by comparing the disposal proceeds with the carrying amount and are included in the Statements of Income / (Loss).

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Description of accounting policy for provisions [text block]

Provisions

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Description of accounting policy for recognition of revenue [text block]

Revenue recognition

License of intellectual property

For collaboration agreements, in addition to receiving upfront payments, the Company is also entitled to milestone and other contingent payments upon achieving pre-defined objectives.

Milestone payments

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Description of accounting policy for research and development expense [text block]

Research and Development Services

Research and development expenditure

Given the stage of development of the Company’s products, all research expenditure is recognized as expense when incurred. Research and development expenditures include:

fees and costs related to regulatory filings and activities;

costs associated with pre-clinical and clinical activities; and

employee-related expenses, including salaries and bonuses, benefits, travel and stock-based compensation expense

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Description of accounting policy for segment reporting [text block]

Segment reporting

The Company has one segment. The Company currently focuses all of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins.

Fact Table
Network	080300 - Disclosure - Summary of significant accounting policies (Tables) (http://acimume.com/role/SummaryOfSignificantAccountingPoliciesTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Schedule of information about property, plant and equipment useful life [Table Text Block]

Depreciation is calculated using a straight-line method to write off the cost of each asset to its residual value over its estimated useful life as follows:

IT equipment	3 years
Laboratory equipment	5 years
Leasehold improvements / furniture	5 years

Fact Table
Network	080400 - Disclosure - Property, plant and equipment (Tables) (http://acimume.com/role/PropertyPlantAndEquipmentTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of detailed information about property, plant and equipment [text block]

	As of December 31, 2017
	Furniture			Computers/IT			Lab Equipment			Leasehold Improvements			Total
Acquisition Cost:
Balance at the end of the previous year		81			298			2,792			103			3,274
Acquisitions		4			271			1,369			169			1,813
Balance at end		85			569			4,161			272			5,087

Accumulated depreciation:
Balance at the end of the previous year		(45	)		(172	)		(1,858	)		(79	)		(2,154	)
Depreciation expense		(14	)		(87	)		(453	)		(26	)		(580	)
Balance at end		(59	)		(259	)		(2,311	)		(105	)		(2,734	)

Carrying Amount:
December 31, 2016		36			126			934			24			1,120
December 31, 2017		26			310			1,850			167			2,353

	As of December 31, 2016
	Furniture			Computers/IT			Lab Equipment			Leasehold Improvements			Total
Acquisition Cost:
Balance at the end of the previous year		43			172			2,058			103			2,376
Acquisitions		38			126			734			-			898
Balance at end		81			298			2,792			103			3,274

Accumulated depreciation:
Balance at the end of the previous year		(36	)		(138	)		(1,629	)		(73	)		(1,876	)
Depreciation expense		(9	)		(34	)		(229	)		(6	)		(278	)
Balance at end		(45	)		(172	)		(1,858	)		(79	)		(2,154	)

Carrying Amount:
December 31, 2015		7			34			429			30			500
December 31, 2016		36			126			934			24			1,120

Fact Table
Network	080600 - Disclosure - Prepaid expenses and accrued income (Tables) (http://acimume.com/role/PrepaidExpensesAndAccruedIncomeTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of detailed information about prepaid expenses and accrued income [Table Text Block]

	For the Years Ended December 31,
in CHF thousands	2017	2016
Prepaid expenses	1,440	1,278
Accrued income	2,799	889
Total	4,239	2,167

Fact Table
Network	080700 - Disclosure - Other current receivables (Tables) (http://acimume.com/role/OtherCurrentReceivablesTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of detailed information about other current receivables [Table Text Block]

	For the Years Ended December 31,
in CHF thousands	2017		2016
Other receivables		691		182
Swiss VAT		112		320
Withholding tax		115		15
Total		918		517

Fact Table
Network	080800 - Disclosure - Cash and cash equivalents (Tables) (http://acimume.com/role/CashAndCashEquivalentsTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of detailed information about cash and cash equivalents [Table Text Block]

	For the Years Ended December 31,
in CHF thousands	2017		2016
Cash		124,377		152,210
Total		124,377		152,210

By Currency
CHF		103,272		41,322
EUR		3,658		6,727
USD		17,447		104,161
Total		124,377		152,210

Fact Table
Network	080900 - Disclosure - Share capital (Tables) (http://acimume.com/role/ShareCapitalTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of classes of share capital [text block]

The table below summarizes the Company’s capital structure:

	For the Years Ended December 31,
	2017		2016
	Number	CHF	Number	CHF
Common shares with a nominal value of CHF 0.02 each	57,355,188	1,147,104	56,773,392	1,135,468
Total	57,355,188	1,147,104	56,773,392	1,135,468

Fact Table
Network	081000 - Disclosure - Trade payables and accrued liabilities (Tables) (http://acimume.com/role/TradePayablesAndAccruedLiabilitiesTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of detailed information about trade payables and accrued liabilities [Table Text Block]

	For the Years Ended December 31,
in CHF thousands	2017		2016
Trade payables and other payables		1,092		4,035
Accrued research and development costs		5,430		3,265
Accrued payroll expenses		2,420		1,419
Other accrued expenses		457		682
Deferred income		355		521
Total		9,754		9,922

Fact Table
Network	081300 - Disclosure - Revenues (Tables) (http://acimume.com/role/RevenuesTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of detailed information about revenue [Table Text Block]

	For the Years Ended December 31,
in CHF thousands	2017	2016	2015
Contract revenue	20,255	23,214	39,090
Total	20,255	23,214	39,090

Fact Table
Network	081400 - Disclosure - Expenses by category (Tables) (http://acimume.com/role/ExpensesByCategoryTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Financial Result, net

	For the Years Ended December 31,
in CHF thousands	2017			2016			2015
Interest income/ (expense)		184			36			55
Foreign currency remeasurement gain/(loss), net		(4,049	)		3,443			1,598
Other finance income/(expense)		(7	)		(119	)		(7	)
Finance result, net		(3,872	)		3,360			1,646

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of general and administrative expense [text block]

General and Administrative

	For the Years Ended December 31,
in CHF thousands	2017		2016		2015
Operating expenses		3,857		3,168		1,377
Payroll expenses		4,984		3,969		1,908
Share-based compensation		1,290		759		132
Total general and administrative expenses		10,131		7,896		3,417

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of research and development expense [text block]

Research and Development

	For the Years Ended December 31,
in CHF thousands	2017		2016		2015
Operating expenses		23,822		18,767		10,763
Payroll expenses		8,552		6,450		5,879
Share-based compensation		289		557		407
Total research and development expenses		32,663		25,774		17,049

Fact Table
Network	081500 - Disclosure - Related-party transactions (Tables) (http://acimume.com/role/RelatedpartyTransactionsTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [text block]

Key management including the Board of Directors (five individuals excluding the CEO) and the Executive Management (four individuals) compensation was:

	For the Years Ended December 31,
in CHF thousands	2017		2016		2015
Short-term employee benefits		2,463		2,251		1,776
Post-employment benefits		166		154		124
Share-based compensation		1,267		832		8
Total		3,896		3,237		1,908

Fact Table
Network	081600 - Disclosure - Income taxes (Tables) (http://acimume.com/role/IncomeTaxesTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of detailed information about income tax losses expiry [Table Text Block]

Deductible temporary differences related to the retirement benefit plan do not expire. Tax losses expiry dates are shown in the table below:

in CHF thousands	2017		2016		2015
Tax losses split by expiry date
December 31, 2017		-		-		-
December 31, 2018		2,175		2,175		2,175
December 31, 2019		16,566		16,566		16,566
December 31, 2020		10,338		10,338		10,388
December 31, 2021		-		-		-
December 31, 2022		-		-		-
December 31, 2023		7,628		7,628		-
December 31, 2024		25,868		-		-
Total		62,575		36,707		29,079

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of detailed information about income tax reconciliation [Table Text Block]

The income tax expense for each year can be reconciled to Income / (loss) before tax as follows:

	For the Years Ended December 31,
in CHF thousands	2017			2016			2015
Income / (loss) before income tax		(26,411	)		(7,096	)		20,270
Tax expense / (benefit) calculated at the statutory rate of 20.5% (21% for 2016 and 22% for 2015)		(5,420	)		(1,504	)		4,566
Effect of Swiss Tax Holidays		-			-			-
Permanent differences		40			(166	)		-
Effect of unrecognized carry forward tax loss		-			-			(4,566	)
Effect of unused tax losses and tax offsets not recognized as deferred tax assets		5,380			1,670			-
Effective income tax rate benefit / (expense)		-			-			-

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of temporary difference, unused tax losses and unused tax credits [text block]

In 2015, AC Immune was able to apply tax loss carryforwards to reduce its effective tax rate to zero.

	For the Years Ended December 31,
in CHF thousands	2017		2016		2015
Unrecognized deductible temporary differences, unused tax losses and unused tax credits
Deductible temporary differences, unused tax losses and unused tax credits for which no deferred tax assets have been recognized are attributable to the following:
- Tax losses		62,575		36,707		29,079
- Deductible temporary differences related to the retirement benefit plan		4,926		3,798		2,787

Total		67,501		40,505		31,866

Fact Table
Network	081700 - Disclosure - Retirement benefit plan (Tables) (http://acimume.com/role/RetirementBenefitPlanTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of fair value of plan assets [text block]

The changes in defined benefit obligation, fair value of plan assets and unrecognized (gains) / losses are as follows:

A.	Change in defined benefit obligation

in CHF thousands	2017			2016			2015
Defined benefit obligation as of January 1		(11,596	)		(9,439	)		(8,091	)
Service cost		(912	)		(742	)		(641	)
Interest cost		(81	)		(75	)		(101	)
Change in demographic assumptions		—			(389	)		—
Change in financial assumptions		—			(26	)		(591	)
Other actuarial gains / (losses)		(735	)		(378	)		(176	)
Plan amendment		—			—			584
Benefit payments		(426	)		(111	)		(48	)
Employees’ contributions		(528	)		(436	)		(375	)
Defined benefit obligation as of December 31		(14,278	)		(11,596	)		(9,439	)

B.	Change in fair value of plan assets

in CHF thousands	2017			2016		2015
Fair value of plan assets as of January 1		7,798			6,652		5,681
Interest income		55			56		76
Employees’ contributions		528			436		375
Employer’s contributions		590			511		441
Benefits payments		426			111		48
Plan assets gains/(losses)		(45	)		32		31
Fair value of plan assets as of December 31		9,352			7,798		6,652

Employer’s contribution to the pension plan for the financial year 2018 are estimated to be CHF 630 thousand.

C.	Change in net defined benefit liability

in CHF thousands	2017			2016			2015
Net defined benefit liabilities as of January 1		3,798			2,787			2,410
Net pension cost through statement of income		938			761			82
Re-measurement through other comprehensive income		780			761			736
Employer’s contribution		(590	)		(511	)		(441	)
Net defined benefit liabilities as of December 31		4,926			3,798			2,787

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of net defined benefit liability (asset) [text block]

The following table sets forth the status of the defined benefit pension plan and the amount that should be recognized in the balance sheet:

	For the Years Ended December 31,
in CHF thousands	2017		2016		2015
Defined benefit obligation	(14,278	)	(11,596	)		(9,439	)
Fair value of plan assets	9,352		7,798			6,652
Total liability	(4,926	)	(3,798	)		(2,787	)

The following amounts have been recorded as net pension cost in the statement of income:

	For the Years Ended December 31,
in CHF thousands	2017			2016			2015
Service cost		912			742			641
Interest cost		81			75			101
Interest income		(55	)		(56	)		(76	)
Impact of plan amendment		-			-			(584	)
Net pension cost		938			761			82

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of sensitivity analysis for actuarial assumptions [text block]

The actuarial assumptions used for the calculation of the pension cost and the defined benefit obligation of the defined benefit pension plan for the year 2017, 2016 and 2015 are as follows:

	For the Years Ended December 31,
	2017			2016			2015
Discount rate		0.70	%		0.70	%		1.25	%
Rate of future increase in compensations		1.50	%		1.50	%		1.50	%
Rate of future increase in current pensions		0.50	%		0.50	%		0.50	%
Mortality and disability rates	BVG 2015G			BVG 2015G			BVG 2010G

A quantitative sensitivity analysis for significant assumption as of December 31, 2017 is as shown below:

		Discount rate				Future salary increase					Future pension cost
Assumptions		+0.5% increase	-0.5% decrease			+0.5% increase			-0.5% decrease		+0.5% increase			-0.5% decrease
	in CHF thousands
Defined benefit obligation		12,707		15,849			14,449			14,121		14,989			13,564
Impact on the net defined benefit obligation		1,571		(1,571	)		(171	)		157		(711	)		714

Fact Table
Network	081800 - Disclosure - Share-based compensation (Tables) (http://acimume.com/role/SharebasedCompensationTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of number and weighted average exercise prices of other equity instruments [text block]

Grantee Type	Number of non-vested share awards granted	Vesting conditions	Contractual life of non-vested share awards
Restricted Share Units
Directors	29,375	1 year service from date of grant, annually	10 years
Executives	95,957	4 years’ service from the date of grant, quarterly	10 years
Restricted Share Awards	4,023	2.75 years’ service from date of grant, quarterly	10 years

	Number of non-vested shares		Weighted average grant date fair value
Non-vested at January 1, 2017		-		-
Forfeited during the year		-		-
Cancelled during the year		-		-
Exercised during the year		-		-
Granted during the year		129,355		9.62
Non-vested at December 31, 2017		122,014		9.59
Vested at December 31, 2017		7,341		10.06

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of number and weighted average exercise prices of share options [text block]

The number and weighted average exercise prices (in CHF) of options under the share option programs for Plans A, B, C1 and 2016 are as follows:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Term (Years)
Outstanding at January 1, 2015		4,006,500			0.21668		4.5
Forfeited during the year		(23,250	)		0.14548		-
Cancelled during the year		(15,250	)		0.14548		-
Exercised during the year		(594,250	)		0.14548		-
Granted during the year		223,250			0.14548		-
Outstanding at December 31, 2015		3,597,000			0.14548		3.6
Exercisable at December 31, 2015		3,032,500			0.14548		3.4
Outstanding at January 1, 2016		3,597,000			0.14548		3.6
Forfeited during the year		(106,000	)		0.14548		-
Cancelled during the year		(19,250	)		0.14548		-
Exercised during the year		(2,069,100	)		0.14548		-
Granted during the year		285,250			0.14548		-
Outstanding at December 31, 2016		1,687,900			0.14548		5.6
Exercisable at December 31, 2016		1,284,525			0.14548		6.5
Outstanding at January 1, 2017		1,687,900			0.14548		5.6
Forfeited during the year		(1,750	)		0.14548		-
Cancelled during the year		(31,250	)		0.14548		-
Exercised during the year		(571,775	)		0.14548		-
Granted during the year		276,766			9.70		-
Outstanding at December 31, 2017		1,359,891			2.09		5.8
Exercisable at December 31, 2017		900,474			0.39		4.3

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of terms and conditions of share-based payment arrangement [text block]

The following table summarizes equity settled share option grants since inception under each plan:

PLAN	Number of options awarded (since inception)	Vesting conditions	Contractual life of options
Share option plan A	362,750	At grant	15.5 years
Share option plan B	819,000	At grant	10.5 years
Share option plan C1	6,775,250	4 years’ service from grant date	10 years
2016 Share Option and Incentive Plan:
Executives and Directors	257,916	4 years’ service from the date of grant, quarterly	10 years
Employees	18,850	4 years’ service from the date of grant, annually	10 years

Fact Table
Network	081900 - Disclosure - Commitments and contingencies (Tables) (http://acimume.com/role/CommitmentsAndContingenciesTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of contingent liabilities [text block]

	For the Years Ended December 31,
in CHF thousands	2017		2016
Within one year		9,686		9,175
Between one and three years		2,546		1,624
Between three and five years		140		-
More than five years		-		-
Total		12,372		10,799

Fact Table
Network	082000 - Disclosure - Earnings per share (Tables) (http://acimume.com/role/EarningsPerShareTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Earnings per share [text block]

	For the Years Ended December 31,
in CHF thousands except for share and per share data	2017			2016			2015
Net income / (loss) attributable to owners of the Company		(26,411	)		(7,096	)		20,270
Earnings per share (EPS):
Basic, income / (loss) for the period attributable to equity holders		(0.46	)		(0.14	)		0.47
Diluted, income / (loss) for the period attributable to equity holders		(0.46	)		(0.14	)		0.44
Weighted-average number of shares used to compute EPS basic		57,084,295			50,096,859			43,412,250
Weighted-average number of shares used to compute EPS fully diluted		57,084,295			50,096,859			46,043,198

Fact Table
Network	082100 - Disclosure - Financial instruments and risk management (Tables) (http://acimume.com/role/FinancialInstrumentsAndRiskManagementTables)
Table	(implied)

Reporting Entity [Axis]

Period [Axis]

Concept

Fact Value

Unit

Rounding

Parenthetical Explanations

0001651625 (http://www.sec.gov/CIK)

2017-01-01 to 2017-12-31

Disclosure of detailed information about carrying amounts of financial assets and financial liabilities [Table Text Block]

The following table shows the carrying amounts of financial assets and financial liabilities:

	For the Years Ended December 31,
in CHF thousands	2017		2016
Financial assets
Other current receivables		918		517
Cash and cash equivalents		124,377		152,210
Total financial assets		125,295		152,727

Financial liabilities
Long-term financing obligation		395		-
Trade and other payables		1,092		4,035
Accrued expenses		8,307		5,366
Total financial liabilities		9,794		9,401

Fact Table
Network	090100 - Disclosure - General information (Details) (http://acimume.com/role/GeneralInformationDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value		Unit	Rounding	Parenthetical Explanations
1	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Number of technology platforms	2		aciu:Platform	INF

Fact Table
Network	090200 - Disclosure - Basis of preparation (Details) (http://acimume.com/role/BasisOfPreparationDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Genentech [Member] * Share Capital [member]	Collaborative arrangements, milestone payment received	14000000	iso4217:CHF	-6
2	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Janssen Pharmaceuticals [Member] * Share Capital [member]	Collaborative arrangements, milestone payment received	4900000	iso4217:CHF	-5
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Genentech [Member] * Share Capital [member]	Collaborative arrangements, milestone payment received	14000000	iso4217:CHF	-6
4	0001651625 (http://www.sec.gov/CIK)	2014-12-31	Entity [Domain] * Share Capital [member]	Cash and cash equivalents	3306000	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Entity [Domain] * Share Capital [member]	Cash and cash equivalents	76522000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Entity [Domain] * Share Capital [member]	Cash and cash equivalents	152210000	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Entity [Domain] * Share Capital [member]	Cash and cash equivalents	124377000	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2016-09-22 to 2016-09-22	Entity [Domain] * Initial Public Offering [Member]	Proceeds from issue of ordinary shares	74500000	iso4217:CHF	-5
9	0001651625 (http://www.sec.gov/CIK)	2016-09-22 to 2016-09-22	Entity [Domain] * Initial Public Offering [Member]	Proceeds from issue of ordinary shares	75900000	iso4217:USD	-5
10	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity [Domain] * Share Capital [member]	Private placement extension financing	29499000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity [Domain] * Share Capital [member]	Private placement extension financing	13206000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2016-04-01 to 2016-04-30	Entity [Domain] * Preference shares, Series E [Member]	Private placement extension financing	13200000	iso4217:CHF	-5
13	0001651625 (http://www.sec.gov/CIK)	2016-04-01 to 2016-04-30	Entity [Domain] * Preference shares, Series E [Member]	Private placement extension financing	13500000	iso4217:USD	-5
14	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity [Domain] * Share Capital [member]	Private placement extension financing	0	iso4217:CHF	-3

Fact Table
Network	090300 - Disclosure - Summary of significant accounting policies, Property, plant and equipment (Details) (http://acimume.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value
1	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Computers / IT [Member]	Useful lives or depreciation rates, property, plant and equipment	3 years
2	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Laboratory equipment [Member]	Useful lives or depreciation rates, property, plant and equipment	5 years
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Leasehold improvements and fixtures and fittings [Member]	Useful lives or depreciation rates, property, plant and equipment	5 years

Fact Table
Network	090302 - Disclosure - Summary of significant accounting policies, Share capital and Initial Public Offering, Preferred Shares (Details) (http://acimume.com/role/SummaryOfSignificantAccountingPoliciesShareCapitalAndInitialPublicOfferingPreferredSharesDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Ordinary shares [member]	Convertible shares, conversion ratio	1	xbrli:pure	INF
2	0001651625 (http://www.sec.gov/CIK)	2016-09-01 to 2016-09-30	Preference shares [member]	Convertible shares, conversion ratio	1	xbrli:pure	INF
3	0001651625 (http://www.sec.gov/CIK)	2016-04-15 to 2016-04-15	Preference shares, Series E [Member]	Increase (decrease) in number of preferred shares issued	1401792	xbrli:shares	INF
4	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Preference shares [member]	Number of capital increases	5	aciu:Increase	INF
5	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Preference shares [member]	Number of classes of preferred stock outstanding	5	aciu:Class	INF
6	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Preference shares [member]	Percentage of shares outstanding held by preference stock owners	0.801	xbrli:pure	INF
7	0001651625 (http://www.sec.gov/CIK)	2016-04-15	Preference shares, Series E [Member]	Share Price, Private Placement, Sale of Stock	0.02	iso4217:CHF/xbrli:shares	INF
8	0001651625 (http://www.sec.gov/CIK)	2016-04-15	Preference shares, Series E [Member]	Share Price, Private Placement, Sale of Stock	9.6384	iso4217:USD/xbrli:shares	INF
9	0001651625 (http://www.sec.gov/CIK)	2016-04-15	Preference shares, Series E [Member]	Share subscription amount	13500000	iso4217:USD	-5
10	0001651625 (http://www.sec.gov/CIK)	2015-10-23 to 2015-10-23	Ordinary shares [member]	Stock split conversion ratio	250	xbrli:pure	INF
11	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Preference shares [member]	Term of equity financing, preferred stock	_1075426
12	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Preference shares [member]	Voting rights, number of votes per share held	1	aciu:Vote	INF
13	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Preference shares [member]	Dividends recognised as distributions to owners	0	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2016-04-15	Preference shares, Series E [Member]	Par value per share	0.02	iso4217:CHF/xbrli:shares	INF
15	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Ordinary shares [member]	Par value per share	0.02	iso4217:CHF/xbrli:shares	INF

Fact Table
Network	090304 - Disclosure - Summary of significant accounting policies, Share capital and Initial Public Offering (Details) (http://acimume.com/role/SummaryOfSignificantAccountingPoliciesShareCapitalAndInitialPublicOfferingDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2016-09-22 to 2016-09-22	Initial Public Offering [Member]	Increase (decrease) to share premium through issuance of equity	64200000	iso4217:CHF	-5
2	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Share Capital [member]	Proceeds from issuing shares, net of underwriting fees	0	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Share Capital [member]	Proceeds from issuing shares, net of underwriting fees	69388000	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2016-09-22 to 2016-09-22	Initial Public Offering [Member]	Proceeds from issuing shares, net of underwriting fees	69300000	iso4217:CHF	-5
5	0001651625 (http://www.sec.gov/CIK)	2016-09-22 to 2016-09-22	Initial Public Offering [Member]	Proceeds from issuing shares, net of underwriting fees	70600000	iso4217:USD	-5
6	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Share Capital [member]	Proceeds from issuing shares, net of underwriting fees	0	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2016-09-22	Initial Public Offering [Member]	Share Price, initial public offering,	11.0	iso4217:USD/xbrli:shares	INF
8	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Ordinary shares [member]	Increase (decrease) in number of ordinary shares issued	6900000	xbrli:shares	-5
9	0001651625 (http://www.sec.gov/CIK)	2016-09-22 to 2016-09-22	Initial Public Offering [Member]	Increase (decrease) in number of ordinary shares issued	6000000	xbrli:shares	-5
10	0001651625 (http://www.sec.gov/CIK)	2016-09-22 to 2016-09-22	Option for Over-Allotment [Member]	Increase (decrease) in number of ordinary shares issued	900000	xbrli:shares	-3
11	0001651625 (http://www.sec.gov/CIK)	2016-09-22 to 2016-09-22	Ordinary shares [member]	Increase (decrease) in number of ordinary shares issued	6900000	xbrli:shares	-5
12	0001651625 (http://www.sec.gov/CIK)	2016-09-22 to 2016-09-22	Initial Public Offering [Member]	Proceeds from issue of ordinary shares	74500000	iso4217:CHF	-5
13	0001651625 (http://www.sec.gov/CIK)	2016-09-22 to 2016-09-22	Initial Public Offering [Member]	Proceeds from issue of ordinary shares	75900000	iso4217:USD	-5

Fact Table
Network	090306 - Disclosure - Summary of significant accounting policies, Income taxes and Segment reporting (Details) (http://acimume.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesAndSegmentReportingDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Income tax loss, Carryforward period	_1058114
2	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Operating segments, number	1	aciu:Segment	INF
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Reportable segments, number	1	aciu:Segment	INF

Fact Table
Network	090400 - Disclosure - Property, plant and equipment (Details) (http://acimume.com/role/PropertyPlantAndEquipmentDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Carrying amount [member] * Property, plant and equipment [member]	Additions other than through business combinations, property, plant and equipment	898000	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Carrying amount [member] * Computers / IT [Member]	Additions other than through business combinations, property, plant and equipment	126000	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Carrying amount [member] * Furniture [Member]	Additions other than through business combinations, property, plant and equipment	38000	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Carrying amount [member] * Laboratory equipment [Member]	Additions other than through business combinations, property, plant and equipment	734000	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Carrying amount [member] * Leasehold Improvements [Member]	Additions other than through business combinations, property, plant and equipment	0	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Carrying amount [member] * Property, plant and equipment [member]	Additions other than through business combinations, property, plant and equipment	1813000	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Carrying amount [member] * Computers / IT [Member]	Additions other than through business combinations, property, plant and equipment	271000	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Carrying amount [member] * Furniture [Member]	Additions other than through business combinations, property, plant and equipment	4000	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Carrying amount [member] * Laboratory equipment [Member]	Additions other than through business combinations, property, plant and equipment	1369000	iso4217:CHF	-3
10	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Carrying amount [member] * Leasehold Improvements [Member]	Additions other than through business combinations, property, plant and equipment	169000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Carrying amount [member] * Property, plant and equipment [member]	Depreciation, property, plant and equipment	287000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Accumulated depreciation and amortisation [member] * Property, plant and equipment [member]	Depreciation, property, plant and equipment	1876000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Accumulated depreciation and amortisation [member] * Computers / IT [Member]	Depreciation, property, plant and equipment	138000	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Accumulated depreciation and amortisation [member] * Furniture [Member]	Depreciation, property, plant and equipment	36000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Accumulated depreciation and amortisation [member] * Laboratory equipment [Member]	Depreciation, property, plant and equipment	1629000	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Accumulated depreciation and amortisation [member] * Leasehold Improvements [Member]	Depreciation, property, plant and equipment	73000	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Carrying amount [member] * Property, plant and equipment [member]	Depreciation, property, plant and equipment	278000	iso4217:CHF	-3
18	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Accumulated depreciation and amortisation [member] * Property, plant and equipment [member]	Depreciation, property, plant and equipment	2154000	iso4217:CHF	-3
19	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Accumulated depreciation and amortisation [member] * Computers / IT [Member]	Depreciation, property, plant and equipment	172000	iso4217:CHF	-3
20	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Accumulated depreciation and amortisation [member] * Furniture [Member]	Depreciation, property, plant and equipment	45000	iso4217:CHF	-3
21	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Accumulated depreciation and amortisation [member] * Laboratory equipment [Member]	Depreciation, property, plant and equipment	1858000	iso4217:CHF	-3
22	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Accumulated depreciation and amortisation [member] * Leasehold Improvements [Member]	Depreciation, property, plant and equipment	79000	iso4217:CHF	-3
23	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Carrying amount [member] * Computers / IT [Member]	Depreciation, property, plant and equipment	34000	iso4217:CHF	-3
24	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Carrying amount [member] * Furniture [Member]	Depreciation, property, plant and equipment	9000	iso4217:CHF	-3
25	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Carrying amount [member] * Laboratory equipment [Member]	Depreciation, property, plant and equipment	229000	iso4217:CHF	-3
26	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Carrying amount [member] * Leasehold Improvements [Member]	Depreciation, property, plant and equipment	6000	iso4217:CHF	-3
27	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Carrying amount [member] * Property, plant and equipment [member]	Depreciation, property, plant and equipment	580000	iso4217:CHF	-3
28	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Accumulated depreciation and amortisation [member] * Property, plant and equipment [member]	Depreciation, property, plant and equipment	2734000	iso4217:CHF	-3
29	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Accumulated depreciation and amortisation [member] * Computers / IT [Member]	Depreciation, property, plant and equipment	259000	iso4217:CHF	-3
30	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Accumulated depreciation and amortisation [member] * Furniture [Member]	Depreciation, property, plant and equipment	59000	iso4217:CHF	-3
31	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Accumulated depreciation and amortisation [member] * Laboratory equipment [Member]	Depreciation, property, plant and equipment	2311000	iso4217:CHF	-3
32	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Accumulated depreciation and amortisation [member] * Leasehold Improvements [Member]	Depreciation, property, plant and equipment	105000	iso4217:CHF	-3
33	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Carrying amount [member] * Computers / IT [Member]	Depreciation, property, plant and equipment	87000	iso4217:CHF	-3
34	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Carrying amount [member] * Furniture [Member]	Depreciation, property, plant and equipment	14000	iso4217:CHF	-3
35	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Carrying amount [member] * Laboratory equipment [Member]	Depreciation, property, plant and equipment	453000	iso4217:CHF	-3
36	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Carrying amount [member] * Leasehold Improvements [Member]	Depreciation, property, plant and equipment	26000	iso4217:CHF	-3
37	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Carrying amount [member] * Property, plant and equipment [member]	Property, plant and equipment	500000	iso4217:CHF	-3
38	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Acquisition Cost [Member] * Property, plant and equipment [member]	Property, plant and equipment	2376000	iso4217:CHF	-3
39	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Acquisition Cost [Member] * Computers / IT [Member]	Property, plant and equipment	172000	iso4217:CHF	-3
40	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Acquisition Cost [Member] * Furniture [Member]	Property, plant and equipment	43000	iso4217:CHF	-3
41	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Acquisition Cost [Member] * Laboratory equipment [Member]	Property, plant and equipment	2058000	iso4217:CHF	-3
42	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Acquisition Cost [Member] * Leasehold Improvements [Member]	Property, plant and equipment	103000	iso4217:CHF	-3
43	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Carrying amount [member] * Computers / IT [Member]	Property, plant and equipment	34000	iso4217:CHF	-3
44	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Carrying amount [member] * Furniture [Member]	Property, plant and equipment	7000	iso4217:CHF	-3
45	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Carrying amount [member] * Laboratory equipment [Member]	Property, plant and equipment	429000	iso4217:CHF	-3
46	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Carrying amount [member] * Leasehold Improvements [Member]	Property, plant and equipment	30000	iso4217:CHF	-3
47	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Carrying amount [member] * Property, plant and equipment [member]	Property, plant and equipment	1120000	iso4217:CHF	-3
48	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Acquisition Cost [Member] * Property, plant and equipment [member]	Property, plant and equipment	3274000	iso4217:CHF	-3
49	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Acquisition Cost [Member] * Computers / IT [Member]	Property, plant and equipment	298000	iso4217:CHF	-3
50	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Acquisition Cost [Member] * Furniture [Member]	Property, plant and equipment	81000	iso4217:CHF	-3
51	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Acquisition Cost [Member] * Laboratory equipment [Member]	Property, plant and equipment	2792000	iso4217:CHF	-3
52	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Acquisition Cost [Member] * Leasehold Improvements [Member]	Property, plant and equipment	103000	iso4217:CHF	-3
53	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Carrying amount [member] * Computers / IT [Member]	Property, plant and equipment	126000	iso4217:CHF	-3
54	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Carrying amount [member] * Furniture [Member]	Property, plant and equipment	36000	iso4217:CHF	-3
55	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Carrying amount [member] * Laboratory equipment [Member]	Property, plant and equipment	934000	iso4217:CHF	-3
56	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Carrying amount [member] * Leasehold Improvements [Member]	Property, plant and equipment	24000	iso4217:CHF	-3
57	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Carrying amount [member] * Property, plant and equipment [member]	Property, plant and equipment	2353000	iso4217:CHF	-3
58	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Acquisition Cost [Member] * Property, plant and equipment [member]	Property, plant and equipment	5087000	iso4217:CHF	-3
59	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Acquisition Cost [Member] * Computers / IT [Member]	Property, plant and equipment	569000	iso4217:CHF	-3
60	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Acquisition Cost [Member] * Furniture [Member]	Property, plant and equipment	85000	iso4217:CHF	-3
61	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Acquisition Cost [Member] * Laboratory equipment [Member]	Property, plant and equipment	4161000	iso4217:CHF	-3
62	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Acquisition Cost [Member] * Leasehold Improvements [Member]	Property, plant and equipment	272000	iso4217:CHF	-3
63	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Carrying amount [member] * Computers / IT [Member]	Property, plant and equipment	310000	iso4217:CHF	-3
64	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Carrying amount [member] * Furniture [Member]	Property, plant and equipment	26000	iso4217:CHF	-3
65	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Carrying amount [member] * Laboratory equipment [Member]	Property, plant and equipment	1850000	iso4217:CHF	-3
66	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Carrying amount [member] * Leasehold Improvements [Member]	Property, plant and equipment	167000	iso4217:CHF	-3

Fact Table
Network	090500 - Disclosure - Financial Assets (Details) (http://acimume.com/role/FinancialAssetsDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Number of escrow deposit accounts	2	aciu:Deposit	INF
2	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Deposits in escrow accounts	86000	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Deposits in escrow accounts	126000	iso4217:CHF	-3

Fact Table
Network	090600 - Disclosure - Prepaid expenses and accrued income (Details) (http://acimume.com/role/PrepaidExpensesAndAccruedIncomeDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Types of contracts [member]	Current accrued income	889000	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Types of contracts [member]	Current accrued income	2799000	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Types of contracts [member]	Current prepayments	1278000	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Types of contracts [member]	Current prepayments	1440000	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Types of contracts [member]	Current prepayments and current accrued income	2167000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Types of contracts [member]	Current prepayments and current accrued income	4239000	iso4217:CHF	-3

Fact Table
Network	090700 - Disclosure - Other current receivables (Details) (http://acimume.com/role/OtherCurrentReceivablesDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Ranges [member]	Current receivables classified as other and value added and withholding taxes	517000	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Ranges [member]	Current receivables classified as other and value added and withholding taxes	918000	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Top of range [member]	Period of maturity, receivables fair value carrying amount	_1004946
4	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Ranges [member]	Current receivables from taxes other than income tax	15000	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Ranges [member]	Current receivables from taxes other than income tax	115000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Ranges [member]	Current value added tax receivables	320000	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Ranges [member]	Current value added tax receivables	112000	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Ranges [member]	Other current receivables	182000	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Ranges [member]	Other current receivables	691000	iso4217:CHF	-3

Fact Table
Network	090800 - Disclosure - Cash and cash equivalents (Details) (http://acimume.com/role/CashAndCashEquivalentsDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2014-12-31	All Currencies [Domain]	Cash and cash equivalents	3306000	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2015-12-31	All Currencies [Domain]	Cash and cash equivalents	76522000	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2016-12-31	All Currencies [Domain]	Cash and cash equivalents	152210000	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Switzerland, Francs	Cash and cash equivalents	41322000	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Euro Member Countries, Euro	Cash and cash equivalents	6727000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2016-12-31	United States of America, Dollars	Cash and cash equivalents	104161000	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2017-12-31	All Currencies [Domain]	Cash and cash equivalents	124377000	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Switzerland, Francs	Cash and cash equivalents	103272000	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Euro Member Countries, Euro	Cash and cash equivalents	3658000	iso4217:CHF	-3
10	0001651625 (http://www.sec.gov/CIK)	2017-12-31	United States of America, Dollars	Cash and cash equivalents	17447000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Euro Member Countries, Euro	Closing foreign exchange rate	1.169	iso4217:EUR/iso4217:CHF	INF
12	0001651625 (http://www.sec.gov/CIK)	2017-12-31	United States of America, Dollars	Closing foreign exchange rate	0.976	iso4217:USD/iso4217:CHF	INF

Fact Table
Network	090900 - Disclosure - Share capital (Details) (http://acimume.com/role/ShareCapitalDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Ordinary shares [member] * Share-based payment arrangements [member]	Convertible shares, conversion ratio	1	xbrli:pure	INF
2	0001651625 (http://www.sec.gov/CIK)	2016-09-01 to 2016-09-30	Preference shares [member] * Share-based payment arrangements [member]	Convertible shares, conversion ratio	1	xbrli:pure	INF
3	0001651625 (http://www.sec.gov/CIK)	2016-04-15 to 2016-04-15	Preference shares, Series E [Member] * Share-based payment arrangements [member]	Increase (decrease) in number of preferred shares issued	1401792	xbrli:shares	INF
4	0001651625 (http://www.sec.gov/CIK)	2016-04-15	Preference shares, Series E [Member] * Share-based payment arrangements [member]	Share Price, Private Placement, Sale of Stock	0.02	iso4217:CHF/xbrli:shares	INF
5	0001651625 (http://www.sec.gov/CIK)	2016-04-15	Preference shares, Series E [Member] * Share-based payment arrangements [member]	Share Price, Private Placement, Sale of Stock	9.6384	iso4217:USD/xbrli:shares	INF
6	0001651625 (http://www.sec.gov/CIK)	2016-04-15	Preference shares, Series E [Member] * Share-based payment arrangements [member]	Share subscription amount	13500000	iso4217:USD	-5
7	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Ordinary shares [member] * Share-based payment arrangements [member]	Shares issued, conversion of stock	38577042	xbrli:shares	INF
8	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Ordinary shares [member] * Share-based payment arrangements [member]	Increase (decrease) in number of ordinary shares issued	6900000	xbrli:shares	-5
9	0001651625 (http://www.sec.gov/CIK)	2016-09-22 to 2016-09-22	Ordinary shares [member] * Share-based payment arrangements [member]	Increase (decrease) in number of ordinary shares issued	6900000	xbrli:shares	-5
10	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Share Capital [member] * Restricted shares [Member]	Increase (decrease) in number of ordinary shares issued	4023	xbrli:shares	INF
11	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Share Capital [member] * Share-based payment arrangements [member]	Issued capital	1135000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Ordinary shares [member] * Share-based payment arrangements [member]	Issued capital	1135468000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Share Capital [member] * Share-based payment arrangements [member]	Issued capital	1147000	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Ordinary shares [member] * Share-based payment arrangements [member]	Issued capital	1147104000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Share Capital [member] * Restricted Stock Units [Member]	Shares vested (in shares)	5998	xbrli:shares	INF
16	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Share Capital [member] * Share-based payment arrangements [member]	Number of share options exercised in share-based payment arrangement	594250	xbrli:shares	INF
17	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Share Capital [member] * Share-based payment arrangements [member]	Number of share options exercised in share-based payment arrangement	2069100	xbrli:shares	INF
18	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Ordinary shares [member] * Share-based payment arrangements [member]	Number of share options exercised in share-based payment arrangement	2069100	xbrli:shares	INF
19	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Share Capital [member] * Share-based payment arrangements [member]	Number of share options exercised in share-based payment arrangement	571775	xbrli:shares	INF
20	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Ordinary shares [member] * Share-based payment arrangements [member]	Number of shares outstanding	56773392	xbrli:shares	INF
21	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Ordinary shares [member] * Share-based payment arrangements [member]	Number of shares outstanding	57355188	xbrli:shares	INF
22	0001651625 (http://www.sec.gov/CIK)	2016-04-15	Preference shares, Series E [Member] * Share-based payment arrangements [member]	Par value per share	0.02	iso4217:CHF/xbrli:shares	INF
23	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Ordinary shares [member] * Share-based payment arrangements [member]	Par value per share	0.02	iso4217:CHF/xbrli:shares	INF

Fact Table
Network	091000 - Disclosure - Trade payables and accrued liabilities (Details) (http://acimume.com/role/TradePayablesAndAccruedLiabilitiesDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Current accrued research and development costs	3265000	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Current accrued research and development costs	5430000	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Accruals	1000000	iso4217:CHF	-5
4	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Accruals	1100000	iso4217:CHF	-5
5	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Current liabilities	9922000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Current liabilities	9754000	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Current provisions for employee benefits	1419000	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Current provisions for employee benefits	2420000	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Deferred income classified as current	521000	iso4217:CHF	-3
10	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Deferred income classified as current	355000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Other current liabilities	682000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Other current liabilities	457000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Trade and other current payables	4035000	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Trade and other current payables	1092000	iso4217:CHF	-3

Fact Table
Network	091100 - Disclosure - Deferred income (Details) (http://acimume.com/role/DeferredIncomeDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Collaboration agreement of 2016, Biogen [Member]	Revenue, upfront fees received	1500000	iso4217:CHF	-5
2	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Collaboration agreement of 2016, Biogen [Member]	Revenue, upfront fees received	1500000	iso4217:USD	-5
3	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Types of contracts [member]	Deferred income classified as current	521000	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Collaboration agreement of 2016, Biogen [Member]	Deferred income classified as current	521000	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Types of contracts [member]	Deferred income classified as current	355000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Collaboration agreement of 2016, Biogen [Member]	Deferred income classified as current	400000	iso4217:CHF	-5

Fact Table
Network	091200 - Disclosure - Long term financing obligation (Details) (http://acimume.com/role/LongTermFinancingObligationDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Grants, LuMind Research Down Syndrome Foundation [Member]	Funding commitment	200000	iso4217:USD	-3
2	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Grants, LuMind Research Down Syndrome Foundation [Member]	Funding commitment	200000	iso4217:USD	-3
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Grants, LuMind Research Down Syndrome Foundation [Member]	Reimbursement percentage of funding commitment.	1.25	xbrli:pure	INF
4	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Types of contracts [member]	Non-current financial liabilities	0	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Types of contracts [member]	Non-current financial liabilities	395000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Types of contracts [member]	Non-current financial liabilities	400000	iso4217:USD	-3
7	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Types of contracts [member]	Non-current interest payable	0	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Types of contracts [member]	Non-current interest payable	99000	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Types of contracts [member]	Non-current interest payable	100000	iso4217:USD	-3

Fact Table
Network	091300 - Disclosure - Revenues (Details) (http://acimume.com/role/RevenuesDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Tau-PET imaging agent in AD [Member] * Ranges [member] * License and collaboration agreement of 2014, Piramal Imaging [Member]	Collaborative agreement, Collaboration contract receivable for clinical milestones	6000000	iso4217:EUR	-6
2	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Tau-PET imaging agent in AD [Member] * Ranges [member] * License and collaboration agreement of 2014, Piramal Imaging [Member]	Collaborative agreement, Collaboration contract receivable for regulatory, commercialization and sales milestones	150000000	iso4217:EUR	-6
3	0001651625 (http://www.sec.gov/CIK)	2014-05-31	Tau-PET imaging agent in AD [Member] * Ranges [member] * License and collaboration agreement of 2014, Piramal Imaging [Member]	Collaborative agreement, Cumulative payments received	500000	iso4217:EUR	-3
4	0001651625 (http://www.sec.gov/CIK)	2014-12-31	Tau Vaccine in AD [Member] * Ranges [member] * Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]	Collaborative agreement, Cumulative payments received	25900000	iso4217:CHF	-5
5	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Tau Vaccine in AD [Member] * Ranges [member] * Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]	Collaborative agreement, Cumulative payments received	1500000	iso4217:CHF	-5
6	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Anti-Abeta antibody in AD [Member] * Ranges [member] * Collaboration agreement of 2006, Genentech [Member]	Collaborative agreement, Cumulative payments received	65000000	iso4217:USD	-6
7	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Anti-Abeta antibody in AD [Member] * Ranges [member] * Collaboration agreement of 2006, Genentech [Member]	Collaborative agreement, Cumulative payments received	70100000	iso4217:CHF	-5
8	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Anti-tau antibody in AD [Member] * Ranges [member] * Collaboration agreement of 2012, Genentech [Member]	Collaborative agreement, Cumulative payments received	59000000	iso4217:CHF	-6
9	0001651625 (http://www.sec.gov/CIK)	2016-04-01 to 2016-04-30	Alpha-synuclein and TDP-43 PET tracer in AD [Member] * Ranges [member] * Collaboration agreement of 2016, Biogen [Member]	Collaborative Agreement, Cumulative Payments Recognized	500000	iso4217:CHF	-5
10	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Recombinant Protein Therapeutic Candidate [Member] * Ranges [member] * Collaboration With Essex Bio-Technology Limited [Member]	Collaborative Agreement, Cumulative Payments Recognized	78000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2017-04-01 to 2017-04-30	Alpha-synuclein and TDP-43 PET tracer in AD [Member] * Ranges [member] * Collaboration agreement of 2016, Biogen [Member]	Collaborative Agreement, Cumulative Payments Recognized	3400000	iso4217:CHF	-5
12	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Tau Vaccine in AD [Member] * Ranges [member] * Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]	Collaborative agreement, Joint research collaboration period	_937882
13	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Tau Vaccine in AD [Member] * Ranges [member] * Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]	Collaborative Agreement, Joint Research Collaboration, Subsequently Amended Period	_938526
14	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Anti-tau antibody in AD [Member] * Ranges [member] * Collaboration agreement of 2012, Genentech [Member]	Collaborative agreement, Milestone payment received	14000000	iso4217:CHF	-6
15	0001651625 (http://www.sec.gov/CIK)	2016-05-01 to 2016-05-31	Tau Vaccine in AD [Member] * Ranges [member] * Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]	Collaborative agreement, Milestone payment received	4900000	iso4217:CHF	-5
16	0001651625 (http://www.sec.gov/CIK)	2016-07-01 to 2016-07-31	Anti-tau antibody in AD [Member] * Ranges [member] * Collaboration agreement of 2012, Genentech [Member]	Collaborative agreement, Milestone payment received	14000000	iso4217:CHF	-6
17	0001651625 (http://www.sec.gov/CIK)	2017-10-01 to 2017-12-31	Anti-tau antibody in AD [Member] * Ranges [member] * Collaboration agreement of 2012, Genentech [Member]	Collaborative agreement, Milestone payment received	14000000	iso4217:CHF	-6
18	0001651625 (http://www.sec.gov/CIK)	2017-10-01 to 2017-12-31	Tau-PET imaging agent in AD [Member] * Ranges [member] * License and collaboration agreement of 2014, Piramal Imaging [Member]	Collaborative agreement, Milestone payment received	1100000	iso4217:CHF	-5
19	0001651625 (http://www.sec.gov/CIK)	2016-04-01 to 2016-06-30	Anti-tau antibody in AD [Member] * Ranges [member] * Collaboration agreement of 2012, Genentech [Member]	Collaborative Agreement, Milestone Payment Recognized	14000000	iso4217:CHF	-6
20	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-03-31	Tau-PET imaging agent in AD [Member] * Ranges [member] * License and collaboration agreement of 2014, Piramal Imaging [Member]	Collaborative Agreement, Milestone Payment Recognized	1100000	iso4217:CHF	-5
21	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Anti-Abeta antibody in AD [Member] * Ranges [member] * Collaboration agreement of 2006, Genentech [Member]	Collaborative agreement, Notice of contract termination period	_943594
22	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Anti-tau antibody in AD [Member] * Ranges [member] * Collaboration agreement of 2012, Genentech [Member]	Collaborative agreement, Notice of contract termination period	_944238
23	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Tau-PET imaging agent in AD [Member] * Ranges [member] * License and collaboration agreement of 2014, Piramal Imaging [Member]	Collaborative agreement, Notice of contract termination period	_944882
24	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Tau Vaccine in AD [Member] * Ranges [member] * Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]	Collaborative agreement, Notice of contract termination period	_945526
25	0001651625 (http://www.sec.gov/CIK)	2014-01-01 to 2014-12-31	Tau Vaccine in AD [Member] * Ranges [member] * Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]	Collaborative agreement, Number of companies entered into joint research collaboration	2	aciu:Company	INF
26	0001651625 (http://www.sec.gov/CIK)	2012-06-01 to 2012-06-30	Anti-tau antibody in AD [Member] * Ranges [member] * Collaboration agreement of 2012, Genentech [Member]	Collaborative agreement, Number of indications	2	aciu:Program	INF
27	0001651625 (http://www.sec.gov/CIK)	2012-06-30	Anti-tau antibody in AD [Member] * Bottom of range [member] * Collaboration agreement of 2012, Genentech [Member]	Collaborative agreement, Receivable expected	400000000	iso4217:CHF	-6
28	0001651625 (http://www.sec.gov/CIK)	2014-05-31	Tau-PET imaging agent in AD [Member] * Ranges [member] * License and collaboration agreement of 2014, Piramal Imaging [Member]	Collaborative agreement, Receivable expected	157000000	iso4217:EUR	-6
29	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Anti-Abeta antibody in AD [Member] * Top of range [member] * Collaboration agreement of 2006, Genentech [Member]	Collaborative agreement, Receivable expected	340000000	iso4217:USD	-6
30	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Recombinant Protein Therapeutic Candidate [Member] * Top of range [member] * Collaboration With Essex Bio-Technology Limited [Member]	Collaborative agreement, Receivable expected	750000	iso4217:CHF	-3
31	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Products and services [member] * Ranges [member] * Grants, Michael J. Fox Foundation [Member]	Grant revenue	95000	iso4217:CHF	-3
32	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Recombinant Protein Therapeutic Candidate [Member] * Ranges [member] * Collaboration With Essex Bio-Technology Limited [Member]	Period for Initial Research Plan	_950546
33	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Alpha-synuclein and TDP-43 PET tracer in AD [Member] * Ranges [member] * Collaboration agreement of 2016, Biogen [Member]	Revenue Recognition Amortization Period	_951190
34	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Tau-PET imaging agent in AD [Member] * Ranges [member] * License and collaboration agreement of 2014, Piramal Imaging [Member]	Revenue recognition deferral period	_951834
35	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Tau Vaccine in AD [Member] * Ranges [member] * Collaboration agreement of 2014, Janssen Pharmaceuticals [Member]	Revenue recognition deferral period	_952478
36	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Products and services [member] * Ranges [member] * Grants, Michael J. Fox Foundation [Member]	Term of grant	_953122
37	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Products and services [member] * Ranges [member] * Types of contracts [member]	Deferred income classified as current	521000	iso4217:CHF	-3
38	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Products and services [member] * Ranges [member] * Collaboration agreement of 2016, Biogen [Member]	Deferred income classified as current	521000	iso4217:CHF	-3
39	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Products and services [member] * Ranges [member] * Types of contracts [member]	Deferred income classified as current	355000	iso4217:CHF	-3
40	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Alpha-synuclein and TDP-43 PET tracer in AD [Member] * Ranges [member] * Collaboration agreement of 2016, Biogen [Member]	Deferred income classified as current	355000	iso4217:CHF	-3
41	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Products and services [member] * Ranges [member] * Collaboration agreement of 2016, Biogen [Member]	Deferred income classified as current	400000	iso4217:CHF	-5
42	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Revenue	39090000	iso4217:CHF	-3
43	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Revenue	23214000	iso4217:CHF	-3
44	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Revenue	20255000	iso4217:CHF	-3
45	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Revenue from contracts with customers	39090000	iso4217:CHF	-3
46	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Revenue from contracts with customers	23214000	iso4217:CHF	-3
47	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Revenue from contracts with customers	20255000	iso4217:CHF	-3

Fact Table
Network	091400 - Disclosure - Expenses by category (Details) (http://acimume.com/role/ExpensesByCategoryDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	General and administrative expense allocation, expense from share-based payment transactions with employees	132000	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	General and administrative expense allocation, expense from share-based payment transactions with employees	759000	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	General and administrative expense allocation, expense from share-based payment transactions with employees	1290000	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	General and administrative expense allocation, operating expense	1377000	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	General and administrative expense allocation, operating expense	3168000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	General and administrative expense allocation, operating expense	3857000	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	General and administrative expense allocation, wages and salaries	1908000	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	General and administrative expense allocation, wages and salaries	3969000	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	General and administrative expense allocation, wages and salaries	4984000	iso4217:CHF	-3
10	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Research and development expense allocation, expense from share-based payment transactions with employees	407000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Research and development expense allocation, expense from share-based payment transactions with employees	557000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Research and development expense allocation, expense from share-based payment transactions with employees	289000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Research and development expense allocation, operating expense	10763000	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Research and development expense allocation, operating expense	18767000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Research and development expense allocation, operating expense	23822000	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Research and development expense allocation, wages and salaries	5879000	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Research and development expense allocation, wages and salaries	6450000	iso4217:CHF	-3
18	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Research and development expense allocation, wages and salaries	8552000	iso4217:CHF	-3
19	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Finance income (cost)	1646000	iso4217:CHF	-3
20	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Finance income (cost)	3360000	iso4217:CHF	-3
21	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Finance income (cost)	-3872000	iso4217:CHF	-3
22	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Foreign exchange gain (loss)	1598000	iso4217:CHF	-3
23	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Foreign exchange gain (loss)	3443000	iso4217:CHF	-3
24	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Foreign exchange gain (loss)	-4049000	iso4217:CHF	-3
25	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Interest income/ (expense)	55000	iso4217:CHF	-3
26	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Interest income/ (expense)	36000	iso4217:CHF	-3
27	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Interest income/ (expense)	184000	iso4217:CHF	-3
28	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Other finance income/(expense)	-7000	iso4217:CHF	-3
29	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Other finance income/(expense)	-119000	iso4217:CHF	-3
30	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Other finance income/(expense)	-7000	iso4217:CHF	-3
31	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Research and development expense	17049000	iso4217:CHF	-3
32	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Research and development expense	25774000	iso4217:CHF	-3
33	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Research and development expense	32663000	iso4217:CHF	-3
34	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Selling, general and administrative expense	3417000	iso4217:CHF	-3
35	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Selling, general and administrative expense	7896000	iso4217:CHF	-3
36	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Selling, general and administrative expense	10131000	iso4217:CHF	-3

Fact Table
Network	091500 - Disclosure - Related-party transactions (Details) (http://acimume.com/role/RelatedpartyTransactionsDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Number of persons, key management, Board of Directors	5	aciu:Individual	INF
2	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Number of persons, key management, Executive Management	4	aciu:Individual	INF
3	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Key management personnel compensation	1908000	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Key management personnel compensation	3237000	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Key management personnel compensation	3896000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Post-employment benefits	124000	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Post-employment benefits	154000	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Post-employment benefits	166000	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Share-based compensation	8000	iso4217:CHF	-3
10	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Share-based compensation	832000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Share-based compensation	1267000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Short-term employee benefits	1776000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Short-term employee benefits	2251000	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Short-term employee benefits	2463000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Board of Directors and Executive Management [Member] * Restricted Stock Units [Member]	Number of restricted shares granted (in shares)	0	xbrli:shares	INF
16	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Restricted Stock Units [Member]	Number of restricted shares granted (in shares)	0	xbrli:shares	INF
17	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Board of Directors and Executive Management [Member] * Restricted Stock Units [Member]	Number of restricted shares granted (in shares)	0	xbrli:shares	INF
18	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Restricted Stock Units [Member]	Number of restricted shares granted (in shares)	0	xbrli:shares	INF
19	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Board of Directors [Member] * Restricted Stock Units [Member]	Number of restricted shares granted (in shares)	29375	xbrli:shares	INF
20	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Executive Management [Member] * Restricted Stock Units [Member]	Number of restricted shares granted (in shares)	95957	xbrli:shares	INF
21	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted Stock Units [Member]	Number of restricted shares granted (in shares)	4023	xbrli:shares	INF
22	0001651625 (http://www.sec.gov/CIK)	2017-10-01 to 2017-12-31	Board of Directors and Executive Management [Member] * Restricted Stock Units [Member]	Number of restricted shares granted (in shares)	125332	xbrli:shares	INF
23	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Granted during the year (in shares)	223250	xbrli:shares	INF
24	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Board of Directors [Member] * Share-based payment arrangements [member]	Granted during the year (in shares)	0	xbrli:shares	INF
25	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Executive Management [Member] * Share-based payment arrangements [member]	Granted during the year (in shares)	45000	xbrli:shares	INF
26	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Granted during the year (in shares)	285250	xbrli:shares	INF
27	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Board of Directors [Member] * Share-based payment arrangements [member]	Granted during the year (in shares)	0	xbrli:shares	INF
28	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Executive Management [Member] * Share-based payment arrangements [member]	Granted during the year (in shares)	98500	xbrli:shares	INF
29	0001651625 (http://www.sec.gov/CIK)	2016-10-01 to 2016-12-31	Former Chief Financial Officer [Member] * Share-based payment arrangements [member]	Granted during the year (in shares)	49250	xbrli:shares	INF
30	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Granted during the year (in shares)	276766	xbrli:shares	INF
31	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Board of Directors [Member] * Share-based payment arrangements [member]	Granted during the year (in shares)	0	xbrli:shares	INF
32	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Executive Management [Member] * Share-based payment arrangements [member]	Granted during the year (in shares)	257916	xbrli:shares	INF
33	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Former Chief Financial Officer [Member] * Share-based payment arrangements [member]	Weighted average fair value at measurement date, share options granted	674000	iso4217:CHF	-3

Fact Table
Network	091600 - Disclosure - Income taxes (Details) (http://acimume.com/role/IncomeTaxesDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Effective tax rate	0	xbrli:pure	INF
2	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Tax benefit, income tax holiday	0	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Tax benefit, income tax holiday	0	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Tax benefit, income tax holiday	0	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Income / (loss) before income tax	20270000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Income / (loss) before income tax	-7096000	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Income / (loss) before income tax	-26411000	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Applicable tax rate	0.22	xbrli:pure	INF
9	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Applicable tax rate	0.21	xbrli:pure	INF
10	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Applicable tax rate	0.205	xbrli:pure	INF
11	0001651625 (http://www.sec.gov/CIK)	2015-12-31	null	Deferred tax assets	0	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Deferred tax assets	0	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Deferred tax assets	0	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2015-12-31	null	Deferred tax liabilities	0	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Deferred tax liabilities	0	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Deferred tax liabilities	0	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Tax expense (income), continuing operations	0	iso4217:CHF	-3
18	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Tax expense (income), continuing operations	0	iso4217:CHF	-3
19	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Tax expense (income), continuing operations	0	iso4217:CHF	-3
20	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense	4566000	iso4217:CHF	-3
21	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense	0	iso4217:CHF	-3
22	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense	0	iso4217:CHF	-3
23	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce deferred tax expense	0	iso4217:CHF	-3
24	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce deferred tax expense	-1670000	iso4217:CHF	-3
25	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce deferred tax expense	-5380000	iso4217:CHF	-3
26	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Tax effect of revenues exempt from taxation	0	iso4217:CHF	-3
27	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Tax effect of revenues exempt from taxation	166000	iso4217:CHF	-3
28	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Tax effect of revenues exempt from taxation	-40000	iso4217:CHF	-3
29	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Tax expense / (benefit) calculated at the statutory rate of 20.5% (21% for 2016 and 22% for 2015)	4566000	iso4217:CHF	-3
30	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Tax expense / (benefit) calculated at the statutory rate of 20.5% (21% for 2016 and 22% for 2015)	-1504000	iso4217:CHF	-3
31	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Tax expense / (benefit) calculated at the statutory rate of 20.5% (21% for 2016 and 22% for 2015)	-5420000	iso4217:CHF	-3

Fact Table
Network	091602 - Disclosure - Income taxes, Unrecognized Deductible Temporary Differences, Unused Tax Losses and Unused Tax Credits (Details) (http://acimume.com/role/IncomeTaxesUnrecognizedDeductibleTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCreditsDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Aggregated time bands [member] * Temporary difference, unused tax losses and unused tax credits [member]	Deferred tax assets	0	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Aggregated time bands [member] * Unused tax credits [member]	Deferred tax assets	2787000	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Aggregated time bands [member] * Unused tax losses [member]	Deferred tax assets	29079000	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Aggregated time bands [member] * Temporary difference, unused tax losses and unused tax credits [member]	Deferred tax assets	0	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Aggregated time bands [member] * Unused tax credits [member]	Deferred tax assets	3798000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Aggregated time bands [member] * Unused tax losses [member]	Deferred tax assets	36707000	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Aggregated time bands [member] * Temporary difference, unused tax losses and unused tax credits [member]	Deferred tax assets	0	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Aggregated time bands [member] * Unused tax credits [member]	Deferred tax assets	4926000	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Aggregated time bands [member] * Unused tax losses [member]	Deferred tax assets	62575000	iso4217:CHF	-3
10	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Aggregated time bands [member] * Temporary difference, unused tax losses and unused tax credits [member]	Deferred tax liability (asset)	31866000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Aggregated time bands [member] * Temporary difference, unused tax losses and unused tax credits [member]	Deferred tax liability (asset)	40505000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Aggregated time bands [member] * Temporary difference, unused tax losses and unused tax credits [member]	Deferred tax liability (asset)	67501000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Aggregated time bands [member] * Temporary difference, unused tax losses and unused tax credits [member]	Increase in tax losses available as an offset	25900000	iso4217:CHF	-5
14	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Aggregated time bands [member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	29079000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Later than five years and not later than six years [Member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	0	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Later than four years and not later than five years [member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	0	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Later than one year and not later than two years [member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	2175000	iso4217:CHF	-3
18	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Later Than Six Years And Not Later Than Eight Years [Member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	0	iso4217:CHF	-3
19	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Later than six years and not later than seven years [Member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	0	iso4217:CHF	-3
20	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Later than three years and not later than four years [member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	10388000	iso4217:CHF	-3
21	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Later than two years and not later than three years [member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	16566000	iso4217:CHF	-3
22	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Loss Expiry, December 31, 2017 [Member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	0	iso4217:CHF	-3
23	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Aggregated time bands [member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	36707000	iso4217:CHF	-3
24	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Later than five years and not later than six years [Member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	0	iso4217:CHF	-3
25	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Later than four years and not later than five years [member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	0	iso4217:CHF	-3
26	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Later than one year and not later than two years [member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	2175000	iso4217:CHF	-3
27	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Later Than Six Years And Not Later Than Eight Years [Member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	0	iso4217:CHF	-3
28	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Later than six years and not later than seven years [Member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	7628000	iso4217:CHF	-3
29	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Later than three years and not later than four years [member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	10338000	iso4217:CHF	-3
30	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Later than two years and not later than three years [member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	16566000	iso4217:CHF	-3
31	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Loss Expiry, December 31, 2017 [Member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	0	iso4217:CHF	-3
32	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Aggregated time bands [member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	62575000	iso4217:CHF	-3
33	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Later than five years and not later than six years [Member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	0	iso4217:CHF	-3
34	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Later than four years and not later than five years [member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	0	iso4217:CHF	-3
35	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Later than one year and not later than two years [member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	2175000	iso4217:CHF	-3
36	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Later Than Six Years And Not Later Than Eight Years [Member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	25868000	iso4217:CHF	-3
37	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Later than six years and not later than seven years [Member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	7628000	iso4217:CHF	-3
38	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Later than three years and not later than four years [member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	10338000	iso4217:CHF	-3
39	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Later than two years and not later than three years [member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	16566000	iso4217:CHF	-3
40	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Loss Expiry, December 31, 2017 [Member] * Temporary difference, unused tax losses and unused tax credits [member]	Unused tax losses for which no deferred tax asset recognised	0	iso4217:CHF	-3

Fact Table
Network	091700 - Disclosure - Retirement benefit plan (Details) (http://acimume.com/role/RetirementBenefitPlanDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Actuarial losses (gains) arising from changes in benefit plan, net defined benefit liability (asset)	584000	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Actuarial losses (gains) arising from changes in benefit plan, net defined benefit liability (asset)	584000	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Actuarial losses (gains) arising from changes in benefit plan, net defined benefit liability (asset)	0	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Actuarial losses (gains) arising from changes in benefit plan, net defined benefit liability (asset)	0	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Actuarial losses (gains) arising from changes in benefit plan, net defined benefit liability (asset)	0	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Actuarial losses (gains) arising from changes in benefit plan, net defined benefit liability (asset)	0	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Defined benefits plan, Employee [Member] * Net defined benefit liability (asset) [member]	Defined benefit plan, percentage of contribution	0.47	xbrli:pure	INF
8	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Defined benefits plan, Employer [Member] * Net defined benefit liability (asset) [member]	Defined benefit plan, percentage of contribution	0.53	xbrli:pure	INF
9	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Interest cost, net defined benefit liability (asset)	101000	iso4217:CHF	-3
10	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Interest cost, net defined benefit liability (asset)	101000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Interest cost, net defined benefit liability (asset)	75000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Interest cost, net defined benefit liability (asset)	75000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Interest cost, net defined benefit liability (asset)	81000	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Interest cost, net defined benefit liability (asset)	81000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Interest income, net defined benefit liability (asset)	76000	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Plan assets [member]	Interest income, net defined benefit liability (asset)	76000	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Interest income, net defined benefit liability (asset)	56000	iso4217:CHF	-3
18	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Plan assets [member]	Interest income, net defined benefit liability (asset)	56000	iso4217:CHF	-3
19	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Interest income, net defined benefit liability (asset)	55000	iso4217:CHF	-3
20	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Plan assets [member]	Interest income, net defined benefit liability (asset)	55000	iso4217:CHF	-3
21	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Current service cost, net defined benefit liability (asset)	641000	iso4217:CHF	-3
22	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Current service cost, net defined benefit liability (asset)	641000	iso4217:CHF	-3
23	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Current service cost, net defined benefit liability (asset)	742000	iso4217:CHF	-3
24	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Current service cost, net defined benefit liability (asset)	742000	iso4217:CHF	-3
25	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Current service cost, net defined benefit liability (asset)	912000	iso4217:CHF	-3
26	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Current service cost, net defined benefit liability (asset)	912000	iso4217:CHF	-3
27	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Increase (decrease) in net defined benefit liability (asset)	82000	iso4217:CHF	-3
28	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Increase (decrease) in net defined benefit liability (asset)	761000	iso4217:CHF	-3
29	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Increase (decrease) in net defined benefit liability (asset)	938000	iso4217:CHF	-3
30	0001651625 (http://www.sec.gov/CIK)	2014-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Non-current provisions for employee benefits	2410000	iso4217:CHF	-3
31	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Non-current provisions for employee benefits	2787000	iso4217:CHF	-3
32	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Domestic defined benefit plans [member] * Plan assets [member]	Non-current provisions for employee benefits	-6652000	iso4217:CHF	-3
33	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Non-current provisions for employee benefits	9439000	iso4217:CHF	-3
34	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Defined benefit plans [member] * Net defined benefit liability (asset) [member]	Non-current provisions for employee benefits	3798000	iso4217:CHF	-3
35	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Non-current provisions for employee benefits	3798000	iso4217:CHF	-3
36	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Domestic defined benefit plans [member] * Plan assets [member]	Non-current provisions for employee benefits	-7798000	iso4217:CHF	-3
37	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Non-current provisions for employee benefits	11596000	iso4217:CHF	-3
38	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Defined benefit plans [member] * Net defined benefit liability (asset) [member]	Non-current provisions for employee benefits	4926000	iso4217:CHF	-3
39	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Non-current provisions for employee benefits	4926000	iso4217:CHF	-3
40	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Domestic defined benefit plans [member] * Plan assets [member]	Non-current provisions for employee benefits	-9352000	iso4217:CHF	-3
41	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Non-current provisions for employee benefits	14278000	iso4217:CHF	-3

Fact Table
Network	091702 - Disclosure - Retirement benefit plan, Changes in Defined Benefit Obligation (Details) (http://acimume.com/role/RetirementBenefitPlanChangesInDefinedBenefitObligationDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Actuarial gains (losses) arising from changes in other assumptions, net defined benefit liability (asset)	-176000	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Actuarial gains (losses) arising from changes in other assumptions, net defined benefit liability (asset)	-378000	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Actuarial gains (losses) arising from changes in other assumptions, net defined benefit liability (asset)	-735000	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Actuarial losses (gains) arising from changes in benefit plan, net defined benefit liability (asset)	584000	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Actuarial losses (gains) arising from changes in benefit plan, net defined benefit liability (asset)	584000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Actuarial losses (gains) arising from changes in benefit plan, net defined benefit liability (asset)	0	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Actuarial losses (gains) arising from changes in benefit plan, net defined benefit liability (asset)	0	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Actuarial losses (gains) arising from changes in benefit plan, net defined benefit liability (asset)	0	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Actuarial losses (gains) arising from changes in benefit plan, net defined benefit liability (asset)	0	iso4217:CHF	-3
10	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Interest cost, net defined benefit liability (asset)	101000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Interest cost, net defined benefit liability (asset)	101000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Interest cost, net defined benefit liability (asset)	75000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Interest cost, net defined benefit liability (asset)	75000	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Interest cost, net defined benefit liability (asset)	81000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Interest cost, net defined benefit liability (asset)	81000	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Actuarial gains (losses) arising from changes in demographic assumptions, net defined benefit liability (asset)	0	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Actuarial gains (losses) arising from changes in demographic assumptions, net defined benefit liability (asset)	-389000	iso4217:CHF	-3
18	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Actuarial gains (losses) arising from changes in demographic assumptions, net defined benefit liability (asset)	0	iso4217:CHF	-3
19	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Actuarial gains (losses) arising from changes in financial assumptions, net defined benefit liability (asset)	-591000	iso4217:CHF	-3
20	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Actuarial gains (losses) arising from changes in financial assumptions, net defined benefit liability (asset)	-26000	iso4217:CHF	-3
21	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Actuarial gains (losses) arising from changes in financial assumptions, net defined benefit liability (asset)	0	iso4217:CHF	-3
22	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Contributions to plan by plan participants, net defined benefit liability (asset)	-375000	iso4217:CHF	-3
23	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Contributions to plan by plan participants, net defined benefit liability (asset)	-436000	iso4217:CHF	-3
24	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Contributions to plan by plan participants, net defined benefit liability (asset)	-528000	iso4217:CHF	-3
25	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Current service cost, net defined benefit liability (asset)	641000	iso4217:CHF	-3
26	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Current service cost, net defined benefit liability (asset)	641000	iso4217:CHF	-3
27	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Current service cost, net defined benefit liability (asset)	742000	iso4217:CHF	-3
28	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Current service cost, net defined benefit liability (asset)	742000	iso4217:CHF	-3
29	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Net defined benefit liability (asset) [member]	Current service cost, net defined benefit liability (asset)	912000	iso4217:CHF	-3
30	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Current service cost, net defined benefit liability (asset)	912000	iso4217:CHF	-3
31	0001651625 (http://www.sec.gov/CIK)	2014-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Net defined benefit liability (asset)	8091000	iso4217:CHF	-3
32	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Net defined benefit liability (asset)	9439000	iso4217:CHF	-3
33	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Net defined benefit liability (asset)	11596000	iso4217:CHF	-3
34	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Net defined benefit liability (asset)	14278000	iso4217:CHF	-3
35	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Payments from plan, net defined benefit liability (asset)	-48000	iso4217:CHF	-3
36	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Payments from plan, net defined benefit liability (asset)	-111000	iso4217:CHF	-3
37	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Present value of defined benefit obligation [member]	Payments from plan, net defined benefit liability (asset)	-426000	iso4217:CHF	-3

Fact Table
Network	091704 - Disclosure - Retirement benefit plan, Changes in Fair Value of Plan Assets (Details) (http://acimume.com/role/RetirementBenefitPlanChangesInFairValueOfPlanAssetsDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Net defined benefit liability (asset) [member]	Interest income, net defined benefit liability (asset)	76000	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Interest income, net defined benefit liability (asset)	76000	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Net defined benefit liability (asset) [member]	Interest income, net defined benefit liability (asset)	56000	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Interest income, net defined benefit liability (asset)	56000	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Net defined benefit liability (asset) [member]	Interest income, net defined benefit liability (asset)	55000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Interest income, net defined benefit liability (asset)	55000	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Net defined benefit liability (asset) [member]	Contributions to plan by employer, net defined benefit liability (asset)	-441000	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Contributions to plan by employer, net defined benefit liability (asset)	441000	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Net defined benefit liability (asset) [member]	Contributions to plan by employer, net defined benefit liability (asset)	-511000	iso4217:CHF	-3
10	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Contributions to plan by employer, net defined benefit liability (asset)	511000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Net defined benefit liability (asset) [member]	Contributions to plan by employer, net defined benefit liability (asset)	-590000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Loss Expiry, December 31, 2017 [Member] * Plan assets [member]	Contributions to plan by employer, net defined benefit liability (asset)	630000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Contributions to plan by employer, net defined benefit liability (asset)	590000	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Contributions to plan by plan participants, net defined benefit liability (asset)	375000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Contributions to plan by plan participants, net defined benefit liability (asset)	436000	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Contributions to plan by plan participants, net defined benefit liability (asset)	528000	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Payments from plan, net defined benefit liability (asset)	48000	iso4217:CHF	-3
18	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Payments from plan, net defined benefit liability (asset)	111000	iso4217:CHF	-3
19	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Payments from plan, net defined benefit liability (asset)	426000	iso4217:CHF	-3
20	0001651625 (http://www.sec.gov/CIK)	2014-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Plan assets, at fair value	5681000	iso4217:CHF	-3
21	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Plan assets, at fair value	6652000	iso4217:CHF	-3
22	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Plan assets, at fair value	7798000	iso4217:CHF	-3
23	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Plan assets, at fair value	9352000	iso4217:CHF	-3
24	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Return on plan assets, net defined benefit liability (asset)	31000	iso4217:CHF	-3
25	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Return on plan assets, net defined benefit liability (asset)	32000	iso4217:CHF	-3
26	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member] * Aggregated time bands [member] * Plan assets [member]	Return on plan assets, net defined benefit liability (asset)	-45000	iso4217:CHF	-3

Fact Table
Network	091706 - Disclosure - Retirement benefit plan, Change in Net Definied Benefit Liability (Details) (http://acimume.com/role/RetirementBenefitPlanChangeInNetDefiniedBenefitLiabilityDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member]	Contributions to plan by employer, net defined benefit liability (asset)	-441000	iso4217:CHF	-3
2	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member]	Contributions to plan by employer, net defined benefit liability (asset)	-511000	iso4217:CHF	-3
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member]	Contributions to plan by employer, net defined benefit liability (asset)	-590000	iso4217:CHF	-3
4	0001651625 (http://www.sec.gov/CIK)	2014-12-31	Domestic defined benefit plans [member]	Non-current provisions for employee benefits	2410000	iso4217:CHF	-3
5	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Domestic defined benefit plans [member]	Non-current provisions for employee benefits	2787000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Defined benefit plans [member]	Non-current provisions for employee benefits	3798000	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Domestic defined benefit plans [member]	Non-current provisions for employee benefits	3798000	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Defined benefit plans [member]	Non-current provisions for employee benefits	4926000	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Domestic defined benefit plans [member]	Non-current provisions for employee benefits	4926000	iso4217:CHF	-3
10	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Defined benefit plans [member]	Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-736000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member]	Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-736000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Defined benefit plans [member]	Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-761000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member]	Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-761000	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Defined benefit plans [member]	Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-780000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member]	Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-780000	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Domestic defined benefit plans [member]	Post-employment benefit expense, defined benefit plans	82000	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Domestic defined benefit plans [member]	Post-employment benefit expense, defined benefit plans	761000	iso4217:CHF	-3
18	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member]	Post-employment benefit expense, defined benefit plans	938000	iso4217:CHF	-3
19	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Domestic defined benefit plans [member]	Weighted average duration of defined benefit obligation	20.5	utr:Y	1

Fact Table
Network	091708 - Disclosure - Retirement benefit plan, Actuarial Assumptions and Sensitivity Analysis (Details) (http://acimume.com/role/RetirementBenefitPlanActuarialAssumptionsAndSensitivityAnalysisDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Actuarial assumptions [member] * Domestic defined benefit plans [member] * Risks [member]	Issued Actuarial Tables, Switzerland	BVG 2010G
2	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Actuarial assumptions [member] * Domestic defined benefit plans [member] * Risks [member]	Issued Actuarial Tables, Switzerland	BVG 2015G
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Actuarial assumptions [member] * Domestic defined benefit plans [member] * Risks [member]	Issued Actuarial Tables, Switzerland	BVG 2015G
4	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Actuarial assumptions [member] * Domestic defined benefit plans [member] * Risks [member]	Actuarial assumption of discount rates	0.0125	xbrli:pure	4
5	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Actuarial assumptions [member] * Domestic defined benefit plans [member] * Risks [member]	Actuarial assumption of discount rates	0.007	xbrli:pure	4
6	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumptions [member] * Domestic defined benefit plans [member] * Risks [member]	Actuarial assumption of discount rates	0.007	xbrli:pure	4
7	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Actuarial assumptions [member] * Domestic defined benefit plans [member] * Risks [member]	Actuarial assumption of expected rates of pension increases	0.005	xbrli:pure	4
8	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Actuarial assumptions [member] * Domestic defined benefit plans [member] * Risks [member]	Actuarial assumption of expected rates of pension increases	0.005	xbrli:pure	4
9	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumptions [member] * Domestic defined benefit plans [member] * Risks [member]	Actuarial assumption of expected rates of pension increases	0.005	xbrli:pure	4
10	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Actuarial assumptions [member] * Domestic defined benefit plans [member] * Risks [member]	Actuarial assumption of expected rates of salary increases	0.015	xbrli:pure	4
11	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Actuarial assumptions [member] * Domestic defined benefit plans [member] * Risks [member]	Actuarial assumption of expected rates of salary increases	0.015	xbrli:pure	4
12	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumptions [member] * Domestic defined benefit plans [member] * Risks [member]	Actuarial assumption of expected rates of salary increases	0.015	xbrli:pure	4
13	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumption of discount rates [member] * Domestic defined benefit plans [member] * Percentage of reasonably possible decrease in actuarial assumption [Member]	Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption	1571000	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumption of expected rates of pension increases [member] * Domestic defined benefit plans [member] * Percentage of reasonably possible decrease in actuarial assumption [Member]	Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption	-714000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumption of expected rates of salary increases [member] * Domestic defined benefit plans [member] * Percentage of reasonably possible decrease in actuarial assumption [Member]	Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption	-157000	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumption of discount rates [member] * Domestic defined benefit plans [member] * Percentage of reasonably possible increase in actuarial assumption [Member]	Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption	1571000	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumption of expected rates of pension increases [member] * Domestic defined benefit plans [member] * Percentage of reasonably possible increase in actuarial assumption [Member]	Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption	-711000	iso4217:CHF	-3
18	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumption of expected rates of salary increases [member] * Domestic defined benefit plans [member] * Percentage of reasonably possible increase in actuarial assumption [Member]	Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption	-171000	iso4217:CHF	-3
19	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumption of discount rates [member] * Domestic defined benefit plans [member] * Percentage of reasonably possible decrease in actuarial assumption [Member]	Net defined benefit liability (asset)	15849000	iso4217:CHF	-3
20	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumption of discount rates [member] * Domestic defined benefit plans [member] * Percentage of reasonably possible increase in actuarial assumption [Member]	Net defined benefit liability (asset)	12707000	iso4217:CHF	-3
21	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumption of expected rates of pension increases [member] * Domestic defined benefit plans [member] * Percentage of reasonably possible decrease in actuarial assumption [Member]	Net defined benefit liability (asset)	13564000	iso4217:CHF	-3
22	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumption of expected rates of pension increases [member] * Domestic defined benefit plans [member] * Percentage of reasonably possible increase in actuarial assumption [Member]	Net defined benefit liability (asset)	14989000	iso4217:CHF	-3
23	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumption of expected rates of salary increases [member] * Domestic defined benefit plans [member] * Percentage of reasonably possible decrease in actuarial assumption [Member]	Net defined benefit liability (asset)	14121000	iso4217:CHF	-3
24	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumption of expected rates of salary increases [member] * Domestic defined benefit plans [member] * Percentage of reasonably possible increase in actuarial assumption [Member]	Net defined benefit liability (asset)	14449000	iso4217:CHF	-3
25	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumptions [member] * Domestic defined benefit plans [member] * Percentage of reasonably possible decrease in actuarial assumption [Member]	Percentage of reasonably possible decrease in actuarial assumption	0.005	xbrli:pure	INF
26	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Actuarial assumptions [member] * Domestic defined benefit plans [member] * Percentage of reasonably possible increase in actuarial assumption [Member]	Percentage of reasonably possible increase in actuarial assumption	0.005	xbrli:pure	3

Fact Table
Network	091800 - Disclosure - Share-based compensation, Plans Outstanding (Details) (http://acimume.com/role/SharebasedCompensationPlansOutstandingDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Maximum term of options granted for share-based payment arrangement	_736480
2	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Employees [Member] * 2016 Share Option and Incentive Plan [Member]	Maximum term of options granted for share-based payment arrangement	_737100
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Executives and Directors [Member] * 2016 Share Option and Incentive Plan [Member]	Maximum term of options granted for share-based payment arrangement	_737720
4	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Stock option plan A [Member]	Maximum term of options granted for share-based payment arrangement	_738340
5	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Stock option plan B [Member]	Maximum term of options granted for share-based payment arrangement	_738960
6	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Stock option plan C1 [Member]	Maximum term of options granted for share-based payment arrangement	_739580
7	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Number of Equity-based Instrument Plans	4	aciu:Plan	INF
8	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Employees [Member] * 2016 Share Option and Incentive Plan [Member]	Vesting requirements for share-based payment arrangement, award vesting period	_740768
9	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Executives and Directors [Member] * 2016 Share Option and Incentive Plan [Member]	Vesting requirements for share-based payment arrangement, award vesting period	_741388
10	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Stock option plan C1 [Member]	Vesting requirements for share-based payment arrangement, award vesting period	_742008
11	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Granted during the year (in shares)	223250	xbrli:shares	INF
12	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Granted during the year (in shares)	285250	xbrli:shares	INF
13	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Share-based payment arrangements [member]	Granted during the year (in shares)	276766	xbrli:shares	INF
14	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Employees [Member] * 2016 Share Option and Incentive Plan [Member]	Granted during the year (in shares)	18850	xbrli:shares	INF
15	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Executives and Directors [Member] * 2016 Share Option and Incentive Plan [Member]	Granted during the year (in shares)	257916	xbrli:shares	INF
16	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Stock option plan A [Member]	Granted during the year (in shares)	362750	xbrli:shares	INF
17	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Stock option plan B [Member]	Granted during the year (in shares)	819000	xbrli:shares	INF
18	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Stock option plan C1 [Member]	Granted during the year (in shares)	6775250	xbrli:shares	INF

Fact Table
Network	091802 - Disclosure - Share-based compensation, Weighted Average Exercise Prices (Details) (http://acimume.com/role/SharebasedCompensationWeightedAverageExercisePricesDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2015-12-31	null	Weighted average remaining contractual life of exercisable share options	3.4	utr:Y	1
2	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Weighted average remaining contractual life of exercisable share options	6.5	utr:Y	1
3	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Weighted average remaining contractual life of exercisable share options	4.3	utr:Y	1
4	0001651625 (http://www.sec.gov/CIK)	2014-12-31	null	Number of share options outstanding in share-based payment arrangement	4006500	xbrli:shares	INF
5	0001651625 (http://www.sec.gov/CIK)	2015-12-31	null	Number of share options outstanding in share-based payment arrangement	3597000	xbrli:shares	INF
6	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Number of share options outstanding in share-based payment arrangement	1687900	xbrli:shares	INF
7	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Number of share options outstanding in share-based payment arrangement	1359891	xbrli:shares	INF
8	0001651625 (http://www.sec.gov/CIK)	2015-12-31	null	Number of share options exercisable in share-based payment arrangement	3032500	xbrli:shares	INF
9	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Number of share options exercisable in share-based payment arrangement	1284525	xbrli:shares	INF
10	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Number of share options exercisable in share-based payment arrangement	900474	xbrli:shares	INF
11	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Number of share options exercised in share-based payment arrangement	594250	xbrli:shares	INF
12	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Number of share options exercised in share-based payment arrangement	2069100	xbrli:shares	INF
13	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Number of share options exercised in share-based payment arrangement	571775	xbrli:shares	INF
14	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Number of share options expired in share-based payment arrangement	15250	xbrli:shares	INF
15	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Number of share options expired in share-based payment arrangement	19250	xbrli:shares	INF
16	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Number of share options expired in share-based payment arrangement	31250	xbrli:shares	INF
17	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Number of share options forfeited in share-based payment arrangement	23250	xbrli:shares	INF
18	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Number of share options forfeited in share-based payment arrangement	106000	xbrli:shares	INF
19	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Number of share options forfeited in share-based payment arrangement	1750	xbrli:shares	INF
20	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Granted during the year (in shares)	223250	xbrli:shares	INF
21	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Granted during the year (in shares)	285250	xbrli:shares	INF
22	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Granted during the year (in shares)	276766	xbrli:shares	INF
23	0001651625 (http://www.sec.gov/CIK)	2015-12-31	null	Weighted average exercise price of share options exercisable in share-based payment arrangement	0.14548	iso4217:CHF	5
24	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Weighted average exercise price of share options exercisable in share-based payment arrangement	0.14548	iso4217:CHF	5
25	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Weighted average exercise price of share options exercisable in share-based payment arrangement	0.39	iso4217:CHF	2
26	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Exercised during the year (in CHF per share)	0.14548	iso4217:CHF	5
27	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Exercised during the year (in CHF per share)	0.14548	iso4217:CHF	5
28	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Exercised during the year (in CHF per share)	0.14548	iso4217:CHF	5
29	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Cancelled during the year (in CHF per share)	0.14548	iso4217:CHF	5
30	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Cancelled during the year (in CHF per share)	0.14548	iso4217:CHF	5
31	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Cancelled during the year (in CHF per share)	0.14548	iso4217:CHF	5
32	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Forfeited during the year (in CHF per share)	0.14548	iso4217:CHF	5
33	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Forfeited during the year (in CHF per share)	0.14548	iso4217:CHF	5
34	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Forfeited during the year (in CHF per share)	0.14548	iso4217:CHF	5
35	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Granted during the year (in CHF per share)	0.14548	iso4217:CHF	5
36	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Granted during the year (in CHF per share)	0.14548	iso4217:CHF	5
37	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Granted during the year (in CHF per share)	9.7	iso4217:CHF	2
38	0001651625 (http://www.sec.gov/CIK)	2014-12-31	null	Weighted average exercise price of share options outstanding in share-based payment arrangement	0.21668	iso4217:CHF	5
39	0001651625 (http://www.sec.gov/CIK)	2015-12-31	null	Weighted average exercise price of share options outstanding in share-based payment arrangement	0.14548	iso4217:CHF	5
40	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Weighted average exercise price of share options outstanding in share-based payment arrangement	0.14548	iso4217:CHF	5
41	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Weighted average exercise price of share options outstanding in share-based payment arrangement	2.09	iso4217:CHF	2
42	0001651625 (http://www.sec.gov/CIK)	2014-12-31	null	Weighted average remaining contractual life of outstanding share options	4.5	utr:Y	1
43	0001651625 (http://www.sec.gov/CIK)	2015-12-31	null	Weighted average remaining contractual life of outstanding share options	3.6	utr:Y	1
44	0001651625 (http://www.sec.gov/CIK)	2016-12-31	null	Weighted average remaining contractual life of outstanding share options	5.6	utr:Y	1
45	0001651625 (http://www.sec.gov/CIK)	2017-12-31	null	Weighted average remaining contractual life of outstanding share options	5.8	utr:Y	1

Fact Table
Network	091804 - Disclosure - Share-based compensation, Summary Information (Details) (http://acimume.com/role/SharebasedCompensationSummaryInformationDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Ranges [member]	Maximum term of options granted for share-based payment arrangement	_686898
2	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Ranges [member]	Expected volatility, share options granted	0.5	xbrli:pure	INF
3	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Ranges [member]	Expected volatility, share options granted	0.8	xbrli:pure	INF
4	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Ranges [member]	Expected volatility, share options granted	0.8	xbrli:pure	INF
5	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Ranges [member]	Option life, share options granted	6	utr:Y	0
6	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Ranges [member]	Option life, share options granted	6	utr:Y	0
7	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Ranges [member]	Option life, share options granted	6	utr:Y	0
8	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Ranges [member]	Risk free interest rate, share options granted	0.0	xbrli:pure	INF
9	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Ranges [member]	Risk free interest rate, share options granted	0.0	xbrli:pure	INF
10	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Ranges [member]	Risk free interest rate, share options granted	0.0	xbrli:pure	INF
11	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Ranges [member]	Exercise price, share options granted	0.14548	iso4217:CHF	5
12	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Ranges [member]	Exercise price, share options granted	0.14548	iso4217:CHF	5
13	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Bottom of range [member]	Exercise price, share options granted	9.53	iso4217:CHF	2
14	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Top of range [member]	Exercise price, share options granted	12.0	iso4217:CHF	2
15	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Ranges [member]	Expense from share-based payment transactions with employees	540000	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Ranges [member]	Expense from share-based payment transactions with employees	1317000	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Ranges [member]	Expense from share-based payment transactions with employees	1579000	iso4217:CHF	-3
18	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Ranges [member]	Incremental fair value granted, modified share-based payment arrangements	238000	iso4217:CHF	-3
19	0001651625 (http://www.sec.gov/CIK)	2016-10-01 to 2016-12-31	Former Chief Executive Financial Officer [Member] * Ranges [member]	Number of restricted shares granted (in shares)	49250	xbrli:shares	INF
20	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Former Chief Executive Financial Officer [Member] * Ranges [member]	Number of other equity instruments forfeited in share-based payment arrangement	98500	xbrli:shares	INF
21	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Ranges [member]	Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise	1.91	iso4217:CHF	2
22	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Ranges [member]	Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise	6.22	iso4217:CHF	2
23	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Ranges [member]	Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise	10.53	iso4217:CHF	2
24	0001651625 (http://www.sec.gov/CIK)	2014-12-31	Entity's total for related parties [member] * Ranges [member]	Weighted average exercise price of share options outstanding in share-based payment arrangement	0.21668	iso4217:CHF	5
25	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Entity's total for related parties [member] * Ranges [member]	Weighted average exercise price of share options outstanding in share-based payment arrangement	0.14548	iso4217:CHF	5
26	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Entity's total for related parties [member] * Ranges [member]	Weighted average exercise price of share options outstanding in share-based payment arrangement	0.14548	iso4217:CHF	5
27	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Entity's total for related parties [member] * Ranges [member]	Weighted average exercise price of share options outstanding in share-based payment arrangement	2.09	iso4217:CHF	2
28	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Entity's total for related parties [member] * Bottom of range [member]	Weighted average exercise price of share options outstanding in share-based payment arrangement	0.14548	iso4217:CHF	5
29	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Entity's total for related parties [member] * Top of range [member]	Weighted average exercise price of share options outstanding in share-based payment arrangement	12.0	iso4217:CHF	2
30	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Former Chief Executive Financial Officer [Member] * Ranges [member]	Weighted average fair value at measurement date, share options granted	674000	iso4217:CHF	-3
31	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Ranges [member]	Weighted average share price	1.91	iso4217:CHF	2
32	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Ranges [member]	Weighted average share price	5.96	iso4217:CHF	2
33	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Ranges [member]	Weighted average share price	8.77	iso4217:CHF	2
34	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Ranges [member]	Weighted average share price, share options granted	1.77	iso4217:CHF	2
35	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Ranges [member]	Weighted average share price, share options granted	5.85	iso4217:CHF	2
36	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Ranges [member]	Weighted average share price, share options granted	7.29	iso4217:CHF	2

Fact Table
Network	091806 - Disclosure - Share-based compensation, Non-vested Share Awards (Details) (http://acimume.com/role/SharebasedCompensationNonvestedShareAwardsDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Board of Directors [Member] * Restricted Stock Units [Member]	Maximum Term Of Other Equity Instruments Granted For Share Based Payment Arrangement	_667562
2	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Executive Management [Member] * Restricted Stock Units [Member]	Maximum Term Of Other Equity Instruments Granted For Share Based Payment Arrangement	_668182
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted shares [Member]	Maximum Term Of Other Equity Instruments Granted For Share Based Payment Arrangement	_668802
4	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Number of other equity instruments vested in share-based payment arrangement	7341	xbrli:shares	INF
5	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Board of Directors [Member] * Restricted Stock Units [Member]	Vesting requirements for share-based payment arrangement, award vesting period	_670030
6	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Executive Management [Member] * Restricted Stock Units [Member]	Vesting requirements for share-based payment arrangement, award vesting period	_670650
7	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted shares [Member]	Vesting requirements for share-based payment arrangement, award vesting period	_671270
8	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Weighted average exercise price of other equity instruments vested in share-based payment arrangement	10.06	iso4217:CHF	2
9	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Number of restricted shares granted (in shares)	0	xbrli:shares	INF
10	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Entity's total for related parties [member] * Restricted Stock Units [Member]	Number of restricted shares granted (in shares)	0	xbrli:shares	INF
11	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Number of restricted shares granted (in shares)	0	xbrli:shares	INF
12	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Entity's total for related parties [member] * Restricted Stock Units [Member]	Number of restricted shares granted (in shares)	0	xbrli:shares	INF
13	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Board of Directors [Member] * Restricted Stock Units [Member]	Number of restricted shares granted (in shares)	29375	xbrli:shares	INF
14	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Executive Management [Member] * Restricted Stock Units [Member]	Number of restricted shares granted (in shares)	95957	xbrli:shares	INF
15	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Number of restricted shares granted (in shares)	129355	xbrli:shares	INF
16	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted shares [Member]	Number of restricted shares granted (in shares)	4023	xbrli:shares	INF
17	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted Stock Units [Member]	Number of restricted shares granted (in shares)	4023	xbrli:shares	INF
18	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Shares vested (in shares)	0	xbrli:shares	INF
19	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted Stock Units [Member]	Shares vested (in shares)	5998	xbrli:shares	INF
20	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Cancelled during the year (in shares)	0	xbrli:shares	INF
21	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Number of other equity instruments forfeited in share-based payment arrangement	0	xbrli:shares	INF
22	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Number of other equity instruments outstanding in share-based payment arrangement	0	xbrli:shares	INF
23	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Number of other equity instruments outstanding in share-based payment arrangement	122014	xbrli:shares	INF
24	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement	0	iso4217:CHF	0
25	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Weighted average exercise price of other equity instruments expired in share-based payment arrangement	0	iso4217:CHF	0
26	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement	0	iso4217:CHF	0
27	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Weighted average exercise price of other equity instruments granted in share-based payment arrangement	9.62	iso4217:CHF	2
28	0001651625 (http://www.sec.gov/CIK)	2015-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement	0	iso4217:CHF	0
29	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement	0	iso4217:CHF	0
30	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Entity's total for related parties [member] * Restricted Shares and Restricted Share Units [Member]	Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement	9.59	iso4217:CHF	2

Fact Table
Network	091900 - Disclosure - Commitments and contingencies (Details) (http://acimume.com/role/CommitmentsAndContingenciesDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Aggregated time bands [member]	Provision, royalty obligation	400000	iso4217:CHF	-5
2	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Aggregated time bands [member]	Provisions, research contracts	9400000	iso4217:CHF	-5
3	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Aggregated time bands [member]	Rental contract, period for notice of cancellation	_658998
4	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Aggregated time bands [member]	Lease liabilities	200000	iso4217:CHF	-5
5	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Aggregated time bands [member]	Provisions	10799000	iso4217:CHF	-3
6	0001651625 (http://www.sec.gov/CIK)	2016-12-31	More Than Five Years [Member]	Provisions	0	iso4217:CHF	-3
7	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Between One and Three Years [Member]	Provisions	1624000	iso4217:CHF	-3
8	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Between Three and Five Years [Member]	Provisions	0	iso4217:CHF	-3
9	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Loss Expiry, December 31, 2017 [Member]	Provisions	9175000	iso4217:CHF	-3
10	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Aggregated time bands [member]	Provisions	12372000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2017-12-31	More Than Five Years [Member]	Provisions	0	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Between One and Three Years [Member]	Provisions	2546000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Between Three and Five Years [Member]	Provisions	140000	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Loss Expiry, December 31, 2017 [Member]	Provisions	9686000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Aggregated time bands [member]	Rental expense	500000	iso4217:CHF	-5

Fact Table
Network	092000 - Disclosure - Earnings per share (Details) (http://acimume.com/role/EarningsPerShareDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Weighted average number of equity awards outstanding,	2784245	xbrli:shares	0
2	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Weighted average number of equity awards outstanding,	1582612	xbrli:shares	0
3	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Adjusted weighted average number of ordinary shares outstanding	46043198	xbrli:shares	0
4	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Adjusted weighted average number of ordinary shares outstanding	50096859	xbrli:shares	0
5	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Adjusted weighted average number of ordinary shares outstanding	57084295	xbrli:shares	0
6	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Basic earnings (loss) per share	0.47	iso4217:CHF/xbrli:shares	2
7	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Basic earnings (loss) per share	-0.14	iso4217:CHF/xbrli:shares	2
8	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Basic earnings (loss) per share	-0.46	iso4217:CHF/xbrli:shares	2
9	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Diluted earnings (loss) per share	0.44	iso4217:CHF/xbrli:shares	2
10	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Diluted earnings (loss) per share	-0.14	iso4217:CHF/xbrli:shares	2
11	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Diluted earnings (loss) per share	-0.46	iso4217:CHF/xbrli:shares	2
12	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Dilutive effect of convertible instruments on number of ordinary shares	1687900	xbrli:shares	INF
13	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Dilutive effect of convertible instruments on number of ordinary shares	1463056	xbrli:shares	INF
14	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Net income / (loss) for the period	20270000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Net income / (loss) for the period	-7096000	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Net income / (loss) for the period	-26411000	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	null	Weighted average number of ordinary shares outstanding	43412250	xbrli:shares	0
18	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	null	Weighted average number of ordinary shares outstanding	50096859	xbrli:shares	0
19	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	null	Weighted average number of ordinary shares outstanding	57084295	xbrli:shares	0

Fact Table
Network	092100 - Disclosure - Financial instruments and risk management (Details) (http://acimume.com/role/FinancialInstrumentsAndRiskManagementDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value	Unit	Rounding
1	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Currency risk [member]	Closing foreign exchange rate, decrease	0.1	xbrli:pure	1
2	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Currency risk [member]	Closing foreign exchange rate, increase	0.1	xbrli:pure	1
3	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Currency risk [member]	Decrease in net loss, foreign exchange rate increase	10900000	iso4217:CHF	-5
4	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Currency risk [member]	Decrease in net loss, foreign exchange rate increase	2100000	iso4217:CHF	-5
5	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Currency risk [member]	Increase in net loss, foreign exchange rate decrease	10900000	iso4217:CHF	-5
6	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Currency risk [member]	Increase in net loss, foreign exchange rate decrease	2100000	iso4217:CHF	-5
7	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Liquidity risk [member]	Liquidity management, rolling forecast period	_631158
8	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Credit risk [member]	Number of banks holding deposits, cash and cash equivalents	1	aciu:Bank	INF
9	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Risks [member]	Financial assets	152727000	iso4217:CHF	-3
10	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Cash on hand and cash equivalents [Member] * Financial liabilities, category [member] * Risks [member]	Financial assets	152210000	iso4217:CHF	-3
11	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Other receivables [Member] * Financial liabilities, category [member] * Risks [member]	Financial assets	517000	iso4217:CHF	-3
12	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Risks [member]	Financial assets	125295000	iso4217:CHF	-3
13	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Cash on hand and cash equivalents [Member] * Financial liabilities, category [member] * Risks [member]	Financial assets	124377000	iso4217:CHF	-3
14	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Other receivables [Member] * Financial liabilities, category [member] * Risks [member]	Financial assets	918000	iso4217:CHF	-3
15	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Risks [member]	Financial liabilities	9401000	iso4217:CHF	-3
16	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Financial assets, category [member] * Accrued Expenses [Member] * Risks [member]	Financial liabilities	5366000	iso4217:CHF	-3
17	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Financial assets, category [member] * Long-term Financial Liabilities [Member] * Risks [member]	Financial liabilities	0	iso4217:CHF	-3
18	0001651625 (http://www.sec.gov/CIK)	2016-12-31	Financial assets, category [member] * Trade and Other Payables [Member] * Risks [member]	Financial liabilities	4035000	iso4217:CHF	-3
19	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Risks [member]	Financial liabilities	9794000	iso4217:CHF	-3
20	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Financial assets, category [member] * Accrued Expenses [Member] * Risks [member]	Financial liabilities	8307000	iso4217:CHF	-3
21	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Financial assets, category [member] * Long-term Financial Liabilities [Member] * Risks [member]	Financial liabilities	395000	iso4217:CHF	-3
22	0001651625 (http://www.sec.gov/CIK)	2017-12-31	Financial assets, category [member] * Trade and Other Payables [Member] * Risks [member]	Financial liabilities	1092000	iso4217:CHF	-3
23	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Risks [member]	Foreign exchange gain (loss)	1598000	iso4217:CHF	-3
24	0001651625 (http://www.sec.gov/CIK)	2015-01-01 to 2015-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Currency risk [member]	Foreign exchange gain (loss)	1600000	iso4217:CHF	-5
25	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Risks [member]	Foreign exchange gain (loss)	3443000	iso4217:CHF	-3
26	0001651625 (http://www.sec.gov/CIK)	2016-01-01 to 2016-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Currency risk [member]	Foreign exchange gain (loss)	3400000	iso4217:CHF	-5
27	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Risks [member]	Foreign exchange gain (loss)	-4049000	iso4217:CHF	-3
28	0001651625 (http://www.sec.gov/CIK)	2017-01-01 to 2017-12-31	Financial assets, category [member] * Financial liabilities, category [member] * Currency risk [member]	Foreign exchange gain (loss)	-4200000	iso4217:CHF	-5

Fact Table
Network	092300 - Disclosure - Post balance sheet events (Details) (http://acimume.com/role/PostBalanceSheetEventsDetails)
Table	(implied)

#	Reporting Entity [Axis]	Period [Axis]	Scenario [Axis]	Concept	Fact Value		Unit	Rounding	Parenthetical Explanations
1	0001651625 (http://www.sec.gov/CIK)	2018-02-02 to 2018-02-02	Major purchases of assets [member]	Additional lease space	4300		utr:sqft	INF
2	0001651625 (http://www.sec.gov/CIK)	2018-02-02 to 2018-02-02	Major purchases of assets [member]	Purchase of lab equipment	750000		iso4217:USD	-3

Rules

Type	Defined	Bound	OK
formula	0	0	0
existenceAssertion	0	0	0
valueAssertion	0	0	0
calculation	95	495	495

Rule Details

Errors and Warnings

Other than rule related. The error Type is just a conjecture on the culprit, because some 'bad reports' may contain some XBRL feature we have not yet covered.

Type	Where	What
bad_report	loadContext/c20151023to20151023_ClassesOfShareCapitalAxis_OrdinarySharesMember	failed((simpleDate(2015-10-23),simpleDate(2015-10-23),2015-10-23@>2015-10-23))
bad_report	loadContext/c20160415to20160415_ClassesOfShareCapitalAxis_PreferenceSharesSeriesEMember	failed((simpleDate(2016-04-15),simpleDate(2016-04-15),2016-04-15@>2016-04-15))
bad_report	loadContext/c20160922to20160922_ClassesOfShareCapitalAxis_InitialPublicOfferingMember	failed((simpleDate(2016-09-22),simpleDate(2016-09-22),2016-09-22@>2016-09-22))
bad_report	loadContext/c20160922to20160922_ClassesOfShareCapitalAxis_OptionForOverAllotmentMember	failed((simpleDate(2016-09-22),simpleDate(2016-09-22),2016-09-22@>2016-09-22))
bad_report	loadContext/c20160922to20160922_ClassesOfShareCapitalAxis_OrdinarySharesMember	failed((simpleDate(2016-09-22),simpleDate(2016-09-22),2016-09-22@>2016-09-22))
bad_report	loadContext/c20180202to20180202_NonadjustingEventsAfterReportingPeriodAxis_MajorPurchasesOfAssetsMember	failed((simpleDate(2018-02-02),simpleDate(2018-02-02),2018-02-02@>2018-02-02))

For more information: http://logicalcontracts.com/xbrl-and-sbrm-reporting/
DISCLAIMER: this analysis is provided by software still under development, and likely incomplete or even erroneous; do NOT use it other than for experimental, inconsequential purposes

Report

User Alterations

Table of Contents

Terms

Model Structures

Fact Tables

Rules

Rule Details

Errors and Warnings